EPICORE Embase Updates: December 2024

Total documents retrieved: 79

Results Generated From:
Embase <1980 to 2024 Week 52>
Embase Weekly Updates (updates since 2024-12-20)

<1>
Accession Number
2036521301
Title
Perioperative aspirin and coronary artery bypass graft surgery: An updated
meta-analysis of randomized controlled trials.
Source
Surgery (United States). 180 (no pagination), 2025. Article Number:
109003. Date of Publication: April 2025.
Author
Gupta A.K.; Zaka A.; Lombardo A.; Tsimiklis J.; Stretton B.; Kovoor J.G.;
Bacchi S.; Ramponi F.; Chan J.C.Y.; Thiagalingam A.; Gould P.;
Sivagangabalan G.; Zaman S.; Chow C.; Kovoor P.; Smith J.A.; Bennetts
J.S.; Maddern G.J.
Institution
(Gupta, Tsimiklis, Stretton, Kovoor, Bacchi, Maddern) Discipline of
Surgery, University of Adelaide, Adelaide, Australia
(Zaka) Gold Coast University Hospital, Southport, Australia
(Lombardo) Princess Alexandra Hospital, Brisbane, Australia
(Ramponi) Yale University, New Haven, CT, United States
(Chan) New York University, New York, NY, United States
(Thiagalingam, Gould, Sivagangabalan, Zaman, Chow, Kovoor) Westmead
Hospital, Westmead, Australia
(Bennetts) School of Medicine, Monash University, Melbourne, Australia
(Smith, Bennetts) Department of Cardiothoracic Surgery, Victorian Heart
Hospital, Melbourne, Australia
(Maddern) Australian Safety and Efficacy Register of New Interventional
Procedures-Surgical, Royal Australasian College of Surgeons, Adelaide,
Australia
(Maddern) Research, Audit and Academic Surgery, Royal Australasian College
of Surgeons, Adelaide, Australia
Publisher
Elsevier Inc.
Abstract
Background: The decision to continue aspirin before elective coronary
artery bypass graft surgery remains contentious because of competing
thrombotic and bleeding risks. We performed a contemporary systematic
review and meta-analysis to compare outcomes between patients undergoing
coronary artery bypass grafting who stopped and continued aspirin before
surgery. Method(s): PubMed, MEDLINE, and CENTRAL databases were
searched from inception to 4 October 2023 for randomized controlled trials
comparing patients undergoing coronary artery bypass grafting who
continued preoperative aspirin with those who discontinued before surgery.
Studies with cointervention arms and multivariable-adjusted or propensity
matched observational studies were excluded. Summary odds ratios were
calculated using a random effects model for dichotomous and continuous
variables. Subgroup and sensitivity analyses were conducted in order to
explore sources of heterogeneity. Result(s): Fifteen eligible
randomized controlled trials were included with a total of 6,188 patients.
Patients who continued aspirin demonstrated no significant difference in
all-cause mortality (odds ratio, 1.37; confidence interval, 0.81-2.33),
perioperative myocardial infarction (odds ratio, 0.81; confidence
interval, 0.55-1.18), and postoperative blood loss (mean difference, 66.12
mL; confidence interval, -1.45 to 133.69). No significant difference was
observed between low-dose and greater doses of aspirin. There was minimal
heterogeneity amongst included studies (I2 = 0%, P = .97,
I2 = 33%, P = .13, and I2= 76, P = .06,
respectively). Studies were of low methodologic quality according to
Cochrane Risk of Bias for Randomized Trials. Conclusion(s): This
largest to-date systematic review and meta-analysis found no significant
difference for risk of all-cause mortality, perioperative myocardial
infarction, and postoperative bleeding between patients continuing and
stopping aspirin before coronary artery bypass grafting. Copyright
© 2024 The Authors

<2>
Accession Number
2036450775
Title
Identifying biomarker-driven subphenotypes of cardiogenic shock: analysis
of prospective cohorts and randomized controlled trials.
Source
eClinicalMedicine. 79 (no pagination), 2025. Article Number: 103013. Date
of Publication: January 2025.
Author
Soussi S.; Tarvasmaki T.; Kimmoun A.; Ahmadiankalati M.; Azibani F.; dos
Santos C.C.; Duarte K.; Gayat E.; Jentzer J.C.; Harjola V.-P.; Hibbert B.;
Jung C.; Johan L.; Levy B.; Lu Z.; Lawler P.R.; Marshall J.C.; Poss J.;
Sadoune M.; Nguyen A.; Raynor A.; Peoc'h K.; Thiele H.; Mathew R.; Mebazaa
A.
Institution
(Soussi) Department of Anesthesiology and Pain Medicine, University of
Toronto, Toronto, ON, Canada
(Soussi, Azibani, Gayat, Sadoune, Nguyen, Mebazaa) University of Paris
Cite, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions
(MASCOT), Paris, France
(Tarvasmaki, Johan) Heart and Lung Center, Cardiology, Helsinki University
Hospital and University of Helsinki, Finland
(Kimmoun, Levy) CHRU de Nancy, 26920, Service de Reanimation Medicale
Brabois, Grand Est, Nancy, France
(Kimmoun, Levy) INSERM, 27102, U 1433 CIC-P, Ile-de-France, Paris, France
(Duarte) Universite de Lorraine, Centre D'Investigations Cliniques
Plurithematique, Institut National de la Sante et de la Recherche Medicale
U1116, Nancy, France
(Ahmadiankalati, Lu) Department of Public Health Sciences, Queen's
University, Kingston, ON, Canada
(dos Santos, Marshall) Interdepartmental Division of Critical Care, St
Michael's Hospital, Keenan Research Centre for Biomedical Science and
Institute of Medical Sciences, Faculty of Medicine, University of Toronto,
Toronto, ON, Canada
(Gayat, Mebazaa) Department of Anaesthesiology, Critical Care,
Lariboisiere - Saint-Louis Hospitals, DMU Parabol, Assistance
Publique-Hopitaux de Paris Nord, University of Paris Cite, France
(Jentzer, Hibbert) Department of Cardiovascular Medicine, Mayo Clinic
Rochester, Rochester, MN 55905, United States
(Harjola) Department of Emergency Medicine, Helsinki University Hospital,
University of Helsinki, Helsinki, Finland
(Hibbert, Mathew) CAPITAL Research Group, Division of Cardiology,
Department of Medicine, University of Ottawa, Heart Institute, Ottawa,
Canada
(Jung) Department of Cardiology, Pulmonology and Angiology, University
Hospital, Dusseldorf, Germany
(Lawler) McGill University Health Centre, Montreal, QC, Canada
(Poss, Thiele) Heart Center Leipzig at University of Leipzig and Leipzig
Heart Science, Leipzig, Germany
(Raynor, Peoc'h) Clinical Biochemistry Laboratory, Bichat Hospital, APHP,
Paris, France
(Peoc'h) Universite Paris Cite, CRI, UMR 1149, Inserm, Paris F-75018,
France
(Kimmoun, Levy) Universite de Lorraine, 137665, CHRU de Nancy, Grand Est,
Nancy, France
(Lawler) Peter Munk, University of Toronto, Toronto, ON, Canada
Publisher
Elsevier Ltd
Abstract
Background: Cardiogenic shock (CS) is a heterogeneous clinical syndrome,
making it challenging to predict patient trajectory and response to
treatment. This study aims to identify biological/molecular CS
subphenotypes, evaluate their association with outcome, and explore their
impact on heterogeneity of treatment effect (ShockCO-OP, NCT06376318).
 Method(s): We used unsupervised clustering to integrate plasma
biomarker data from two prospective cohorts of CS patients: CardShock (N =
205 [2010-2012, NCT01374867]) and the French and European Outcome reGistry
in Intensive Care Units (FROG-ICU) (N = 228 [2011-2013, NCT01367093]) to
determine the optimal number of classes. Thereafter, a simplified
classifier (Euclidean distances) was used to assign the identified CS
subphenotypes in three completed randomized controlled trials (RCTs)
(OptimaCC, N = 57 [2011-2016, NCT01367743]; DOREMI, N = 192 [2017-2020,
NCT03207165]; and CULPRIT-SHOCK, N = 434 [2013-2017, NCT01927549]) and
explore heterogeneity of treatment effect with respect to 28-day mortality
(primary outcome). Finding(s): Four biomarker-driven CS subphenotypes
('adaptive', 'non-inflammatory', 'cardiopathic', and 'inflammatory') were
identified separately in the two cohorts. Patients in the inflammatory and
cardiopathic subphenotypes had the highest 28-day mortality (p (log-rank
test) = 0.0099 and 0.0055 in the CardShock and FROG-ICU cohorts,
respectively). Subphenotype membership significantly improved risk
stratification when added to traditional risk factors including the
Society for Cardiovascular Angiography and Interventions (SCAI) shock
stages (increase in Harrell's C-index by 4% (p = 0.033) and 6% (p =
0.0068) respectively in the CardShock and the FROG-ICU cohorts). The
simplified classifier identified CS subphenotypes with similar
biological/molecular and outcome characteristics in the three independent
RCTs. No significant interaction was observed between treatment effect and
subphenotypes. Interpretation(s): Subphenotypes with the highest
concentration of biomarkers of endothelial dysfunction and inflammation
(inflammatory) or myocardial injury/fibrosis (cardiopathic) were
associated with mortality independently from the SCAI shock stages.
 Funding(s): Dr Sabri Soussi was awarded theCanadian Institutes of
Health Research (CIHR)Doctoral Foreign Study Award (DFSA) and the Merit
Awards Program (Department of Anesthesiology and Pain Medicine, University
of Toronto, Canada) for the current study. Copyright © 2024 The
Author(s)

<3>
Accession Number
2036500927
Title
Magnitude of effect of low dose colchicine, a newly food and drug
administration approved treatment for stroke prevention.
Source
Journal of Stroke and Cerebrovascular Diseases. 34(2) (no pagination),
2025. Article Number: 108186. Date of Publication: February 2025.
Author
Escalera E.; Saver J.L.
Institution
(Escalera) David Geffen School of Medicine, University of California, Los
Angeles, CA, United States
(Saver) Comprehensive Stroke Center and Department of Neurology, Ronald
Reagan - UCLA Medical Center, Los Angeles, CA, United States
Publisher
W.B. Saunders
Abstract
Background: As the Food and Drug Administration in June 2023 approved low
dose colchicine for primary prevention of stroke and other cardiovascular
events, an updated meta-analysis of stroke outcomes in randomized trials
would help inform clinical practice.**** Methods: Systematic, study-level
meta-analysis of randomized clinical trials of long-term colchicine in
patients with established atherosclerotic cardiovascular disease (ASCVD,
preponderantly primary prevention for stroke) or following
non-cardioembolic ischemic stroke/transient ischemic attack (secondary
prevention). Heterogeneity was assessed with the I2 statistic
and Cochrane's Q and potential bias assessed with the Risk of Bias 2.0
scale. Result(s): Six randomized control trials met selection
criteria, enrolling 14,987 patients (7495 colchicine, 7492 placebo), with
median follow-up 26.3 months. Colchicine dosage in all trials was 0.5 mg
once-daily. Across all trials, colchicine treatment produced a 28 %
relative risk reduction in stroke (1.77 % vs 2.54 %, risk ratio (RR)=0.72,
95 %CI: 0.58-0.89; p = 0.003) and a comparable relative reduction on major
adverse cardiovascular events. There was potential heterogeneity by
subgroup (p<inf>interaction</inf> = 0.06), with a stronger relative
reduction for stroke in the five ASCVD trials (RR=0.48, 95 %CI:0.30-0.77;
p = 0.003) than the non-cardioembolic ischemic stroke/TIA population
(RR=0.80, 95 %CI:0.63-1.02; p = 0.07). Colchicine was associated with a
small, non-significant increase in all-cause mortality (RR: 1.09; 95 %Cl:
0.85-1.40, p = 0.49) but not cardiovascular death (RR: 0.92; 95 %Cl:
0.65-1.29, p = 0.61). Conclusion(s): Low-dose colchicine treatment
decreases stroke and major adverse cardiovascular event risk in patients
with ASCVD and potentially in patients following a non-cardioembolic
ischemic stroke/TIA. Among every 1000 patients treated over 2 years,
approximately 6.6 strokes and 24 major adverse cardiovascular events are
avoided. Copyright © 2024

<4>
Accession Number
2036470109
Title
TransCatheter aortic valve implantation and fractional flow reserve-guided
percutaneous coronary intervention versus conventional surgical aortic
valve replacement and coronary bypass grafting for treatment of patients
with aortic valve stenosis and complex or multivessel coronary disease
(TCW): an international, multicentre, prospective, open-label,
non-inferiority, randomised controlled trial.
Source
The Lancet. 404(10471) (pp 2593-2602), 2024. Date of Publication: 21 Dec
2024.
Author
Kedhi E.; Hermanides R.S.; Dambrink J.-H.E.; Singh S.K.; Ten Berg J.M.;
van Ginkel D.; Hudec M.; Amoroso G.; Amat-Santos I.J.; Andreas M.;
Campante Teles R.; Bonnet G.; Van Belle E.; Conradi L.; van Garsse L.;
Wojakowski W.; Voudris V.; Sacha J.; Cervinka P.; Lipsic E.; Somi S.;
Nombela-Franco L.; Postma S.; Piayda K.; De Luca G.; Kolkman E.;
Malinowski K.P.; Modine T.
Institution
(Kedhi) Royal Victoria Hospital, McGill University Health Center,
Montreal, QC, Canada
(Kedhi, Wojakowski) Department of Cardiology and Structural Heart Disease,
Medical University of Silesia, Katowice, Poland
(Hermanides, Dambrink) Department of Cardiology, Isala Heart Center,
Zwolle, Netherlands
(Singh) Department of Thoracic Surgery, Isala Heart Center, Zwolle,
Netherlands
(Ten Berg, van Ginkel) Department of Cardiology, St Antonius Hospital,
Nieuwegein, Netherlands
(Ten Berg, van Ginkel) Cardiovascular Research Institute Maastricht,
Maastricht University Medical Center, Maastricht, Netherlands
(Hudec) Stredoslovensky Ustav Srdcovych a Cievnych Chorob, Banska,
Bystrica, Slovakia
(Amoroso) Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam,
Netherlands
(Amat-Santos) Centro de Investigacion Biomedica en Red, Enfermedades
Cardiovasculares, Madrid, Spain
(Amat-Santos) Hospital Clinico Universitario de Valladolid, Valladolid,
Spain
(Andreas) Department of Cardiac Surgery, Medical University of Vienna,
Vienna, Austria
(Campante Teles) Hospital de Santa Cruz, Carnaxide, Portugal
(Campante Teles) Comprehensive Health Research Center, Nova Medical
School, Lisbon, Portugal
(Bonnet, Modine) Hopital haut Leveque, Unite Medico Chirurgicale, Centre
Hospitalier Universitaire de Bordeaux, Bordeaux, France
(Van Belle) Department of Cardiology, Department of Interventional
Cardiology for Coronary, Valves and Structural Heart Diseases and Institut
Coeur Poumon, Centre Hospitalier Universitaire Lille, Lille, France
(Van Belle) INSERM U1011, Lille, France
(Van Belle) Universite de Lille, Lille, France
(Conradi) Klinik und Poliklinik fur Herz- und Gefaschirurgie,
Universitares Herz- und Gefaszentrum Hamburg, Hamburg, Germany
(van Garsse) Department of Cardiothoracic Surgery, Radboud University
Medical Centre, Nijmegen, Netherlands
(Voudris) Interventional Department of Cardiology, Onassis Cardiac Surgery
Center, Athens, Greece
(Sacha) Department of Cardiology, University Hospital, Institute of
Medical Sciences, University of Opole, Opole, Poland
(Sacha) Faculty of Physical Education and Physiotherapy, Opole University
of Technology, Opole, Poland
(Cervinka) 1st Department Medicine-Cardioangiology, Charles University
Prague, Medical Faculty and University Hospital Hradec Kralove, Prague,
Czechia
(Cervinka) University of Jan Evangelista Purkyne, Usti nad Labem, Czechia
(Lipsic) Department of Cardiology, University Medical Center Groningen,
University of Groningen, Groningen, Netherlands
(Somi) Department of Cardiology, Haga Hospital, The Hague, Netherlands
(Nombela-Franco) Cardiovascular Institute, Hospital Clinico San Carlos
IdISSC, Madrid, Spain
(Postma, Kolkman) Diagram Research, Zwolle, Netherlands
(Piayda) Department of Cardiology and Vascular Medicine, Medical Faculty,
Justus-Liebig-University Giessen, Giessen, Germany
(De Luca) Division of Cardiology, Azienda Ospedaliera Universitaria
Policlinico Gaetano Martino, University of Messina, Messina, Italy
(De Luca) Division of Cardiology, IRCCS Hospital Galeazzi-Sant'Ambrogio,
Milan, Italy
(Malinowski) Center for Digital Medicine and Robotics, Faculty of
Medicine, Jagiellonian University Medical College, Krakow, Poland
(Malinowski) Department of Bioinformatics and Telemedicine, Faculty of
Medicine, Jagiellonian University Medical College, Krakow, Poland
Publisher
Elsevier B.V.
Abstract
Background: Patients with severe aortic stenosis present frequently (~50%)
with concomitant obstructive coronary artery disease. Current guidelines
recommend combined surgical aortic valve replacement (SAVR) and coronary
artery bypass grafting (CABG) as the preferred treatment. Transcatheter
aortic valve implantation (TAVI) and fractional flow reserve (FFR)-guided
percutaneous coronary intervention (PCI) represent a valid treatment
alternative. We aimed to test the non-inferiority of FFR-guided PCI plus
TAVI versus SAVR plus CABG in patients with severe aortic stenosis and
complex coronary artery disease. Method(s): This international,
multicentre, prospective, open-label, non-inferiority, randomised
controlled trial was conducted at 18 tertiary medical centres across
Europe. Patients (aged >=70 years) with severe aortic stenosis and complex
coronary artery disease, deemed feasible for percutaneous or surgical
treatment according to the on-site Heart Team, were randomly assigned
(1:1) to FFR-guided PCI plus TAVI or SAVR plus CABG according to a
computer-generated sequence with random permuted blocks sizes stratified
by site. The primary endpoint was a composite of all-cause mortality,
myocardial infarction, disabling stroke, clinically driven target-vessel
revascularisation, valve reintervention, and life-threatening or disabling
bleeding at 1 year post-treatment. The trial was powered for
non-inferiority (with a margin of 15%) and if met, for superiority. The
primary and safety analyses were done per an intention-to-treat principle.
This trial is registered with ClinicalTrials.gov (NCT03424941) and is
closed. Finding(s): Between May 31, 2018, and June 30, 2023, 172
patients were enrolled, of whom 91 were assigned to the FFR-guided PCI
plus TAVI group and 81 to the SAVR plus CABG group. The mean age of
patients was 76.5 years (SD 3.9). 118 (69%) of 172 patients were male and
54 (31%) patients were female. FFR-guided PCI plus TAVI resulted in
favourable outcomes for the primary endpoint (four [4%] of 91 patients)
versus SAVR plus CABG (17 [23%] of 77 patients; risk difference -18.5 [90%
CI -27.8 to -9.7]), which was below the 15% prespecified non-inferiority
margin (p<inf>non-inferiority</inf><0.001). FFR-guided PCI plus TAVI was
superior to SAVR plus CABG (hazard ratio 0.17 [95% CI 0.06-0.51];
p<inf>superiority</inf><0.001), which was driven mainly by all-cause
mortality (none [0%] of 91 patients vs seven (10%) of 77 patients;
p=0.0025) and life-threatening bleeding (two [2%] vs nine [12%]; p=0.010).
 Interpretation(s): The TCW trial is the first trial to compare
percutaneous treatment versus surgical treatment in patients with severe
aortic stenosis and complex coronary artery disease, showing favourable
primary endpoint and mortality outcomes with percutaneous treatment.
 Funding(s): Isala Heart Centre and Medtronic. Copyright ©
2025 Elsevier Ltd

<5>
Accession Number
2031677261
Title
Multicentre, randomized, double-blind, prospective study on the effects of
ImmunoAdSorptiOn on cardiac function in patients with Dilated
CardioMyopathy (IASO-DCM): Rationale and design.
Source
European Journal of Heart Failure. 26(11) (pp 2464-2473), 2024. Date of
Publication: November 2024.
Author
Dorr M.; Bohm M.; Erdmann E.; Gross S.; Mahabadi A.-A.; Nauck M.;
Nickening G.; Schultheiss H.-P.; Staudt A.; Werdan K.; Waagstein F.;
Hjalmarson A.; Felix S.B.
Institution
(Dorr, Gros, Felix) Department of Internal Medicine B, University
Medicine, Greifswald, Germany
(Dorr, Gros, Nauck, Felix) DZHK (German Center for Cardiovascular
Research), Partner site Greifswald, Greifswald, Germany
(Bohm) Department of Internal Medicine III, Saarland University, Homburg,
Germany
(Erdmann) Department of Internal Medicine III, University of Cologne,
Cologne, Germany
(Mahabadi) Department of Cardiology and Vascular Medicine, West German
Heart and Vascular Center Essen, University Hospital Essen, Essen, Germany
(Nauck) Institute of Clinical Chemistry and Laboratory Medicine,
University Medicine, Greifswald, Germany
(Nickening) Department of Internal Medicine II - Pneumology/Cardiology,
University Hospital Bonn, Bonn, Germany
(Schultheiss) Institute of Cardiac Diagnostics and Therapy, IKDT GmbH,
Berlin, Germany
(Staudt) Helios-Kliniken Schwerin, Department of Cardiology and Angiology,
Schwerin, Germany
(Werdan) Department of Internal Medicine III - Cardiology, Angiology and
Internal Intensive Care Medicine, Mid-German Heart Center, University
Hospital Halle (Saale), Halle, Germany
(Waagstein, Hjalmarson) Wallenberg Laboratory, Sahlgrenska University
Hospital, Goteborg, Sweden
Publisher
John Wiley and Sons Ltd
Abstract
Aims: Pilot studies indicate that immunoadsorption with subsequent IgG
substitution (IA/IgG) induces beneficial effects in patients with dilated
cardiomyopathy (DCM) and heart failure. This placebo-controlled study
investigates whether IA/IgG treatment enhances left ventricular (LV)
systolic function as compared to a control group receiving
pseudo-treatment. Method(s): This multicentre, randomized,
double-blind, parallel-group trial aims to include 200 patients with heart
failure due to DCM (LV ejection fraction [LVEF] <40%) on optimized
guideline-directed heart failure medication. Participants are randomly
assigned in a 1:1 ratio to IA/IgG using protein-A columns, or to
pseudo-immunoadsorption followed by an intravenous infusion without IgG.
Follow-up visits take place by telephone after 1 and 3 months and at the
study centres after 6, 12 and 24 months. The primary efficacy endpoint is
the change in LVEF from baseline to 6 months determined by contrast
echocardiography, analysed at a core lab. In addition, LV end-diastolic
and end-systolic volumes will be analysed as secondary endpoints over the
entire study period to assess whether IA/IgG affects LV remodelling. As
main secondary outcome, a composite of all-cause death, cardiac
resuscitation, hospitalization for heart failure, and need for cardiac
surgery to improve myocardial pump function will be evaluated after 24
months. In addition, exploratory outcomes as well as safety endpoints
related to the treatment will be assessed throughout the whole study
period. Conclusion(s): IASO-DCM is a randomized study which will
provide comprehensive insights into the effects of immunoadsorption with
subsequent IgG substitution in patients with DCM. Copyright ©
2024 The Author(s). European Journal of Heart Failure published by John
Wiley & Sons Ltd on behalf of European Society of Cardiology.

<6>
Accession Number
2036437775
Title
In HF with secondary MR at high surgical risk, TEER was noninferior to
surgery for CV events and reduced safety events at 1 y.
Source
Annals of Internal Medicine. 177(12) (pp JC137), 2024. Date of
Publication: December 2024.
Author
Kaur S.; Borzak S.
Institution
(Kaur, Borzak) University of Miami, HCA Florida JFK Hospital, Atlantis,
FL, United States
Publisher
American College of Physicians

<7>
Accession Number
2036443817
Title
Glycoprotein IIb/IIIa inhibitors in acute myocardial infarction and
angiographic microvascular obstruction: the REVERSE-FLOW trial.
Source
European Heart Journal. 45(47) (pp 5058-5067), 2024. Date of Publication:
14 Dec 2024.
Author
Eitel I.; Saraei R.; Jurczyk D.; Fach A.; Hambrecht R.; Wienbergen H.;
Frerker C.; Schmidt T.; Allali A.; Joost A.; Marquetand C.; Kurz T.; Haaf
P.; Fahrni G.; Mueller C.; Desch S.; Thiele H.; Stiermaier T.
Institution
(Eitel, Saraei, Jurczyk, Frerker, Schmidt, Allali, Joost, Marquetand,
Kurz, Stiermaier) Medical Clinic II, University Heart Center Lubeck,
Ratzeburger Allee 160, Lubeck 23538, Germany
(Eitel, Saraei, Jurczyk, Stiermaier) German Center for Cardiovascular
Research (DZHK), Partner Site Hamburg - Kiel - Lubeck, Ratzeburger Allee
160, Lubeck 23538, Germany
(Fach, Hambrecht, Wienbergen) Bremen Institute for Heart and Circulation
Research (BIHKF), Senator-Wesling-Strase, Bremen 228277, Germany
(Haaf, Fahrni, Mueller) Cardiovascular Research Institute Basel (CRIB),
Department of Cardiology, University Hospital Basel, University of Basel,
Basel, Switzerland
(Desch, Thiele) Department of Internal Medicine/Cardiology and Leipzig
Heart Science, Heart Center Leipzig at University of Leipzig, Leipzig,
Germany
Publisher
Oxford University Press
Abstract
Background and Aims: Glycoprotein (GP) IIb/IIIa inhibitors are recommended
in acute myocardial infarction (AMI) for bailout treatment in case of
angiographic microvascular obstruction (MVO), also termed no-reflow
phenomenon, after percutaneous coronary intervention (PCI) with, however,
lacking evidence (class IIa, level C). Method(s): The
investigator-initiated, international, multicentre REVERSE-FLOW trial
randomized 120 patients with AMI and thrombolysis in myocardial infarction
flow grade <= 2 after primary PCI to optimal medical therapy with or
without GP IIb/IIIa inhibitor. The primary endpoint was infarct size
[percentage of left ventricular (LV) mass assessed by cardiac magnetic
resonance (CMR). Secondary endpoints included CMR-derived MVO and 30-day
adverse clinical events. The trial is registered with ClinicalTrials.gov:
NCT02739711. Result(s): The population was predominantly male (76.7%)
with a median age of 66 years and ST-elevation myocardial infarction in
73.3% of patients. Clinical and angiographic characteristics were well
balanced between the cohorts. Patients in the treatment group (n = 62)
received eptifibatide (n = 41) or tirofiban (n = 21). Infarct size
assessed by CMR imaging was similar in both study groups [25.4% of LV mass
(%LV) vs. 25.2%LV; P =. 386]. However, the number of patients with
evidence of CMR-derived MVO (74.5% vs. 92.2%; P =. 017) and the extent of
MVO (2.1%LV vs. 3.4%LV; P =. 025) were significantly reduced in the GP
IIb/IIIa inhibitor group compared with controls. Thirty-day outcome showed
an increased bleeding risk after GP IIb/IIIa inhibitor administration
restricted to non-life-threatening bleedings (22.6% vs. 6.9%; P =. 016)
without differences in all-cause mortality (4.8% vs. 3.4%; P =. 703).
 Conclusion(s): Bailout GP IIb/IIIa inhibition in AMI patients with
angiographic MVO failed to reduce the primary endpoint infarct size but
decreased CMR-derived MVO and led to an increase in non-fatal bleeding
events. Copyright © 2024 The Author(s). Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved.

<8>
[Use Link to view the full text]
Accession Number
2035901140
Title
CTCA Prior to Invasive Coronary Angiography in Patients With Previous
Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilization,
and Cardiac Events at 3 Years From the BYPASS-CTCA Trial.
Source
Circulation: Cardiovascular Interventions. 17(12) (pp e014142), 2024. Date
of Publication: 01 Dec 2024.
Author
Kelham M.; Beirne A.-M.; Rathod K.S.; Andiapen M.; Wynne L.; Learoyd A.E.;
Forooghi N.; Ramaseshan R.; Moon J.C.; Davies C.; Bourantas C.V.; Baumbach
A.; Manisty C.; Wragg A.; Ahluwalia A.; Pugliese F.; Mathur A.; Jones D.A.
Institution
(Kelham, Beirne, Rathod, Andiapen, Wynne, Forooghi, Ramaseshan, Baumbach,
Ahluwalia, Mathur, Jones) Centre for Cardiovascular Medicine and Devices,
Faculty of Medicine and Dentistry, Queen Mary University of London, United
Kingdom
(Kelham, Beirne, Rathod, Andiapen, Wynne, Forooghi, Ramaseshan, Bourantas,
Baumbach, Wragg, Mathur, Jones) Barts Interventional Group, Barts Heart
Centre, Barts Health National Health Service Trust, London, United Kingdom
(Moon, Davies, Manisty, Pugliese) Department of Cardiac Imaging, Barts
Heart Centre, Barts Health National Health Service Trust, London, United
Kingdom
(Kelham, Beirne, Rathod, Andiapen, Wynne, Forooghi, Ramaseshan, Moon,
Bourantas, Baumbach, Manisty, Wragg, Ahluwalia, Pugliese, Mathur, Jones)
National Institute for Health and Care Research Barts Biomedical Research
Centre, Barts Heart Centre, William Harvey Research Institute, Queen Mary
University of London, United Kingdom
(Learoyd, Ahluwalia, Jones) Barts Cardiovascular Clinical Trials Unit,
Faculty of Medicine and Dentistry, Queen Mary University of London, United
Kingdom
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: In patients with previous coronary artery bypass grafting,
computed tomography cardiac angiography (CTCA) before invasive coronary
angiography (ICA) was demonstrated in the BYPASS-CTCA trial (Randomized
Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography
Can Improve Invasive Coronary Angiography in Bypass Surgery Patients) to
reduce procedure time and incidence of contrast-associated acute kidney
injury, with greater levels of patient satisfaction. Patient-related
outcomes, utilization of further diagnostic imaging resources, and
longer-term incidence of major adverse cardiac events were key secondary
end points not yet reported. METHOD(S): Patients with prior coronary
artery bypass grafting referred for ICA were randomized 1:1 to undergo
CTCA before ICA or ICA alone and followed up for a median of 3 (2.2-3.4)
years. Angina status was assessed using the Seattle Angina Questionnaire
and overall quality of life using the EQ-5D-5L. The incidence of
noninvasive imaging use and major adverse cardiac events were compared
between the 2 groups. RESULT(S): In all, 688 patients were
randomized, 344 to CTCA+ICA and 344 to ICA only. The mean age of
participants was 69.8 years, with 45% undergoing ICA for acute coronary
syndromes and the remainder stable angina. At 3 months follow-up, patients
in the CTCA+ICA group were more likely to be angina-free (51.7% versus
43.2%; P=0.03) with greater quality of life (EQ-5D-5L index, 81.6 versus
74.4; P=0.001), although these improvements did not persist. At 3 years
follow-up, imaging resource use (35.8% versus 45.1%; odds ratio, 0.68 [95%
CI, 0.50-0.92]; P=0.013) and incidence of major adverse cardiac events
were lower in the CTCA+ICA group (35.8% versus 43.5%; hazard ratio, 0.73
[95% CI, 0.58-0.93]; P=0.010). CONCLUSION(S): In patients with prior
coronary artery bypass grafting undergoing ICA, CTCA before ICA leads to
reductions in the use of imaging resources and the rate of major cardiac
events out to 3 years, but with similar patient-related outcome measures.
Together with the initial findings of BYPASS-CTCA, these data are
supportive of routinely undertaking a CTCA before ICA in patients with
prior coronary artery bypass grafting. Copyright © 2024 American
Heart Association, Inc.

<9>
Accession Number
2035902310
Title
Valve Choice for TAVR: Much Left to re-SOLVE.
Source
Journal of the American College of Cardiology. 85(1) (pp 83-85), 2025.
Date of Publication: 07 Jan 2025.
Author
Butala N.M.; Krishnaswamy A.
Institution
(Butala) Rocky Mountain Regional VA Medical Center, Aurora, CO, United
States
(Butala) University of Colorado School of Medicine, Aurora, CO, United
States
(Krishnaswamy) Department of Cardiovascular Medicine, Heart, Vascular and
Thoracic Institute, Cleveland Clinic, Cleveland Ohio, United States
Publisher
Elsevier Inc.

<10>
Accession Number
2035902137
Title
Effect of Valve Type and Anesthesia Strategy for TAVR: 5-Year Results of
the SOLVE-TAVI Trial.
Source
Journal of the American College of Cardiology. 85(1) (pp 74-82), 2025.
Date of Publication: 07 Jan 2025.
Author
Feistritzer H.-J.; Kurz T.; Vonthein R.; Schroder L.; Stachel G.; Eitel
I.; Marquetand C.; Saraei R.; Kirchhof E.; Heringlake M.; Abdel-Wahab M.;
Desch S.; Thiele H.
Institution
(Feistritzer, Stachel, Abdel-Wahab, Desch, Thiele) Heart Center Leipzig at
University of Leipzig, Leipzig, Germany
(Kurz, Eitel, Marquetand, Saraei, Heringlake) University Heart Center
Lubeck, Lubeck, Germany
(Kurz, Eitel, Marquetand, Saraei, Heringlake, Desch) German Center for
Cardiovascular Research (DZHK), Partner Site Hamburg-Kiel-Lubeck, Lubeck,
Germany
(Vonthein, Schroder) Institute of Medical Biometry and Statistics, Lubeck,
Germany
(Stachel) Clinic and Policlinic for Cardiology, Leipzig University Clinic,
Leipzig, Germany
(Kirchhof) Helios Health Institute, Leipzig, Germany
Publisher
Elsevier Inc.
Abstract
Background: In the randomized SOLVE-TAVI (compariSon of secOnd-generation
seLf-expandable vs. balloon-expandable Valves and gEneral vs. local
anesthesia in Transcatheter Aortic Valve Implantation) trial comparing
newer-generation self-expanding valves (SEV) and balloon-expandable valves
(BEV), as well as conscious sedation (CS) and general anesthesia (GA),
clinical outcomes were similar both for valve and anesthesia comparison at
30 days and 1 year. Prosthesis durability may affect clinical outcomes
during long-term follow-up. Moreover, the impact of the anesthesia
strategy on long-term clinical outcomes is unknown so far.
 Objective(s): The authors sought to compare clinical outcomes during
5-year follow-up in the randomized SOLVE-TAVI trial. Method(s): In
the randomized, multicenter, 2 x 2 factorial, open-label SOLVE-TAVI trial,
447 intermediate- to high-risk patients with severe, symptomatic aortic
stenosis were randomly assigned to transfemoral transcatheter aortic valve
replacement (TAVR) using either SEV (Evolut R, Medtronic) or BEV (SAPIEN
3, Edwards Lifesciences) and also to CS vs GA. Patients were followed-up
for 5 years. Result(s): During 5 years of follow-up, the combined
predefined endpoint of all-cause mortality, stroke, moderate or severe
paravalvular leakage, and permanent pacemaker implantation was similar in
the SEV and BEV groups (67.7% vs 63.4%; HR: 0.89; 95% CI: 0.70-1.13; P =
0.34). Stroke rates at 5 years were lower in the SEV group (2.2% vs 9.6%;
HR: 4.84; 95% CI: 1.65-14.18; P = 0.002). Regarding the anesthesia
comparison, the primary endpoint of all-cause mortality, stroke,
myocardial infarction, and acute kidney injury occurred in 51.4% in the CS
group and 61.3% in the GA group (HR: 0.80; 95% CI: 0.62-1.04; P = 0.09).
All-cause mortality at 5 years was lower for CS (41.5% vs 54.3%; HR: 0.70;
95% CI: 0.53-0.94; P = 0.02). Conclusion(s): Transfemoral TAVR using
either SEV and BEV as well as CS and GA showed similar clinical outcomes
at 5 years using a combined clinical endpoint. Copyright © 2025
American College of Cardiology Foundation

<11>
Accession Number
2031590426
Title
Effects of early mobilization in elderly patients undergoing cardiac
surgery.
Source
Irish Journal of Medical Science. 193(6) (pp 2733-2744), 2024. Date of
Publication: December 2024.
Author
Ceylan I.; Mhmood A.H.; Al-Janabi R.Q.K.
Institution
(Ceylan) Department of Hand Rehabilitation, School of Physical Therapy and
Rehabilitation, Kirsehir Ahi Evran University, Kirsehir, Turkey
(Mhmood, Al-Janabi) Department of Physiotherapy and Rehabilitation,
Al-Bitar Cardiac Surgery Hospital, Baghdad, Iraq
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Although early mobilization is associated with improved
outcomes in postoperative cardiac patients, implementation of early
mobilization in elderly patients is still a challenge. Aim(s): In
this study, we aimed to design and assess an early mobilization program
for cardiac rehabilitation. Method(s): We conducted a clinical trial
in elderly patients aged over 65 years after coronary artery bypass graft
surgery. Patients were randomly assigned to an early mobilization group
(Group A) or a routine therapy group (Group B). Short-Form International
Physical Activity Questionnaire (SF-IPAQ), to assessment balance Time Up
and Go (TUG), to assessment functional capacity the 2-min walking test
(2MWT) and the short physical performance battery (SPPB) were used as a
reference to formulate and monitor the early mobilization regimen.
 Result(s): A total of 100 patients were enrolled (n = 50 per group).
The mean walking distance in Group A was significantly higher at 135.6 +/-
9.29 than the mean walking distance in Group B which was lower at 123.4
+/- 8.48. Also, the patients in Group B had a mean SF-IPAQ of 389.44 with
an SD of 85.7, P < 0.001, whereas the mean SF-IPAQ amount in Group A was
556.16 with an SD of 91.47. In early mobilization group, a strong positive
connection was indicated by the correlation coefficient of r = 0.957
between the amount of SF-IPAQ and 2 MWT and there was a significant
negative association r = - 0.768 between 2MWT and TUG. Conclusion(s):
Our study's findings suggest that early mobilization and functional
exercises enhanced balance, functionality, and life quality for older
cardiac patients. Copyright © The Author(s), under exclusive
licence to Royal Academy of Medicine in Ireland 2024.

<12>
Accession Number
2036440906
Title
Radiofrequency and Cryoablation as Energy Sources in the Cox-Maze
Procedure: A Meta-Analysis of Rhythm Outcomes.
Source
Heart Lung and Circulation. (no pagination), 2024. Date of Publication:
2024.
Author
Baudo M.; Rosati F.; D'Alonzo M.; Benussi S.; Muneretto C.; Di Bacco L.
Institution
(Baudo, Rosati, D'Alonzo, Benussi, Muneretto, Di Bacco) Department of
Cardiac Surgery, Spedali Civili di Brescia, University of Brescia,
Brescia, Italy
Publisher
Elsevier Ltd
Abstract
Aim: Cox-maze IV is the most effective surgical procedure for atrial
fibrillation (AF) treatment to date; however, few studies have compared
the outcomes of the different energy sources applied to achieve
transmurality. This study aimed to analyse the impact of the different
energy sources on Cox-maze IV results in terms of sinus rhythm
restoration. Method(s): A systematic review and meta-analysis was
conducted by including studies reporting rhythm outcomes on biatrial
Cox-maze AF ablation with bipolar radio-frequency (BRF), cryoenergy
(Cryo), or both (BRF+Cryo). The primary endpoints were the early and late
rhythm outcomes of AF ablation using the different energy sources. Late AF
recurrences were evaluated through timepoint analysis, and freedom from AF
from Kaplan-derived data. Sixty articles including 8,293 patients were
selected (3,364 patients Cryo, 1,937 BRF, and 2,992 BRF+Cryo).
 Result(s): At 6 months, AF incidence was significantly lower in the
Cryo group at 6.73%; it was 25.52% in the BRF and 16.79% in the BRF+Cryo
groups (p=0.0112). At the 4-year timepoint, AF incidence was lower in the
Cryo group compared with the BRF and BRF+Cryo: 6.14% vs 51.59% vs 16.09%,
respectively (p=0.0392). Freedom from AF was 76.7%+/-2.2%, 60.9%+/-2.2%,
and 66.3%+/-1.6% for Cryo, BRF, and BRF+Cryo at 4 years, respectively
(p<0.001). At meta-regression, mean left atrial diameter was positively
associated with higher AF recurrences (OR 1.04, 95% CI 1.01-1.08;
p=0.0159). Conclusion(s): When performing this procedure,
cryoablation seems to be associated with improved rhythm outcomes when
compared with bipolar radiofrequency ablation. Copyright © 2024
Australian and New Zealand Society of Cardiac and Thoracic Surgeons
(ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)

<13>
Accession Number
2029068341
Title
Perioperative Pain Management for Thoracic Surgery: A Multi-Layered
Approach.
Source
Seminars in Cardiothoracic and Vascular Anesthesia. 28(4) (pp 215-229),
2024. Date of Publication: December 2024.
Author
Tong L.; Solla C.; Staack J.B.; May K.; Tran B.
Institution
(Tong, Tran) Virginia Commonwealth University, Richmond, VA, United States
(Solla, Staack, May) University of Tennessee, Knoxville, TN, United States
Publisher
SAGE Publications Inc.
Abstract
Cardiothoracic surgeries frequently pose unique challenges in the
management of perioperative acute pain that require a multifaceted and
personalized approach in order to optimize patient outcomes. This article
discusses various analgesic strategies including regional anesthesia
techniques such as thoracic epidurals, erector spinae plane blocks, and
serratus anterior plane blocks and underscores the significance of
perioperative multimodal medications, while providing nuanced
recommendations for their use. This article further attempts to provide
evidence for the efficacy of the different modalities and compares the
effectiveness of the choice of analgesia. The roles of Acute Pain Services
(APS) and Transitional Pain Services (TPS) in mitigating opioid dependence
and chronic postsurgical pain are also discussed. Precision medicine is
also presented as a potential way to offer a patient tailored analgesic
strategy. Supported by various randomized controlled trials and
meta-analyses, the article concludes that an integrated, patient-specific
approach encompassing regional anesthesia and multimodal medications,
while also utilizing the services of the Acute Pain Service can help to
enhance pain management outcomes in cardiothoracic surgery. Copyright
© The Author(s) 2024.

<14>
Accession Number
646062304
Title
The effect of virtual reality on postoperative anxiety and pain in
patients following cardiac surgery: a randomized controlled trial.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 66(6) (no pagination),
2024. Date of Publication: 28 Nov 2024.
Author
El Mathari S.; Shehadeh S.; Zwaan W.P.; Boulidam N.; Kuitert L.; Twisk
J.W.R.; Klautz R.J.M.; de Lind van Wijngaarden R.; Veen K.; Kluin J.
Institution
(El Mathari, Shehadeh, Zwaan, Boulidam, Kuitert, Klautz, de Lind van
Wijngaarden) Department of Cardiothoracic Surgery, Amsterdam University
Medical Center, Amsterdam, Netherlands
(El Mathari, Veen, Kluin) Department of Cardiothoracic Surgery, Erasmus
University Medical Center, Rotterdam, Netherlands
(Twisk) Department of Epidemiology and Data Science, Amsterdam University
Medical Center, Amsterdam, Netherlands
(Klautz) Department of Cardiothoracic Surgery, Leiden University Medical
Center, Leiden, Netherlands
Abstract
OBJECTIVES: The VRECOVERY investigated the impact of virtual reality (VR)
distraction therapy on postoperative pain, anxiety and quality of recovery
in patients undergoing coronary artery bypass grafting surgery.
 METHOD(S): A single-centre randomized controlled trial was conducted
involving 192 participants, allocated to either the intervention or
control group. Participants in the intervention group received VR
distraction therapy on postoperative days 1, 2 and 3, while the control
group received standard postoperative care. Primary outcomes were measured
in both groups directly following the VR sessions of the intervention
group. Outcomes included (i) postoperative pain [Numeric Rating Scale
(NRS)], (ii) postoperative anxiety [State Trait Anxiety Inventory 6
questionnaire (STAI-6)] and (iii) quality of postoperative recovery
[Quality of Recovery 15 questionnaire (QoR-15)]. RESULT(S): A total
of 100 participants completed the study, including 39 patients (mean age
69.1+/-7.7years) in the intervention group and 61 patients (mean age
66.8+/-8.2years) in the control group. Eighty-nine percent of participants
was male. VR-distraction therapy demonstrated a significant difference in
postoperative pain decrease between groups (NRS score; intervention group
-1.45/day vs control group -0.73/day, P=0.007), and an important overall
difference in postoperative anxiety slopes (STAI-6 score; intervention
group -0.60/day vs control group +0.09/day, P=0.06). There was no effect
observed on postoperative quality of recovery (P=0.11).
 CONCLUSION(S): The VRECOVERY trial suggests a beneficial impact of VR
distraction therapy in reducing postoperative pain. There was no
significant effect on postoperative anxiety and quality of
recovery. Copyright © The Author(s) 2024. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<15>
Accession Number
2036547446
Title
Prophylactic ablation during cardiac surgery in patients without atrial
fibrillation: a systematic review and meta-analysis of randomized trials.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 39(6) (no
pagination), 2024. Article Number: ivae195. Date of Publication: 01 Dec
2024.
Author
Visanji M.; Belley-Cote E.P.; Pandey A.; Amit Y.; McClure G.R.; Young J.;
Um K.J.; Oraii A.; Healey J.S.; Whitlock R.P.; McIntyre W.F.
Institution
(Visanji, Belley-Cote, Um, Healey, McIntyre) Department of Medicine,
McMaster University, Hamilton, ON, Canada
(Belley-Cote, McClure, Um, Oraii, Healey, Whitlock, McIntyre) Population
Health Research Institute, Hamilton, ON, Canada
(Pandey) Department of Pharmacology and Toxicology, University of Toronto,
Toronto, ON, Canada
(Amit) Department of Physiology, McGill University, Montreal, QC, Canada
(McClure, Whitlock) Department of Surgery, McMaster University, Hamilton,
ON, Canada
(Young) Health Sciences Library, McMaster University, Hamilton, ON, Canada
Publisher
Oxford University Press
Abstract
OBJECTIVES. Atrial fibrillation is the most common complication of cardiac
surgery and occurs frequently in patients without a history of the
arrhythmia. We conducted a systematic review and meta-analysis of
randomized controlled trials to assess whether prophylactic ablation
during cardiac surgery in patients without a history of atrial
fibrillation prevents atrial fibrillation. METHODS. We searched CENTRAL,
MEDLINE and Embase from inception to August 2024. We included randomized
trials of adults without a history of atrial fibrillation undergoing
cardiac surgery. The intervention of interest was ablation during surgery.
We pooled data using random-effects models. The primary outcome was
new-onset early postoperative atrial fibrillation within 30days following
surgery. The key secondary outcome was incident clinical atrial
fibrillation at follow-up (minimum 6months). We assessed risk of bias
using the Cochrane Collaboration's risk of bias tool v.2 and evidence
quality using Grading of Recommendations, Assessment, Development and
Evaluation (GRADE). RESULTS. We included 7 trials (n=687). The
intervention was pulmonary vein isolation in 6 trials and ganglion plexi
ablation in 1. Patients who received prophylactic ablation were less
likely to have early postoperative atrial fibrillation (21% vs 37%, risk
ratio [RR] 0.5, 95% confidence interval 0.3-0.8, I2 = 64%) and
incident clinical atrial fibrillation at longest follow-up (range
6months-2years; 3% vs 10%, RR 0.3, 95% confidence interval 0.2-0.7,
I2 = 0%). The quality of evidence was low. CONCLUSIONS.
Prophylactic ablation during cardiac surgery may prevent atrial
fibrillation in patients without a history of the arrhythmia. A definitive
randomized trial is needed to confirm effects and safety. Copyright
© The Author(s) 2024.

<16>
Accession Number
2036520926
Title
Hemoperfusion with the HA330/HA380 Cartridge in Intensive Care Settings: A
State-Of-The-Art Review.
Source
Blood Purification. (no pagination), 2024. Date of Publication: 2024.
Author
Li Y.; Han M.; Yang M.; Su B.
Institution
(Li, Han, Su) Department of Nephrology, Kidney Research Institute, West
China Hospital of Sichuan University, Chengdu, China
(Yang) Department of Nephrology, The First People's Hospital of Shuangliu
District, Chengdu, China
(Su) Med+ Biomaterial Institute of West China Hospital, West China School
of Medicine, Sichuan University, Chengdu, China
(Su) Med-X Center for Materials, Sichuan University, Chengdu, China
Publisher
S. Karger AG
Abstract
Background: Hemoperfusion with the HA330/HA380 cartridge has markedly
evolved during the past decade and has thus been widely used in intensive
care settings to treat critical or hyperinflammatory illnesses. Numerous
clinical studies have demonstrated that HA330/HA380 hemoperfusion might
mitigate systemic inflammatory response syndrome and organ dysfunction in
ICU patients by removing inflammatory mediators and metabolic toxins from
the blood. However, there is currently lacking a systematic evaluation on
the safety and efficacy of HA330/HA380 hemoperfusion in intensive care
settings. Summary: We searched the PubMed database, Chinese Clinical
Trial Registry, and ClinicalTrials.gov for articles published from
inception to June 20, 2024 (updated on September 10, 2024) to perform a
state-of-theart review of HA330/HA380 hemoperfusion in daily critical care
practice. We discuss the basic technique characteristics and ex vivo
investigations of the HA330/HA380 cartridge and summarize the latest
clinical evidence regarding the use of HA330/HA380 hemoperfusion for the
treatment of sepsis, severe COVID-19, cardiac surgery, acute pancreatitis,
liver failure, and blunt trauma. Ex vivo studies suggest that the
HA330/HA380 cartridge demonstrates satisfactory biocompatibility and
substantial adsorption capacity for inflammatory cytokines, such as
interleukin-6, interleukin-10, and tumor necrosis factor-a. Small-scale
clinical studies indicate that HA330/HA380 hemoperfusion may help reduce
plasma levels of inflammatory mediators, alleviate organ dysfunction, and
improve survival in some critically ill patients with sepsis, severe
COVID-19, acute pancreatitis, and blunt trauma. Key Messages: (i) The
HA330/HA380 cartridge contains abundant, coated, biocompatible sorbent
beads made of styrene-divinylbenzene copolymers. (ii) HA330/HA380
hemoperfusion, with or without combined continuous renal replacement
therapy, is a promising treatment option for some critically ill patients
by removing proinflammatory mediators and alleviating organ dysfunction.
(iii) The HA330/HA380 cartridge may adversely adsorb antibiotics, and
appropriate antibiotic dosing adjustment and plasma drug level monitoring
is recommended. (iv) There are currently numerous ongoing clinical trials
evaluating the safety and efficacy of HA330/HA380 hemoperfusion in
critically ill patients who develop sepsis or undergo cardiopulmonary
bypass, which will certainly sharpen our future practice of HA330/HA380
hemoperfusion in ICU. Copyright © 2024 S. Karger AG, Basel.

<17>
Accession Number
2032699721
Title
Comparing FFR-Guided Complete Revascularization and Conservative
Management for Non-Culprit Lesions in STEMI Patients With Multivessel
Disease: A Systematic Review and Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2024.
Date of Publication: 2024.
Author
Gonnah A.R.; Helmy A.E.; Elsnhory A.B.; Shazly O.; Abousalima S.A.; Labib
A.; Saoudy H.; Awad A.K.; Roberts D.H.
Institution
(Gonnah, Saoudy) Department of Medicine, Imperial College Healthcare NHS
Trust, London, United Kingdom
(Awad, Shazly, Abousalima) Faculty of Medicine, Ain Shams University,
Cairo, Egypt
(Helmy, Elsnhory) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Labib) Department of Medicine, Northern Lincolnshire and Goole Hospitals
NHS Foundation Trust, Hull, United Kingdom
(Awad) Faculty of Medicine, Galala University, Cairo, Egypt
(Roberts) Department of Interventional Cardiology, Lancashire Cardiac
Centre, Blackpool, United Kingdom
(Roberts) School of Medicine, University of Liverpool, Liverpool, United
Kingdom
Publisher
John Wiley and Sons Inc
Abstract
Background: In patients with ST-segment elevation myocardial infarction
(STEMI) and multivessel coronary artery disease, the optimal management
strategy for non-culprit lesions is a subject of ongoing debate. There has
been an increasing use of physiology-guidance to assess the extent of
occlusion in non-culprit lesions, and hence the need for stenting.
Fractional flow reserve (FFR) is commonly used as a technique. This
analysis compares FFR versus conservative management in the management of
non-culprit lesions in STEMI patients with multivessel disease.
 Method(s): A comprehensive literature search was conducted on
databases from inception to May 25, 2024. We conducted a random-effects
meta-analysis using RevMan version 5.3.0, employing the Der-Simonian and
Laird method to combine the data. Result(s): The analysis of five
RCTs including 3759 patients revealed a significantly lower incidence of
major adverse cardiovascular events (composite of all-cause mortality,
non-fatal myocardial infarction and the need for repeat revascularization
[PCI or CABG]) in the FFR group compared to the conservative management
group (RR = 0.65, 95% CI: 0.44-0.96, p = 0.03). The revascularization
rates were significantly lower in the FFR group (RR = 0.53, 95% CI:
0.43-0.66, p < 0.00001). Additionally, unplanned hospitalization leading
to urgent repeat revascularization and any cause hospitalization were
significantly lower in the FFR group (RR = 0.72, 95% CI: 0.56-0.94, p =
0.01), and (RR = 0.62, 95% CI: 0.46-0.84, p = 0.002), respectively. The
FFR group had a higher risk of definite stent thrombosis (RR = 2.26, 95%
CI: 1.10-4.64, p = 0.03). No significant differences were observed between
the two groups in mortality, hospitalization for heart failure, or
myocardial infarction. Similarly, bleeding rates, cerebrovascular
accidents (CVAs), and contrast-induced nephropathy (CIN) were comparable
between both groups. Conclusion(s): Our findings support FFR-guided
PCI to manage non-culprit lesions in STEMI patients with multivessel
disease as it is potentially safe, with comparable rates of bleeding, CVAs
and CIN. It also improves clinical outcomes, as well as reduces
revascularization and hospitalization rates. The risk of stent thrombosis
remains a concern, and hence the decision making for FFR-guided complete
revascularization should take into account the complexity/risk of the
procedure, as well as the patients' individual co-morbidities and
preferences. Copyright © 2024 Wiley Periodicals LLC.

<18>
Accession Number
2032698291
Title
Comparison of remimazolam and sevoflurane for general anesthesia during
transcatheter aortic valve implantation: a randomized trial.
Source
Canadian Journal of Anesthesia. (no pagination), 2024. Article Number:
e013080. Date of Publication: 2024.
Author
Harimochi S.; Godai K.; Nakahara M.; Matsunaga A.
Institution
(Harimochi, Nakahara, Matsunaga) Department of Anesthesiology and Critical
Care Medicine, Graduate School of Medical and Dental Sciences, Kagoshima
University, Kagoshima, Japan
(Godai, Matsunaga) Operating Room, Kagoshima University Hospital,
Kagoshima, Japan
(Godai) Department of Anesthesiology and Critical Care Medicine, Graduate
School of Medical and Dental Sciences, Kagoshima University, 8-35-1
Sakuragaoka, Kagoshima 890-8520, Japan
Publisher
Springer
Abstract
Purpose: Safe perioperative management of patients undergoing
transcatheter aortic valve implantation (TAVI) is crucial. Remimazolam is
a newly developed short-acting benzodiazepine. We hypothesized that
combining remimazolam and flumazenil would reduce emergence time compared
with sevoflurane in patients undergoing general anesthesia for TAVI.
 Method(s): We conducted a prospective, randomized, parallel-design,
open-label, single-centre clinical trial between June 2022 and August 2023
at Kagoshima University Hospital. We allocated patients randomly to either
the remimazolam/flumazenil group or the sevoflurane group. Patients in the
remimazolam group received iv remimazolam whereas patients in the
sevoflurane group received sevoflurane for general anesthesia maintenance.
Patients in both groups received a remifentanil infusion throughout the
TAVI procedure (0.2 mug.kg-1.min-1iv). Remimazolam
and sevoflurane were adjusted to maintain a Bispectral IndexTM
(Covidien/Medtronic, Minneapolis, MN, USA) of 40-60. In the remimazolam
group, flumazenil (0.2 mg iv) was administered immediately after
remimazolam discontinuation. The primary outcome was time to extubation.
Secondary outcomes included intraoperative variables (hemodynamic
variables and vasopressor dose), rate of intra- and postoperative
complications, and recovery of muscle strength. Result(s): Overall,
60 patients were enrolled, and data from 56 were included. The median
[interquartile range] time to extubation was significantly shorter in the
remimazolam group than in the sevoflurane group (6.5 [5.1-8.1] min vs 14.2
[10.9-15.9] min; difference in medians, -6.9 min; 95% confidence interval,
-8.7 to -5.0; P < 0.001). Statistically significant differences were
observed in the perfusion index (P = 0.03) and regional cerebral oxygen
saturation (P = 0.03) between the groups. No significant differences
between the two groups were seen in other secondary outcomes.
 Conclusion(s): Compared with sevoflurane, a combination of
remimazolam and flumazenil significantly reduced the time to extubation in
patients undergoing general anesthesia for TAVI. Therefore, remimazolam
may be a suitable choice for general anesthesia in patients undergoing
TAVI. Study registration: UMIN.ac.jp (UMIN000047892); first posted 30 May
2022. Copyright © The Author(s) 2024.

<19>
Accession Number
646063058
Title
Systematic Review of Stereotactic Ablative Radiotherapy (SABR)/
Stereotactic Body Radiation Therapy (SBRT) for Treatment of High-Risk
Patients with Stage I Non-Small Cell Lung Cancer.
Source
Seminars in thoracic and cardiovascular surgery. (no pagination), 2024.
Date of Publication: 12 Dec 2024.
Author
Wolf A.; Loo B.W.; Mak R.H.; Liptay M.; Pettiford B.; Rocco G.; Lanuti M.;
Merritt R.E.; Keshavarz H.; Suh R.D.; Brunelli A.; Criner G.J.; Mazzone
P.J.; Walsh G.; Eileen Wafford Q.; Murthy S.; Blair Marshall M.; Tong B.;
Luketich J.; Schuchert M.J.; Varghese T.K.; D'Amico T.A.; Swanson S.J.;
Pennathur A.
Institution
(Wolf) Department of Thoracic Surgery, The Icahn School of Medicine at
Mount Sinai and Mount Sinai Hospital, New York, NY
(Loo) Department of Radiation Oncology & Stanford Cancer Institute,
Stanford University School of Medicine, Stanford, CA, United States
(Mak) Department of Radiation Oncology, Brigham and Women's Hospital and
Dana-Farber Cancer Institute, Boston, MA, United States
(Liptay) Department of Cardiovascular and Thoracic Surgery, Rush
University Medical Center, Chicago, IL, United States
(Pettiford) Section of Cardiothoracic Surgery, Ochsner Health System, New
Orleans, LA, United States
(Rocco) Thoracic Service, Department of Surgery, Memorial Sloan Kettering
Cancer Center, New York, NY
(Lanuti) Division of Thoracic Surgery, Massachusetts General Hospital,
Boston, MA, United States
(Merritt) Division of Thoracic Surgery, Ohio State University-Wexner
Medical Center, Columbus, OH, United States
(Keshavarz, Eileen Wafford) American Association for Thoracic Surgery,
Beverly, MA, United States
(Suh) Department of Radiological Sciences, UCLA Medical Center, David
Geffen School of Medicine at UCLA, Los Angeles, CA, United States
(Brunelli) Department of Thoracic Surgery, St. James University Hospital,
Leeds, United Kingdom
(Criner) Department of Thoracic Medicine and Surgery, Lewis Katz School of
Medicine at Temple University, Philadelphia, PA, United States
(Mazzone) Respiratory Institute, Cleveland Clinic, Cleveland, OH, United
States
(Walsh) Department of Thoracic Surgery, University of Texas M.D. Anderson
Cancer Center, Houston, TX, United States
(Murthy) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Columbus, OH, United States
(Blair Marshall) Sarasota Memorial Hospital, Sarasota, FL, Puerto Rico
(Tong) Department of Thoracic Surgery, Duke University Hospital, Durham,
NC, United States
(Luketich, Schuchert, Pennathur) Department of Cardiothoracic Surgery,
University of Pittsburgh School of Medicine, University of Pittsburgh
Medical Center, UPMC Hillman Cancer Center. Pittsburgh, PA, United States
(Varghese) Division of Cardiothoracic Surgery, University of Utah,
Huntsman Cancer Center, Salt Lake City, UT, United States
(D'Amico) Department of Surgery, Duke Cancer Institute, Durham, NC, United
States
(Swanson) Division of Thoracic Surgery, Harvard Medical School and Brigham
and Women's Hospital, Boston, MA, United States
Abstract
Stereotactic ablative radiotherapy (SABR) has emerged as an alternative,
non-surgical treatment for high-risk patients with stage I non-small cell
lung cancer (NSCLC) with increased use over time. The American Association
for Thoracic Surgery (AATS) Clinical Practice Standards Committee (CPSC)
assembled an expert panel and conducted a systematic review of the
literature evaluating the results of SABR, which is also referred to as
stereotactic body radiation therapy (SBRT) or stereotactic radiosurgery
(SRS), prior to developing treatment recommendations for high-risk
patients with stage I NSCLC based on expert consensus. Publications
detailing the findings of 16 prospective studies of SABR and 14
retrospective studies of SABR for the management of early-stage lung
cancer in 54697 patients were identified by systematic review of the
literature with further review by members of our expert panel. Medical
inoperability (93-95%) was the primary reason for utilizing SABR. The
median rate of histologically confirmed cancer in treated patients was 67%
(range 57-86%). In retrospective studies and prospective studies, the most
common dosing regimens were 48-54 Gy in 3-5 fractions and 44-66 Gy in 3-5
fractions respectively. The median follow-up after SABR was 30 months
(range 15-50). The complications, oncological results and quality of life
after SABR in high-risk patients with early-stage NSCLC are summarized in
this Expert Review article. Further prospective randomized trials are
needed and are currently underway to compare outcomes after SABR with
outcomes after sublobar resection to fully evaluate treatment options
applicable this high-risk group of patients. Copyright © 2024.
Published by Elsevier Inc.

<20>
Accession Number
646062594
Title
Deferral of routine percutaneous coronary intervention in patients
undergoing transcatheter aortic valve implantation: rationale and design
of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
Source
American heart journal. (no pagination), 2024. Date of Publication: 12
Dec 2024.
Author
Aarts H.M.; Hemelrijk K.I.; Broeze G.M.; van Ginkel D.J.; Versteeg G.A.A.;
Overduin D.C.; Tijssen J.G.; Beijk M.A.M.; Baan J.; Vis M.M.; Lemkes J.S.;
de Winter R.J.; Dickinson M.G.; Kraaijeveld A.O.; Mokhles M.M.; Dessing
T.C.; Grundeken M.J.; Claessen B.E.P.M.; Tonino P.A.L.; Schotborgh C.E.;
Meuwissen M.; van Houwelingen G.K.; Wykrzykowska J.J.; Amoroso G.;
Vossenberg T.N.; Vriesendorp P.A.; van Royen N.; Ten Berg J.M.; Delewi R.;
Voskuil M.
Institution
(Aarts) Department of Cardiology, University Medical Center Utrecht,
Utrecht, The Netherlands; Department of Cardiology, Amsterdam University
Medical Center, Amsterdam, The Netherlands
(Hemelrijk, Broeze, Tijssen, Beijk, Baan, Vis, Lemkes, de Winter,
Grundeken, Claessen, Delewi) Department of Cardiology, Amsterdam
University Medical Center, Amsterdam, Netherlands
(van Ginkel, Overduin) Department of Cardiology, St. Antonius Hospital,
Nieuwegein, Netherlands
(Versteeg, van Royen) Department of Cardiology, Radboud University Medical
Centre, Nijmegen, Netherlands
(Dickinson, Kraaijeveld, Voskuil) Department of Cardiology, University
Medical Center Utrecht, Utrecht, Netherlands
(Mokhles, Dessing) Department of Cardiothoracic Surgery, University
Medical Center Utrecht, Utrecht, Netherlands
(Tonino) Department of Cardiology, Catharina Hospital Eindhoven,
Eindhoven, The Netherlands; Department of Biomedical Engineering,
Technical University Eindhoven, Eindhoven, The Netherlands
(Schotborgh) Department of Cardiology, Haga Hospital, The Hague,
Netherlands
(Meuwissen) Department of Cardiology, Amphia Hospital, Breda, Netherlands
(van Houwelingen) Department of Cardiology, Thoraxcentrum Twente, Medisch
Spectrum Twente, Enschede, Netherlands
(Wykrzykowska) Department of Cardiology, Groningen UMC, Groningen,
Netherlands
(Amoroso) Department of Cardiology, OLVG, Amsterdam, Netherlands
(Vossenberg) Department of Cardiology, Medical Center Leeuwarden,
Leeuwarden, Netherlands
(Vriesendorp) Department of Cardiology, Maastricht University Medical
Center, Maastricht, Netherlands
(Ten Berg) Department of Cardiology, St. Antonius Hospital, Nieuwegein,
The Netherlands; Cardiovascular Research Institute Maastricht (CARIM),
Maastricht, The Netherlands
Abstract
BACKGROUND: Concomitant coronary artery disease (CAD) is highly prevalent
in patients with severe aortic stenosis undergoing transcatheter aortic
valve implantation (TAVI). The optimal treatment strategy for CAD is a
topic of debate. An initial conservative strategy for CAD in patients
undergoing TAVI may be favorable as multiple studies have failed to show
an evident beneficial effect of percutaneous coronary intervention (PCI)
on mortality after TAVI. However, more randomized, controlled trials are
warranted. METHOD(S): The PeRcutaneous cOronary Intervention before
Transcatheter Aortic Valve Implantation (PRO-TAVI) trial is an
investigator-initiated, multicenter, open-label, randomized controlled
trial comparing TAVI with or without routine preprocedural PCI. A total of
466 patients undergoing TAVI will be randomized in a 1:1 ratio to PCI
(reference group) or no PCI (index group). Concomitant CAD is defined as
at least one stenosis of 70% to 99%, or at least one stenosis between 40%
to 70% combined with positive physiological measurement in a coronary
artery with a minimal diameter of 2.5 mm or bypass graft. The primary
endpoint is a composite of all-cause mortality, myocardial infarction,
stroke, or type 2 - 4 bleeding at 12 months after randomization, in
accordance with Valve Academic Research Consortium-3 criteria. Key
secondary endpoints include the individual components of the primary
endpoint, revascularization, quality of life and cost-effectiveness. The
primary endpoint will be analyzed to assess non-inferiority of deferral of
routine PCI in patients undergoing TAVI against the prespecified margin of
11 percentage points. CONCLUSION(S): The PeRcutaneous cOronary
intervention before Transcatheter Aortic Valve Implantation (PRO-TAVI)
trial is designed to investigate the hypothesis that deferral of routine
PCI in patients undergoing TAVI is non-inferior to TAVI with preceding
PCI. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov. Unique identifier
NCT05078619. Copyright © 2024. Published by Elsevier Inc.

<21>
Accession Number
646062390
Title
Effect of Continuous Erector Spinae Plane Block on Postoperative Recovery
in Patients Undergoing Minimally Invasive Cardiac Surgery: A Prospective,
Randomized Controlled Clinical Trial.
Source
Current medical science. (no pagination), 2024. Date of Publication: 14
Dec 2024.
Author
Jin L.; Yu Y.; Miao P.; Huang Y.-H.; Yu S.-Q.; Guo K.-F.
Institution
(Jin, Yu, Miao, Huang, Yu, Guo) Department of Anesthesia, Zhongshan
Hospital, Fudan University, Shanghai 200032, China
Abstract
OBJECTIVE: To investigate whether continuous erector spinae plane block
(ESPB) improves the quality of recovery (QoR) and decreases postoperative
acute and chronic pain in patients undergoing minimally invasive cardiac
surgery. METHOD(S): This was a single-center, double-blind,
prospective, randomized, placebo-controlled trial. A total of 120 patients
were randomized to groups at a 1:1 ratio. They received general
anaesthesia and an ESP catheter (ropivacaine or normal saline) before
surgery, and received patient-controlled intravenous analgesia with
sufentanil and continuous ESPB with a pulse injection of 8 mL (ropivacaine
or normal saline) per h after 20 mL of the experimental drug was
administered at the end of surgery. The primary outcome was the 15-item
quality of recovery scale (QoR-15) score at 24 h after surgery. The
secondary outcomes included the severity of pain, sufentanil consumption,
incidence of rescue analgesia, and proportion of patients with chronic
pain. RESULT(S): The QoR-15 score was greater in the ESPB group than
in the control group at 24 h after surgery [112 (108-118) vs. 109
(101-114), P=0.023]. ESPB was associated with a lower cough visual
analogue scale (VAS) score (44 vs. 47, P=0.001), resting VAS score (28 vs.
35.5, P=0.003), sufentanil consumption (104.8 microg vs. 145.5 microg,
P=0.000), and incidence of rescue analgesia (20.0% vs. 43.3%, P=0.006).
 CONCLUSION(S): Continuous ESPB mildly improved the QoR-15 score in
patients undergoing minimally invasive cardiac surgery and reduced
postoperative pain scores, opioid consumption, and the incidence of rescue
analgesia. Copyright © 2024. Huazhong University of Science and
Technology.

<22>
Accession Number
2035254989
Title
Intraoperative Use of Sodium Bicarbonate Ringer's Solution Instead of
Sodium Lactate Ringer's Solution to Reduce Endothelial Glycocalyx
Degradation and Improve Postoperative Recovery During Cardiopulmonary
Bypass Cardiac Surgery: A Single-Center Prospective Cohort Study.
Source
Drug Design, Development and Therapy. 18 (pp 5881-5893), 2024. Date of
Publication: 2024.
Author
Shi Y.; Tao Y.; Xu B.; Wang X.; Xie Y.; Zhang M.
Institution
(Shi, Tao, Xu, Wang, Xie, Zhang) Department of Anesthesiology, The First
Affiliated Hospital of USTC, Division of Life Sciences and Medicine,
University of Science and Technology of China, Anhui, Hefei 230001, China
(Shi) Department of Anesthesiology, Wannan Medical College, Anhui, Wuhu
241000, China
Publisher
Dove Medical Press Ltd
Abstract
Objective: To investigate the effect of sodium bicarbonate Ringer's
solution (BRS) on the degradation of endothelial glycocalyx components in
patients undergoing cardiopulmonary bypass (CPB) during cardiac surgery,
and to evaluate its impact on endothelial glycocalyx preservation and
postoperative recovery. Patients and Methods: A total of eight
patients scheduled for elective CPB heart surgery were included and
randomly divided into two groups: the sodium lactate Ringer's solution
(LRS) group and the BRS group. ELISA was used to measure plasma
concentrations of syndecan-1, matrix metalloproteinase-9 (MMP-9), matrix
metalloproteinase-3 (MMP-3), IL-6, IL-8, TNF-alpha, and TGF-beta at
predefined time points: T0 (before induction of anesthesia), T3
(immediately after weaning from CPB), T5 and T6 (24 and 72 hours
postoperatively). Serum creatinine concentrations were measured within 48
hours postoperatively. The incidence of postoperative delirium (POD) was
assessed three days after surgery. Postoperative mechanical ventilation
time, duration of stay in the intensive care unit and hospital stay were
also documented. Result(s): The BRS group had significantly lower
plasma concentrations of syndecan-1 at T3 (7.98 [7.43, 8.92] ng/mL vs 9.54
[8.4, 10.73] ng/mL, P < 0.001) and T5 (4.20 [3.31, 4.96] ng/mL vs 5.40
[3.95, 6.55] ng/mL, P = 0.001) in comparison with the LRS group (P<0.01).
Syndecan-1 levels in both groups were similar at T6 (3.18 [2.88, 3.5]ng/mL
vs 3.12 [2.77, 3.45] ng/mL, P > 0.05). Additionally, MMP-9, MMP-3, IL-6
and IL-8 were significantly lower at T3 and T5 in the BRS group (P<0.05
and P<0.01, respectively). However, no significant differences were
observed between the two groups in the incidence of acute kidney injury
(AKI) or POD (P > 0.05). Conclusion(s): BRS has the potential to
reduce glycocalyx degradation in patients undergoing heart valve surgery
with CPB. However, both groups demonstrated similar post-postoperative
clinical outcomes, including the rates of AKI and POD. Copyright
© 2024 Shi et al.

<23>
Accession Number
2032653807
Title
Comparative outcomes of video-assisted thoracic surgery versus open
thoracic surgery in pediatric pulmonary metastasectomy: a systematic
review and meta-analysis.
Source
Pediatric Surgery International. 41(1) (no pagination), 2025. Article
Number: 34. Date of Publication: December 2025.
Author
da Nobrega Oliveira R.E.N.; de Andrade Pontual Peres C.; Oliveira A.C.;
Onyeji P.; Kemczenski F.
Institution
(da Nobrega Oliveira) Department of Thoracic Surgery, Barretos Cancer
Hospital, Street Antenor Duarte Vilela, 1331, Dr. Paulo Prata, SP,
Barretos 14784-400, Brazil
(de Andrade Pontual Peres) University of Pernambuco, Recife, Brazil
(Oliveira) Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
(Onyeji) All Saints University, Goodwill, Dominica
(Kemczenski) University of Joinville's Region, Joinville, Brazil
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
This meta-analysis aimed to compare the outcomes of video-assisted
thoracic surgery (VATS) and open thoracotomy in pediatric patients
undergoing pulmonary metastasectomy for various malignancies. We
systematically searched PubMed, Embase, and Cochrane Library databases for
studies comparing VATS and open thoracotomy in pediatric patients. The
treatment effects for continuous outcomes were compared using mean
differences (MDs), and binary endpoints were evaluated using odds ratios
(ORs), with 95% confidence intervals (CIs). Heterogeneity was assessed
with I2 statistics. Statistical analyses were performed using R
software, version 4.4.1. A total of 4 studies involving 1,541 patients
were included. There were no significant differences in overall survival
(OR 0.65; 95% CI 0.36-1.18; p = 0.16) or disease-free survival (DFS) (OR
1.65; 95% CI 0.88-3.10; p = 0.12) between groups. However, VATS was
associated with a significantly reduced length of hospital stay (MD -2.06
days; 95% CI - 2.93 to - 1.20; p < 0.01). This meta-analysis suggests that
VATS significantly reduces hospitalization duration compared to open
thoracotomy, with no significant difference in survival outcomes. Future
prospective studies are needed to validate these findings and optimize
patient selection criteria. International Prospective Register of
Systematic Reviews; No: CRD42024581284; URL:
https://www.crd.york.ac.uk/prospero/. Copyright © The Author(s),
under exclusive licence to Springer-Verlag GmbH Germany, part of Springer
Nature 2024.

<24>
Accession Number
2036338322
Title
Crossing borders to meet cardiac surgical needs: A scoping review on
patients seeking cardiac surgery abroad.
Source
American Journal of Surgery. 240 (no pagination), 2025. Article Number:
116133. Date of Publication: February 2025.
Author
Mourad N.; Stefanyk K.; Vervoort D.
Institution
(Mourad, Stefanyk) Faculty of Medicine, University of British Columbia,
Vancouver, BC, Canada
(Vervoort) Division of Cardiac Surgery, University of Toronto, Toronto,
ON, Canada
Publisher
Elsevier Inc.
Abstract
Background: Over 100 countries do not have a local cardiac surgeon,
whereas capacity, coverage, or cultural constrains may limit access to
cardiac surgical care in-country. This scoping review aims to summarize
the current literature of patients seeking cardiac surgical care abroad
and determine research gaps for this understudied aspect of global
surgical care. Method(s): A scoping review was conducted on patients
seeking cardiac surgery outside of their home country using MEDLINE,
EMBASE, CINAHL, SCOPUS, WHO Global Index Medicus, and PubMed databases.
Relevant articles were descriptively and quantitatively summarized.
 Result(s): Out of a total of 49 articles and 6351 patients, the most
common procedures were coronary artery bypass grafts & valve procedures (N
= 3948; 62 %) and congenital heart disease repairs (N = 2049; 32 %). The
most prevalent countries of origin were Japan, Nigeria, and the United
Arab Emirates. The United States, France, and the United Kingdom were the
most common destination countries. Most patients (N = 1483; 23 %) sought
care abroad due to limited therapeutic options in the home country.
Funding sources stemmed comparably from government funding,
non-governmental organization funding, and out-of-pocket payments.
 Conclusion(s): The extent of and reasons for individuals traveling
abroad for cardiac surgery are poorly described. Localizing cardiac care,
while requiring significant resources, may lead to substantial cost
savings and improved access to care. Until then, improving access to
international travel for cardiac surgery remains an important
strategy. Copyright © 2024 Elsevier Inc.

<25>
Accession Number
2036334706
Title
Ferric carboxymaltose with or without phosphate substitution in iron
deficiency or iron deficiency anemia before elective surgery - The DeFICIT
trial.
Source
Journal of Clinical Anesthesia. 101 (no pagination), 2025. Article Number:
111727. Date of Publication: February 2025.
Author
Kaserer A.; Braun J.; Mair A.; Akbas S.; Rossler J.; Bischoff-Ferrari
H.A.; Turina M.; Clavien P.-A.; Opitz I.; Hulsmeier A.; Karsai G.;
Gasciauskaite G.; Spahn G.H.; Schlapfer M.; Spahn D.R.
Institution
(Kaserer, Mair, Akbas, Rossler, Gasciauskaite, Spahn, Schlapfer, Spahn)
Institute of Anesthesiology, University of Zurich and University Hospital
Zurich, Zurich, Switzerland
(Braun) Departments of Epidemiology and Biostatistics, Epidemiology,
Biostatistics and Prevention Institute, University of Zurich, Zurich,
Switzerland
(Bischoff-Ferrari) Department of Geriatrics and Aging Research, University
of Zurich and University Hospital Zurich, Zurich, Switzerland
(Bischoff-Ferrari) Centre on Aging and Mobility, University of Zurich,
Zurich, Switzerland
(Turina, Clavien) Department of Surgery and Transplantation, University of
Zurich and University Hospital Zurich, Zurich, Switzerland
(Clavien) Wyss Zurich Translational Center, ETH Zurich and Swiss Medical
Network and Faculty of Medicine, University of Zurich, Zurich, Switzerland
(Opitz) Department of Thoracic Surgery, University of Zurich and
University Hospital Zurich, Zurich, Switzerland
(Hulsmeier, Karsai) Institute of Clinical Chemistry, University of Zurich
and University Hospital Zurich, Zurich, Switzerland
(Schlapfer) Institute of Physiology, University of Zurich, Zurich,
Switzerland
Publisher
Elsevier Inc.
Abstract
Background: Iron deficiency anemia in the perioperative setting is treated
predominantly with intravenous iron formulation, of which ferric
carboxymaltose may induce hypophosphatemia by modulating fibroblast growth
factor 23. Method(s): In this single-center, prospective, randomized,
double-blind trial, we consented 92 adult patients scheduled for elective
major abdominal or thoracic surgery. These patients either had isolated
iron deficiency (plasma ferritin <100 ng/mL or transferrin saturation < 20
%) or iron deficiency anemia (hemoglobin (Hb) 100-130 g/L with plasma
ferritin <100 ng/mL or transferrin saturation < 20 %). Preoperatively,
participants received a single preoperative intravenous dose of ferric
carboxymaltose and were then randomly assigned to receive either phosphate
or placebo, administered orally three times a day for 30 days
corresponding to an 18 mmol dose of daily phosphate supplementation in the
intervention group. The primary endpoint was the minimum serum phosphate
concentration during follow-up visits. The key secondary efficacy endpoint
was mean perioperative hemoglobin concentration of postoperative days 0, 2
and 4, assessing the non-inferiority of additional phosphate
supplementation. Result(s): We randomly consented 46 patients in each
group (mean +/- SD age 56 +/- 17 years, 57 % female). Minimal phosphate
concentration was 0.49 +/- 0.21 mmol/L in the treatment group and 0.42 +/-
0.17 mmol/L in the placebo group (p = 0.12, two-sided p-value). Average
mean hemoglobin was 110 +/- 16 g/L in the treatment and 113 +/- 13 g/L in
the placebo group (p = 0.023, one-sided p-value for non-inferiority).
Hypophosphatemia occurred in 32 patients (70 %) of the treatment group and
in 39 patients (85 %) of the placebo group (odds ratio 0.15, 95 % CI from
0.02 to 0.77, p = 0.014). Secondary outcomes, such as rescue medication
use, core muscle strength and MOCA test scores, did not differ between
groups. Conclusion(s): Co-administration of oral phosphate
supplementation to ferric carboxymaltose cannot prevent hypophosphatemia.
However, hypophosphatemia occurs in fewer patients. Phosphate
co-administration did not impede the treatment of iron deficiency anemia
with ferric carboxymaltose. Copyright © 2024 The Authors

<26>
Accession Number
2032569349
Title
REmoval of cytokines during CArdiac surgery (RECCAS): a randomised
controlled trial.
Source
Critical Care. 28(1) (no pagination), 2024. Article Number: 406. Date of
Publication: December 2024.
Author
Hohn A.; Malewicz-Oeck N.M.; Buchwald D.; Annecke T.; Zahn P.K.; Baumann
A.
Institution
(Hohn, Annecke) Faculty of Medicine, University of Cologne, Kerpener Str.
62, Cologne 50937, Germany
(Hohn) Department of Anesthesiology and Intensive Care Medicine, Cologne
University Hospital, Kerpener Str. 62, Cologne 50937, Germany
(Hohn) Department of Anaesthesiology and Intensive Care Medicine, Kliniken
Maria Hilf GmbH, Viersener Str. 450, Moenchengladbach 41063, Germany
(Malewicz-Oeck, Zahn, Baumann) Department of Anaesthesiology, Intensive
Care Medicine and Pain Medicine, Medical Faculty of Ruhr-University
Bochum, BG University Hospital Bergmannsheil gGmbH,
Burkle-de-la-Camp-Platz 1, Bochum 44789, Germany
(Buchwald) Department of Cardiothoracic Surgery, BG University Hospital
Bergmannsheil, Burkle-de-la-Camp-Platz 1, Bochum 44789, Germany
(Annecke) Department of Anaesthesiology and Intensive Care Medicine,
Kliniken der Stadt Koln GmbH, University of Witten Herdecke, Cologne,
Ostmerheimer Strase 200, Cologne 51109, Germany
Publisher
BioMed Central Ltd
Abstract
Background: Cardiopulmonary bypass (CPB) triggers marked cytokine release
often followed by a systemic inflammatory response syndrome, associated
with adverse postoperative outcomes. This trial investigates the
intraoperative use of haemoadsorption (HA) during cardiac surgery with CPB
to assess its impact on postoperative systemic inflammatory response.
 Method(s): In this prospective randomised controlled trial (ethics
approval no. 5094-14DRKS00007928), patients (> 65 years) undergoing
elective on-pump cardiac surgery were randomised to intraoperative HA
(CytoSorb) during CPB or standard care without HA. Primary outcome was the
difference in mean interleukin (IL)-6 serum concentrations between groups
on intensive care unit (ICU) admission. The secondary outcomes included
various clinical and biochemical endpoints. Statistical methods included
paired and unpaired t-tests, Wilcoxon, Mann-Whitney U-tests, and
chi-square tests. Result(s): Thirty-eight patients were allocated to
receive either intraoperative HA (n = 19) or standard care (n = 19). The
primary outcome, IL-6 levels on ICU admission, did not differ between the
study group and controls (214.4 +/- 328.8 vs. 155.8 +/- 159.6 pg/ml, p =
0.511). During surgery pre- versus post-adsorber IL-2, IL-6, IL-8, IL-10,
heparan sulfate and myoglobin post- levels were reduced. Furthermore, IL-6
levels did not differ between the study groups on day 1 and 2 in the ICU.
While sequential organ failure assessment scores, lactate levels, and
C-reactive protein and procalcitonin (PCT) showed no statistically
significant differences. Regarding haemodynamic stability in the treatment
group the cardiac index (3.2 +/- 0.7 vs. 2.47 +/- 0.47
l/min/m2, p = 0.012) on ICU day 2 increased, and lower fluid
requirements as well as decreased fibrinogen requirement were observed.
Need for renal replacement therapy did not differ though a shorter
duration was observed in the treatment group. Time on ventilator,
respiratory parameters, infectious complications, delirium scores, ICU and
hospital lengths of stay, and mortality did not differ between groups.
 Conclusion(s): HA did not reduce the IL-6 level on ICU admission or
afterwards. Even though HA reduced cytokine load during cardiac surgery in
the treatment group. There were no significant differences between groups
in the postoperative course of other cytokine concentrations, organ
dysfunction, ICU and hospital lengths of stay and mortality rates. Trial
registration prospectively DRKS00007928 and published under: Baumann A,
Buchwald D, Annecke T, Hellmich M, Zahn PK, Hohn A. RECCAS - REmoval of
Cytokines during Cardiac Surgery: study protocol for a randomised
controlled trial. Trials. 2016;17: 137. Copyright © The Author(s)
2024.

<27>
Accession Number
2036409790
Title
Efficacy of Erector Spinae Plane Block (ESPB) in pediatric cardiac
surgeries: a systematic review and meta-analysis.
Source
Brazilian Journal of Anesthesiology (English Edition). 75(2) (no
pagination), 2025. Article Number: 844579. Date of Publication: 01 Mar
2025.
Author
Damiao V.P.; Andrade P.P.; de Oliveira L.S.G.; Braga A.D.F.A.; Carvalho
V.H.
Institution
(Damiao, Braga, Carvalho) Universidade Estadual de Campinas (UNICAMP), SP,
Campinas, Brazil
(Andrade) Pontificia Universidade Catolica de Campinas (PUC-Campinas), SP,
Campinas, Brazil
(de Oliveira) Faculdade de Ciencias Medicas de Minas Gerais (FCMMG), MG,
Belo Horizonte, Brazil
Publisher
Elsevier Editora Ltda
Abstract
Background: Erector Spinae Plane Block (ESPB) effectively reduces pain
scores for sternotomy in adults. However, evidence is insufficient to
assert that the same result occurs in children. The aim of this systematic
review and meta-analysis was to evaluate the efficacy of ESPB in pediatric
cardiac surgeries. Method(s): Systematic Medline, Embase and Cochrane
searches were conducted for studies that compared ESPB versus no block or
sham block for pediatric cardiac surgery under sternotomy. The primary
outcome was cumulative opioid consumption for up to 48 hours. Statistical
analyses were carried out with the use of RStudio version 1.2.1335.
Heterogeneity was assessed by Cochran's Q test and I2
statistics. Quality assessment and risk of bias assessment complied with
Cochrane recommendations. Result(s): Five studies, involving 328
patients (3 Randomized Controlled Trials [RCT], and 2 cohorts) were
included. Of the 328 patients, 160 (48.7%) underwent ESPB. There were
significant reductions in cumulative opioid consumption up to 48 hours
after ESPB (SMD -0.68; 95% CI -1.13 - -0.23; p < 0.01). In the following
outcomes ESPB failed to show superiority: postoperative nausea and
vomiting (OR = 0.56; 95% CI 0.25-1.23; p = 0.54), fever (OR = 0.75; 95% CI
0.24-2.31; p = 0.58), length of intensive care unit stay in hours (MD
-2.42; 95% CI -5.47-0.64; p < 0.01] and length of hospital stay in days
(MD -0.87; 95% CI -2.69-0.96; p = 0.02). Only one cohort study had a high
risk of bias. Conclusion(s): ESPB potentially reduces postoperative
pain by significant reductions in cumulative opioid consumption up to 48
hours in pediatric cardiac surgery patients. Copyright © 2024
Sociedade Brasileira de Anestesiologia

<28>
Accession Number
2036539120
Title
Effect of chronic total occlusion of coronary arteries on cardiovascular
outcomes in patients undergoing transcatheter aortic valve replacement: A
systematic review and meta-analysis.
Source
International Journal of Cardiology: Cardiovascular Risk and Prevention.
24 (no pagination), 2025. Article Number: 200356. Date of Publication:
March 2025.
Author
Goyal A.; Tariq M.D.; Ahsan A.; Hurjkaliani S.; Singh A.; Hamza H.M.; Jain
H.; Bharadwaj H.R.; Daoud M.; Sheikh A.B.
Institution
(Goyal) Department of Internal Medicine, Seth GS Medical College and KEM
Hospital, Mumbai, India
(Tariq, Ahsan, Hamza) Department of Internal Medicine, Foundation
University Medical College, Islamabad, Pakistan
(Hurjkaliani, Singh) Department of Internal Medicine, Dow University of
Health Sciences, Karachi, Pakistan
(Jain) Department of Internal Medicine, All India Institute of Medical
Sciences (AIIMS), Jodhpur, India
(Bharadwaj) Faculty of Biology Medicine and Health, The University of
Manchester, Manchester, United Kingdom
(Daoud) Department of Internal Medicine, Bogomolets National Medical
University, Kyiv, Ukraine
(Sheikh) Department of Internal Medicine, University of New Mexico Health
Sciences Center, Albuquerque, NM, United States
Publisher
Elsevier B.V.
Abstract
Background: Transcatheter aortic valve replacement (TAVR) has
significantly advanced the treatment of severe aortic stenosis (AS),
particularly in elderly patients who often have coexisting coronary artery
disease (CAD). Chronic total occlusion (CTO), a severe form of CAD, may
negatively impact outcomes in TAVR patients, though data are limited. This
meta-analysis aims to evaluate the impact of CTO on TAVR outcomes.
 Method(s): A comprehensive literature search was conducted across
multiple electronic databases to identify studies comparing TAVR outcomes
in patients with and without CTO. Pooled risk ratios (RR) with 95 %
confidence intervals (CIs) were calculated using a random-effects model.
The primary outcome was all-cause mortality, with several secondary
endpoints also assessed. Result(s): Six studies involving a total of
331,159 TAVR patients were included in this meta-analysis. CTO was
associated with a significantly increased risk of in-hospital mortality
(RR: 1.24; 95 % CI: 1.01, 1.52; p = 0.04), acute myocardial infarction
(RR: 1.67; 95 % CI: 1.48, 1.89; p < 0.00001), acute kidney injury (RR:
1.46; 95 % CI: 1.37, 1.56; p < 0.00001), and vascular complications (RR:
1.47; 95 % CI: 1.28, 1.69; p < 0.00001). No significant differences were
observed in all-cause mortality (RR: 1.21; 95 % CI: 0.76, 1.93; p = 0.42),
stroke (RR: 1.09; 95 % CI: 0.91, 1.30; p = 0.37), or bleeding events (RR:
1.19; 95 % CI: 1.00, 1.41; p = 0.06). Conclusion(s): CTO poses a
significant risk in TAVR patients, particularly for in-hospital mortality
and acute myocardial infarction. A multidisciplinary approach is
recommended for these patients, with consideration given to
revascularization before TAVR. Further studies are needed to evaluate the
potential benefits of prior CTO-PCI. Copyright © 2024 The Authors

<29>
Accession Number
2036486483
Title
Transcatheter or surgical treatment of paravalvular leaks: A meta-analysis
of 13 studies and 2003 patients.
Source
IJC Heart and Vasculature. 56 (no pagination), 2025. Article Number:
101583. Date of Publication: February 2025.
Author
Improta R.; Di Pietro G.; Odeh Y.; Morena A.; Saade W.; D'Ascenzo F.;
Mancone M.; Miraldi F.
Institution
(Improta, Di Pietro, Saade, Mancone, Miraldi) Department of Clinical
Internal, Anesthesiology and Cardiovascular Sciences, Umberto I Hospital,
Sapienza University of Rome, Italy
(Odeh, Morena, D'Ascenzo) Division of Cardiology, Cardiovascular and
Thoracic Department, AOU Citta della Salute e della Scienza di Torino and
University of Turin, Italy
Publisher
Elsevier Ireland Ltd
Abstract
Background: Significant paravalvular leak is a rare but serious
complication of heart valve replacement, leading to symptomatic heart
failure and hemolysis. Due to the paucity of comparative data between
surgical and transcatheter paravalvular leak correction, we performed a
systematic review and meta-analysis of available studies. Method(s):
Studies comparing transcatheter and surgical treatment of paravalvular
leak were systematically identified. Short-term all-cause mortality was
the primary outcome. Technical and procedural success, 30-day persistence
of significant paravalvular leak, length of hospital stay and long-term
mortality, persistence of symptoms and paravalvular leak were the main
secondary endpoints. Result(s): Thirteen studies with 2003 patients
were included, treating in most of the cases a mitral prothesis.
Transcatheter closure was associated with lower short-term mortality rate
(30 days OR 0.28, 95 % CI 0.18-0.42, p < 0.001) compared to surgical
treatment. Technical and procedural success did not differ among the two
groups. 30-day and long-term rates of persistence of moderate or severe
paravalvular leak were higher in the transcatheter group (OR 3.56, 95 % CI
1.49-8.49, p = 0.004 and OR 2.20, 95 % CI 1.27-3.81, p = 0.005
respectively). Long-term death and re-hospitalization events did not
differ among the two treatment modalities. The mean difference in days of
length of stay was significantly lower in the transcatheter group (mean
difference -9.66, 95 % CI -12.37 to -6.94, p < 0.001). Conclusion(s):
Transcatheter closure of paravalvular leaks is associated with lower
short-term mortality rates but higher persistence of moderate-severe
paravalvular leak and heart failure symptoms at short and long-term
follow-up compared to surgical treatment. Copyright © 2024

<30>
Accession Number
2036321789
Title
Nontuberculous Mycobacterial Infective Endocarditis: A Systematic Review
of Clinical Characteristics and Outcomes.
Source
Open Forum Infectious Diseases. 11(12) (no pagination), 2024. Article
Number: ofae688. Date of Publication: 01 Dec 2024.
Author
Meena D.S.; Kumar D.; Bohra G.K.; Midha N.; Garg M.K.
Institution
(Meena, Kumar, Bohra, Midha, Garg) Division of Infectious Diseases,
Department of Internal Medicine, All India Institute of Medical Sciences,
Jodhpur, India
Publisher
Oxford University Press
Abstract
Background. Infective endocarditis (IE) due to nontuberculous mycobacteria
(NTM) is a rare infection, and several outbreaks have been reported in the
last 2 decades. However, the clinical spectrum is still poorly understood.
This systematic review aimed to evaluate the clinical characteristics and
outcomes in NTM IE. Methods. We searched the major electronic databases
(PubMed, Scopus, and Google Scholar) with appropriate keywords to December
2023. We included studies based on predefined diagnostic criteria, and
relevant data were collected on clinical presentation and treatment
outcomes. The study was registered with PROSPERO (CRD42023492577).
Results. A total of 97 studies were reviewed, encompassing 167 patients
with NTM IE. The earliest cases were reported in 1975, involving M
chelonae and M fortuitum. M chimaera was the most prevalent species
(38.9%), though rapidly growing NTM (RGM) were more common than
slow-growing NTM (SGM; 59.3% vs 40.7%). Disseminated NTM infection
occurred in 84% of cases, with bone marrow infiltration and osteomyelitis
as frequent manifestations. Prosthetic valves were the main risk factor,
present in 63.5% of cases. In native valve IE, nearly all cases (n = 27,
96%) were attributed to RGM. The overall mortality rate was 44.9%, with
conservative management without surgery associated with poorer outcomes
(66.7% vs 30.6%). Mortality was comparable between SGM and RGM IE,
although relapses were more common in SGM IE (17.6% vs 1.9%). Conclusions.
This review highlights the changing epidemiology of NTM IE with the
emergence of RGM IE. Disseminated infections in the setting of prosthetic
valves warrant NTM evaluation. The high mortality rate necessitates the
role of early surgery. Copyright © The Author(s) 2024.

<31>
[Use Link to view the full text]
Accession Number
2036267653
Title
Effectiveness of virtual reality in cardiac rehabilitation patients for
exercise capacity and negative emotions: A systematic review and
meta-analysis.
Source
Medicine (United States). 103(49) (pp e40812), 2024. Date of Publication:
06 Dec 2024.
Author
Zhang M.; Liu S.; Xiong X.; Liu M.; Wang Y.; Yang Y.; Xiang Q.
Institution
(Zhang, Liu, Xiong, Liu) Department of Nursing, The Second Affiliated
Hospital of Nanchang University, Jiangxi Medical College, Nanchang
University, Jiangxi, Nanchang, China
(Zhang, Liu, Liu, Wang, Yang, Xiang) School of Nursing, Jiangxi Medical
College, Nanchang University, Jiangxi, Nanchang, China
Publisher
Lippincott Williams and Wilkins
Abstract
Background: The significance of virtual reality (VR) technology as an
alternative or complementary modality to traditional cardiac
rehabilitation is of increasing interest. Numerous studies have examined
the effects of virtual reality technology in cardiac rehabilitation
patients, but the results have been inconsistent. Method(s): We
conducted a systematic search of the Cochrane Library, Web of Science,
PubMed, Embase, Scopus, ProQuest, OVID, CINAHL, SinoMed, CNKI, WanFang,
VIP Database, and ReadShow databases following the Program for Systematic
Review and Meta-Analysis guidelines. The search included studies published
up until June 30, 2024. The Cochrane Risk of Bias Tool was used to examine
the methodological quality of the included randomized controlled studies.
When feasible, a meta-analysis was performed to calculate the pooled
effects using Review Manager (version 5.3). Otherwise, narrative summaries
were performed. Result(s): A total of 11 studies with 1093 patients
were included. The results of systematic review and meta-analysis showed
that virtual reality technology improved patients' exercise capacity (mean
difference: 53.26, 95% confidence interval [CI]: 45.14-61.37; P<.00001);
anxiety (standardized mean difference [SMD]: -0.39, 95% CI: -0.69, -0.08,
P=.01); depression (SMD: -0.48, 95% CI: -0.79, -0.17; P=.003); stress
(SMD: -0.72, 95% CI: -1.03, -0.40; P<.00001); emotional tension (SMD:
-0.81, 95% CI: -1.15, -0.47; P<.00001); emotional tension (SMD: -0.64, 95%
CI: -0.98, -0.30; P=.0002), and intrapsychic stress (SMD: -0.56, 95% CI:
-0.90, -0.23; P=.0009). Conclusion(s): Virtual reality-based
interventions can be effective in improving patients' exercise capacity
and negative emotions. However, further research is needed to determine
the efficacy of VR for other clinical outcomes. Copyright © 2024
the Author(s).

<32>
Accession Number
2032638214
Title
The IMproving treatment decisions for Patients with AortiC stenosis
Through Shared Decision Making (IMPACT SDM) Study: study protocol for a
cluster randomized stepped wedge trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 820. Date of
Publication: December 2024.
Author
Sepucha K.; Elmariah S.; Valentine K.D.; Cavender M.A.; Chang Y.;
Devireddy C.M.; Dickert N.W.; Gama K.D.; Knoepke C.E.; Korngold E.;
Kumbhani D.J.; Matlock D.D.; Messenger J.C.; Strong S.; Thourani V.H.;
Nathan A.; Quader N.; Brescia A.A.
Institution
(Sepucha, Valentine, Chang) Division of General Internal Medicine,
Massachusetts General Hospital, Boston, MA, United States
(Sepucha, Valentine) Harvard Medical School, Boston, MA, United States
(Elmariah) Division of Cardiology, University of California San Francisco,
San Francisco, CA, United States
(Cavender) Division of Cardiology, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States
(Devireddy, Dickert) Division of Cardiology, Department of Medicine, Emory
University School of Medicine, Atlanta, United States
(Gama, Messenger) Division of Cardiology, Department of Medicine,
University of Colorado School of Medicine, Aurora, CO, United States
(Knoepke) Division of Cardiology, Adult and Child Center for Outcomes
Research and Delivery Science (ACCORDS), Colorado Program for
Patient-Centered Decisions, University of Colorado School of Medicine,
Aurora, United States
(Korngold) Division of Cardiology, Providence Heart Institute, Portland,
OR, United States
(Kumbhani) Division of Cardiology, UT Southwestern Medical Center, Dallas,
TX, United States
(Matlock) Division of Geriatric Medicine, Department of Medicine,
University of Colorado School of Medicine, Aurora, CO, United States
(Matlock) VA Eastern Colorado Geriatric Research Education and Clinical
Center, Denver, CO, United States
(Strong) Heart Valve Voice-US, Washington, DC, United States
(Thourani) Department of Cardiovascular Surgery, Marcus Valve Center,
Piedmont Heart Institute, Atlanta, GA, United States
(Nathan) Division of Cardiovascular Medicine, University of Pennsylvania,
Philadelphia, PA, United States
(Quader) Cardiovascular Division, Department of Medicine, Washington
University in St. Louis, St. Louis, MO, United States
(Brescia) Division of Cardiothoracic Surgery, Washington University in St.
Louis, St. Louis, MO, United States
Publisher
BioMed Central Ltd
Abstract
Background: The American College of Cardiology, American Heart
Association, and Centers for Medicare and Medicaid Services recommend
shared decision-making (SDM) for patients with severe aortic stenosis
choosing between transcatheter aortic valve replacement (TAVR) and
surgical aortic valve replacement (SAVR). Although tools such as patient
decision aids (DAs) and training in SDM have been shown to improve SDM,
implementation of SDM and DAs is limited. The IMproving treatment
decisions for Patients with AortiC stenosis Through Shared Decision Making
(IMPACT SDM) study aims to (1) determine the effectiveness of the
interventions (a DA and clinician SDM training) in achieving SDM (primary
outcome) and improving the quality of decisions about aortic valve
replacement, (2) determine the reach of the DAs and adoption of training,
and (3) explore potential mechanisms of effectiveness and implementation
at the patient-, clinician-, and clinic-level. Method(s): The study
is a hybrid type II effectiveness-implementation study using a cluster
randomized batched stepped wedge trial with 8 sites across the USA.
Eligible patients will be surveyed before and after visits with the heart
valve team; clinicians will be surveyed after visits. Reach of DAs and
adoption of training will be tracked. Clinicians will be interviewed
regarding barriers and facilitators to implementation. Discussion(s):
The IMPACT SDM Study seeks to provide evidence of the ability of the
interventions to improve SDM and decision quality, and also to shed light
on barriers and facilitators to SDM implementation to promote future
implementation efforts. Trial registration: ClinicalTrials.gov
NCT06171737. Registered on December 15, 2023. Copyright © The
Author(s) 2024.

<33>
Accession Number
2035257625
Title
Epinephrine Versus Dopamine in Children, What Is the Current Evidence and
What Do We Need? A Systematic Review and Meta-analysis.
Source
Journal of Pediatric Pharmacology and Therapeutics. 29(6) (pp 578-586),
2024. Date of Publication: 2024.
Author
Loomba R.S.; Patel R.D.; Villarreal E.G.; Farias J.S.; Flores S.
Institution
(Loomba, Patel) Division of Pediatric Cardiac Critical Care, Advocate
Children's Hospital, Oak Lawn, IL, United States
(Loomba) Department of Pediatrics, Chicago Medical School/Rosalind
Franklin University of Medicine and Science, Chicago, IL, United States
(Villarreal, Farias) Escuela de Medicina y Ciencias de la Salud,
Tecnologico de Monterrey, Monterrey, Mexico
(Flores) Section of Critical Care Medicine and Cardiology, Texas
Children's Hospital, Houston, TX, United States
(Flores) Department of Pediatrics, Baylor College of Medicine, Houston,
TX, United States
Publisher
Pediatric Pharmacy Advocacy Group, Inc.
Abstract
INTRODUCTION Pediatric patients often receive vasoactive agents following
cardiothoracic surgery or when in shock. The use of vasoactive agents
varies between different settings and has largely changed because of
anecdotal observations or small observational studies. Although vasoactive
agents are frequently used, there are limited studies in pediatric
populations comparing them to one another. The purpose of this systematic
review is to quantify the comparative effects of epinephrine and dopamine
while identifying gaps in knowledge. METHODS A systematic review of
published manuscripts was completed to identify full-text manuscripts in
English using PubMed, Embase, and Cochrane databases. Studies were
included if they included clinical data using dopamine and epinephrine in
different patients and included data for the same end points for patients
receiving epinephrine or dopamine. RESULTS A total of 5 studies with 397
patients were included. Of the included patients, 187 received epinephrine
and 210 received dopamine. The mean age for all the patients was 45
months. When all patient data were pooled, a significantly lower mortality
was associated with epinephrine compared with dopamine (risk ratio, 0.74;
95% CI, 0.55-0.99). When only neonatal data were pooled, epinephrine was
associated with a significantly higher average heart rate (10 bpm; 95% CI,
2.0-18.7) and a significantly lower average mean arterial blood pressure
(-2.5 mm Hg; 95% CI, -4.6 to -0.4). CONCLUSION Limited data are available
comparing dopamine to epinephrine in pediatric patients. The available
data demonstrate an apparent mortality benefit associated with the use of
epinephrine. Copyright © 2024, Pediatric Pharmacy Advocacy Group,
Inc.. All rights reserved.

<34>
Accession Number
2036362437
Title
Human placenta in vascular neurosurgery training: a comprehensive review
of laboratory models, possible exercises, and assessments for skills
improvement.
Source
Journal of Neurosurgical Sciences. 68(6) (pp 646-659), 2024. Date of
Publication: December 2024.
Author
Restelli F.; Mazzapicchi E.; Falco J.; Broggi M.; Vterano I.G.; Ferroli
P.; Acerbi F.
Institution
(Restelli, Mazzapicchi, Falco, Broggi, Acerbi) neurosurgical
revascularization unit, Department of neurosurgery, irccs carlo Besta
neurologic institute foundation, Milan, Italy
(Restelli, Mazzapicchi, Falco, Broggi, Acerbi) Microsurgical experimental
laboratory, irccs carlo Besta neurologic institute foundation, Milan,
Italy
(Restelli, Mazzapicchi, Falco, Broggi, Ferroli) skull Base and
neurovascular unit, Department of neurosurgery, irccs carlo Besta
neurologic institute foundation, Milan, Italy
(Acerbi) Department of Translational research and new Technologies in
Medicine and surgery, university of Pisa, Pisa, Italy
(Acerbi) neurosurgery Departm ent, azienda ospedaliero-universitaria
Pisana, Pisa, Italy
Publisher
Edizioni Minerva Medica
Abstract
INTRODUCTION: Simulation is increasingly recognized as an important tool
to enhance neurosurgical education. In this field, especially in
neurovascular surgery, human placenta (hPl) is being recognized as a
valuable training model because of its abundant availability, ethical
acceptance, and analogous vasculature with other vessels of the human
body. nevertheless, although a rising body of literature is witnessing a
renovated interest toward this "old" model, to date no comprehensive
reviews on the topics are available. Main objective of this paper is to
comprehensively review hPl use in neurovascular surgery training, focusing
on model preparation, type of possible exercises along with assessment
ools which can be used to check for trainees learning. eViDence
acQuisiTion: a systematic review of the pertinent literature was
performed, following PrisMa guidelines, searching the fol-owing key words
in "title/abstract" fields in only English-written works: "placenta and
neurosurgery." We focused on preclinical works concernng use of hPl models
in neurovascular surgery training. We included studies published in the
last 40 years, till December 31st, 2023. EVIDENCE SYNTHESIS: A
total of 950 scientific publications were initially screened, and 23
papers met the inclusion and exclusion criteria. in summary, the chorionic
surface of hPl may be used as a neurovascular gym where different
exercises can be performed. Placenta models can be produced with or
without the use of intravascular dyes and or/pumping systems to resemble a
beating-heart vascular system. The three main neurovascular surgical
fields where hPl is being considered to be highly simulative are: 1)
Sylvian fissure dissection; 2) aneurysm dissection and clipping; 3) bypass
training. Considering the simulative purpose, face, content and construct
validify of hPl model have been tested and verified by many authors,
although still few data are available regarding transfer/predictive
validity. Conclusion(s): This systematic review highlighted the
easiness of preparation and availability along with the strong didactical
meaning that he use of hPl-based models may have in the field of
neurovascular surgery training. In view of current progressive lowering of
surgical vascular cases and increasing technical demand related to their
management, further studies aimed to assess if this simulator could be
able to produce a earning effect and improve performance with continued
use are strongly needed. Copyright © 2024 eDiZioni MinerVa
MeDica.

<35>
Accession Number
2036411931
Title
Incidence and assessment of delirium following open cardiac surgery: A
systematic review and meta-Analysis.
Source
European Journal of Cardiovascular Nursing. 23(8) (pp 825-832), 2024. Date
of Publication: 01 Nov 2024.
Author
Petersson N.B.; Hansen M.H.; Hjelmborg J.V.B.; Instenes I.; Christoffersen
A.S.; Larsen K.L.; Schmidt H.; Riber L.P.S.; Norekval T.M.; Borregaard B.
Institution
(Petersson, Hansen, Christoffersen, Larsen, Riber, Borregaard) Department
of Cardiothoracic and Vascular Surgery, Odense University Hospital, J.B.
Winslows Vej 4, Odense 5000, Denmark
(Hjelmborg) Department of Public Health, Epidemiology, Biostatistics and
Biodemography, University of Southern Denmark, Odense C, Denmark
(Instenes, Norekval) Department of Heart Disease, Haukeland University
Hospital, Bergen, Norway
(Instenes, Norekval) Department of Clinical Science, University of Bergen,
Bergen, Norway
(Larsen, Riber, Borregaard) Faculty of Health Science, University of
Southern Denmark, Odense, Denmark
(Schmidt) Department of Anaesthesiology and Intensive Care, Odense
University Hospital, Odense, Denmark
(Borregaard) Department of Cardiology, Odense University Hospital, Odense,
Denmark
Publisher
Oxford University Press
Abstract
Aims: This systematic review and meta-Analysis sought (i) to provide an
overview of the incidence of delirium following open cardiac surgery and
(ii) to investigate how incidences of delirium are associated with
different assessment tools. Methods and Results: A systematic search
of studies investigating delirium following open cardiac surgery was
conducted in Medline (Ovid), EMBASE, PsycINFO, CiNAHL, and the Cochrane
Database. Only studies with patients diagnosed or screened with a
validated tool were included. Studies published from 2005-2021 were
included in the meta-Analysis. Of 7126 individual studies retrieved, 106
met the inclusion criteria for the meta-Analysis, hereof 31% of high
quality. The weighted pooled incidence of delirium following open cardiac
surgery across all studies was 23% (95% CI 20-26%), however we found a
considerable heterogeneity (I2 = 99%), which could not be explained by
subgroups or further sensitivity analyses. The most commonly applied
screening tool for delirium is CAM/CAM-ICU. The lowest estimates of
delirium were found by applying the Delirium Observation Scale (incidence
14%, 95% CI 8-20%), and the highest estimates in studies using 'other'
screening tools (Organic Brain Symptom Scale, Delirium Symptom Interview)
with a pooled incidence of 43% (95% CI 19-66%), however, only two studies
applied these. Conclusion(s): Delirium following open cardiac surgery
remains a complication with a high incidence of overall 23%, when applying
a validated tool for screening or diagnosis. Nevertheless, this systematic
review and meta-Analyses highlight the significant inconsistency in
current evidence regarding assessment tools and regimens. Registration:
Prospero CRD42020215519. Copyright © 2024 The Author(s).
Published by Oxford University Press on behalf of the European Society of
Cardiology. All rights reserved.

<36>
Accession Number
2032332692
Title
Totally Endoscopic Coronary Artery Bypass Graft: Systematic Review and
Meta-Analysis of Reconstructed Patient-Level Data.
Source
Innovations: Technology and Techniques in Cardiothoracic and Vascular
Surgery. 19(6) (pp 616-625), 2024. Date of Publication: November/December
2024.
Author
Zoupas I.; Manaki V.; Tasoudis P.T.; Karela N.-R.; Avgerinos D.V.; Mylonas
K.S.
Institution
(Zoupas, Manaki, Tasoudis, Karela) Cardiothoracic and Vascular Surgery
Working Group, Society of Junior Doctors, Athens, Greece
(Zoupas) Department of Cardiac Surgery, Hygeia Hospital, Athens, Greece
(Manaki) Department of Vascular Surgery, AHEPA University Hospital,
Thessaloniki, Greece
(Karela) Department of Neurosurgery, "Panagiotis & Aglaia Kyriakou"
Children's Hospital, Athens, Greece
(Avgerinos, Mylonas) Department of Cardiac Surgery, Onassis Cardiac
Surgery Center, Athens, Greece
(Mylonas) Department of Pediatric Cardiothoracic Surgery, University of
Rochester, NY, United States
Publisher
SAGE Publications Ltd
Abstract
Objective: The standard approach for coronary artery bypass grafting is
open surgery. Totally endoscopic coronary artery bypass has emerged as an
alternative for selected patients. This meta-analysis sought to evaluate
clinical outcomes with this emerging technique. Method(s): A
PRISMA-compliant search was performed up to December 14, 2022, in PubMed
(MEDLINE), Scopus, and Cochrane. Time-to-event data were reconstructed
using Kaplan-Meier curves from source literature. Result(s): A total
of 2,774 patients with symptomatic coronary artery disease underwent
totally endoscopic coronary artery bypass in 18 eligible studies. The mean
patient age was 63.2 +/- 12.3 years, and 77.5% (95% confidence interval
[CI]: 72.2% to 82.4%) of the included patients were males. The mean
operative time was 304.2 +/- 155 min, whereas the mean internal mammary
artery takedown time was 38.3 +/- 18.4 min. Of the patients, 4.7% (95% CI:
1.6% to 9.1%) required conversions to open surgery. The 30-day
complication rate was 5.9% (95% CI: 1.2% to 13.1%), whereas late
complications developed in 4.8% (95% CI: 1.9% to 8.5%) of the patients.
Freedom from major adverse cardiac events was 93.4% (95% CI: 85.3% to
94.8%) and 1-year, 5-year, and 10-year survival rates were 95.2%, 83.2%,
and 81.7%, respectively. Reintervention was required in 3.3% (95% CI: 2.3%
to 4.4%) of the cohort within a mean follow-up of 42.5 +/- 27.8 months.
 Conclusion(s): Totally endoscopic coronary artery bypass may be a
safe and viable alternative for selected patients with coronary artery
disease. Long-term follow-up will help define the place of robotic
endoscopic treatment in the armamentarium of myocardial
revascularization. Copyright © The Author(s) 2024.

<37>
[Use Link to view the full text]
Accession Number
2036328268
Title
ASCVD Risk Refinement with NT-proBNP for Statin Allocation among Low- and
Intermediate-Risk Individuals.
Source
Circulation. 150(25) (pp 2070-2072), 2024. Date of Publication: 17 Dec
2024.
Author
Pavlovic J.; Kavousi M.; Ikram M.K.; Ikram M.A.; Bos D.; Leening M.J.G.
Institution
(Pavlovic, Kavousi, Ikram, Ikram, Bos, Leening) Department of
Epidemiology, Erasmus Medical Center-University Medical Center Rotterdam,
Netherlands
(Ikram) Department of Neurology, Erasmus Medical Center-University Medical
Center Rotterdam, Netherlands
(Bos, Leening) Department of Radiology and Nuclear Medicine, Erasmus
Medical Center-University Medical Center Rotterdam, Netherlands
(Leening) Department of Cardiology, Erasmus Medical Center-University
Medical Center Rotterdam, Netherlands
(Bos) Department of Neuroscience, Katholieke Universiteit Leuven, Belgium
(Bos) Department of Clinical Epidemiology, Harvard Tseng-Hsi Chan School
of Public Health, Boston, MA, United States
Publisher
Lippincott Williams and Wilkins

<38>
Accession Number
2036419520
Title
Relative Blood Volume Monitoring during Continuous Renal Replacement
Therapy: A Prospective Observational Study.
Source
Blood Purification. 53(11-12) (pp 884-892), 2024. Date of Publication: 01
Dec 2024.
Author
Maeda A.; Baldwin I.; Spano S.; Chaba A.; Phongphithakchai A.; Pattamin
N.; Hikasa Y.; Bellomo R.; See E.
Institution
(Maeda, Baldwin, Spano, Chaba, Phongphithakchai, Pattamin, Hikasa,
Bellomo, See) Department of Intensive Care, Austin Hospital, Melbourne,
VIC, Australia
(Maeda) Department of Emergency and Critical Care Medicine, The University
of Tokyo Hospital, Tokyo, Japan
(Bellomo) Data Analytics Research and Evaluation (DARE) Centre, Austin
Hospital, Melbourne, Victoria, Australia
(Bellomo) ANZICS-Research Centre, Melbourne, VIC, Australia
(Bellomo) Monash University School and Public Health and Preventive
Medicine, Monash University, Melbourne, Victoria, Australia
(Bellomo) Department of Critical Care, University of Melbourne, Melbourne,
VIC, Australia
(See) Department of Intensive Care, Royal Melbourne Hospital, Melbourne,
VIC, Australia
Publisher
S. Karger AG
Abstract
Introduction: Hematocrit monitoring during continuous renal replacement
therapy (CRRT) allows the continuous estimation of relative blood volume
(RBV). This may enable early detection of intravascular volume depletion
prior to clinical sequelae. We aimed to investigate the feasibility of
extended RBV monitoring and its epidemiology during usual CRRT management
by clinicians unaware of RBV. Moreover, we studied the association between
changes in RBV and net ultrafiltration (NUF) rates. Method(s): In a
cohort of adult intensive care unit patients receiving CRRT, we
continuously monitored hematocrit and RBV using a pre-filter noninvasive
optical sensor. We analyzed temporal changes in RBV and investigated the
association between RBV change and NUF rates, using the classification of
NUF rates into low, moderate, or high based on predefined cut-offs.
 Result(s): We obtained >60,000 minute-by-minute measurements in
>1,000 CRRT hours in 36 patients. The median RBV change was negative
(decrease) in 69% of patients and the median peak change in RBV was -9.3%
(interquartile range: -3.9% to -14.3%). Moreover, the median RBV decreased
from baseline by >5% in 40.2% of measurements and by >10% in 20.6% of
measurements. Finally, RBV decreased significantly more when patients
received a high NUF rate (>1.75 mL/kg/ h) compared to low or moderate NUF
rates (5.32% vs. 1.93% or 1.97%, p < 0.001). Conclusion(s):
Continuous hematocrit and RBV monitoring during CRRT was feasible. RBV
decreased significantly during CRRT, and decreases were greater with
higher NUF rates. RBV monitoring may help optimize NUF management and
prevent the occurrence of intravascular volume depletion. Copyright
© 2024 S. Karger AG, Basel.

<39>
Accession Number
2036441020
Title
Effectiveness of the Individualized Self-Care Program Based on Orem's
Self-Care Theory: Impact on Learning Needs and Self-Care Behaviors
Following Coronary Artery Bypass Surgery - A Randomized Controlled Trial.
Source
Asian Nursing Research. 18(5) (pp 516-524), 2024. Date of Publication:
December 2024.
Author
Jamil Alkuwaisi M.; Alsaqri S.H.; AL-Rashidi A.M.; Ali Alshowkan A.;
Mostoles R.P.; Terence Ong Cornejo L.
Institution
(Jamil Alkuwaisi, Alsaqri, AL-Rashidi) Medical Surgical Department,
College of Nursing, University of Hail, Saudi Arabia
(Ali Alshowkan) Community Nursing Department, College of Nursing, Imam
Abdulrahman Bin Faisal University, Saudi Arabia
(Mostoles, Terence Ong Cornejo) Community Nursing Department, College of
Nursing, University of Hail, Saudi Arabia
Publisher
Korean Society of Nursing Science
Abstract
Purpose: This study aimed to investigate the specific learning needs of
patients within the experimental group after receiving the Individualized
Self-Care Program (ISCP) at two key time points: Time 2 (Day 2, Week 1)
and Time 3 (Day 15, Week 3). Furthermore, it aimed to compare the
effectiveness of the ISCP in improving self-care behavior between the
experimental group and the control group, which received standard health
education. Method(s): The study utilized a randomized controlled
trial (RCT) design and included a consecutive sample of 128 patients who
had undergone their first Coronary Artery Bypass Graft (CABG) procedure.
These patients were randomly divided into two groups: the experimental
group (n = 64) and the control group (n = 64). The experimental group
received an ISCP at Time 2 and Time 3 after being discharged, whereas the
control group received standard health education. Statistical analyses
included paired t-tests to assess differences in learning needs over time
and Repeated Measures Analysis of Variance (ANOVA) to evaluate the
effectiveness of the ISCP on self-care behavior. Result(s): A paired
t-test indicated a statistically significant difference in the total
number of learning needs identified within the experimental group between
Time 2 and Time 3 assessments. Patients in the experimental group
initially identified more learning needs at Time 2 (4.3 +/- 1.5), but
their knowledge significantly improved at Time 3, leading to fewer
learning needs (2.6 +/- 1.1). Furthermore, an ANOVA comparing the
experimental and control groups showed that the ISCP effectively improved
self-care behavior in the experimental group, with significantly greater
improvements compared to the control group, which received standard health
education. Conclusion(s): ISCP delivered in early recovery enhances
self-care behaviors and addresses postdischarge gaps. The study also
revealed that patients' learning needs change over time during home
recovery, emphasizing the importance of tailored self-care programs for
CABG patients after discharge. Trial registration: IRCT registration
number: ISRCTN96836216. Copyright © 2024

<40>
Accession Number
2036438656
Title
Preventing, identifying and managing myocardial injury after non cardiac
surgery - A narrative review.
Source
Current Opinion in Anaesthesiology. (no pagination), 2024. Date of
Publication: 2024.
Author
Wittmann M.; Dinc T.; Kunsorg A.; Marcucci M.; Ruetzler K.
Institution
(Wittmann, Dinc, Kunsorg) Department of Anesthesiology and Intensive Care
Medicine, University Hospital Bonn, Bonn, Germany
(Marcucci) Population Health Research Institute, Hamilton, Canada
(Marcucci) Clinical Epidemiology and Research Centre, Humanitas
University, IRCCS Humanitas Research Hospital, Milan, Italy
(Marcucci) Department of Health Research Methods, Evidence, and Impact,
McMaster University, Hamilton, Canada
(Ruetzler) Center for OUTCOMES RESEARCH, Department of Anesthesiology,
UTHealth, Houston, TX, United States
(Ruetzler) Division of Multispecialty Anesthesiology, Department of
General Anesthesiology, Cleveland Clinic, Cleveland, OH, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of review There is mounting and convincing evidence that patients
with postoperative troponin elevation, with or without any clinical
symptoms, are at higher risk for both, short- and long-term morbidity and
mortality. Myocardial injury after noncardiac surgery (MINS) is a
relatively newly described syndrome, and the pathogenesis is not fully
understood yet. MINS is now an established syndrome and multiple
guidelines address potential etiologies, triggers, as well as preventive
and management strategies. Recent findings Surveillance in high-risk
patients is required, as most MINS would otherwise be missed. There is no
reliable and established preventive strategy, but several potentially
avoidable triggers like hypotension, pain and anemia have been identified.
Managing patients with MINS postoperatively includes minimizing triggers
(such as hemodynamic abnormalities and anemia) that can continue the
damage. Long-term pharmacologic strategies include beta-blockers, statins,
antiplatelet agents, and anticoagulation. Summary MINS affects up to 20%
of surgical patients, remains clinically mostly silent, but is associated
with elevated morbidity and mortality. A multidisciplinary approach, that
includes involvement of anesthesiologists, for the prevention, diagnosis,
and treatment of MINS is recommended. Copyright © 2024 Wolters
Kluwer Health, Inc. Unauthorized reproduction of this article is
prohibited.

<41>
Accession Number
2036493670
Title
Comparison of Outcomes between Fractional-Flow-Reserve- and
Angiography-Directed Intervention in Non-ST Elevation Acute Coronary
Syndrome.
Source
Journal of the College of Physicians and Surgeons Pakistan. 29(3) (pp
268-273), 2019. Date of Publication: March 2019.
Author
Jianjun Y.; Xiaohua P.; Xuemei T.; Gang H.; Hailong W.
Institution
(Jianjun, Xiaohua, Xuemei, Hailong) Department of Cardiology, Heart
Center, Chongqing Three Gorges Central Hospital, Chongqing, Wanzhou
404000, China
(Gang) Department of Cardiology, Suining Central Hospital, Sichuan,
Suining 629000, China
Publisher
College of Physicians and Surgeons Pakistan
Abstract
Among the sick patients suffering from non-ST segment elevation acute
coronary syndrome (NSTEACS), the accuracy of fractional flow reserve
(FFR)-directed percutaneous coronary intervention (PCI) or coronary artery
bypass grafting (CABG) is still ambiguous. Studies were obtained from
PubMed, Embase, Wanfang Data, and Cochrane Library electronic statistics
from their initiation up to April 2018, to explore the differences between
the FFR-directed approach and the coronary angiography (CA)/stress
perfusion scintigraphy (SPS)-directed approach in the outcomes of NSTACS
patients. Odds ratio was determined for individual studies, quality
assessments, heterogeneity, and publishing bias analyses. In total, there
were 5 studies involving 1,366 patients (606 FFR patients and 760 CA
patients). Compared with CA, the collection of the studies indicated that
FFR had a lower incidence of myocardial infarction (MI) (OR, 0.61; 95% CI:
0.39-0.96; p <0.05). However, none showed important disparities in main
adverse cardiovascular events (MACE, OR, 0.74; 95% CI: 0.53-1.03; p=0.07),
all-cause death rate (OR, 0.83; 95% CI: 0.45-1.54; p = 0.56), and major
bleeding (OR, 1.00; 95%CI: 0.25-4.03; p=1). The FFR-directed management of
patients with NSTEACS had a close relationship with the serious decrease
in incidence of MI without statistical significance. Future large-scale
research, which is carried out at random and with a control, is needed to
confirm these conclusions. Copyright © 2019 College of Physicians
and Surgeons Pakistan. All rights reserved.

<42>
Accession Number
646049514
Title
Transplant Trial Watch.
Source
Transplant international : official journal of the European Society for
Organ Transplantation. 37 (pp 14062), 2024. Date of Publication: 2024.
Author
O'Callaghan J.M.; Knight S.R.; Rana Magar R.
Institution
(O'Callaghan, Knight, Rana Magar) Centre for Evidence in Transplantation,
Nuffield Department of Surgical Sciences, University of Oxford, Oxford,
United Kingdom
(O'Callaghan) University Hospitals Coventry and Warwickshire, Coventry,
United Kingdom
(Knight) Oxford Transplant Centre, Churchill Hospital, Oxford, United
Kingdom

<43>
Accession Number
2032665712
Title
Using artificial intelligence to predict post-operative outcomes in
congenital heart surgeries: a systematic review.
Source
BMC Cardiovascular Disorders. 24(1) (no pagination), 2024. Article Number:
718. Date of Publication: December 2024.
Author
Mohammadi I.; Rajai Firouzabadi S.; Hosseinpour M.; Akhlaghpasand M.;
Hajikarimloo B.; Zeraatian-Nejad S.; Sardari Nia P.
Institution
(Mohammadi, Rajai Firouzabadi, Hosseinpour, Akhlaghpasand, Hajikarimloo,
Zeraatian-Nejad) Cardiovascular Surgery Research and Development
Committee, Iran University of Medical Sciences (IUMS), PO box 14665-354,
Tehran, Iran, Islamic Republic of
(Rajai Firouzabadi) Student Research Committee, School of Medicine, Shahid
Beheshti University of Medical Sciences, Teheran, Iran, Islamic Republic
of
(Akhlaghpasand, Zeraatian-Nejad) Department of Surgery, Surgery Research
Center, School of Medicine, Rasool-E Akram Hospital, Iran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Sardari Nia) Department of Cardiothoracic Surgery, Maastricht University
Medical Centre, Maastricht, Netherlands
(Sardari Nia) Foundation Heart Team Academy, Maastricht, Netherlands
Publisher
BioMed Central Ltd
Abstract
Introduction: Congenital heart disease (CHD) represents the most common
group of congenital anomalies, constitutes a significant contributor to
the burden of non-communicable diseases, highlighting the critical need
for improved risk assessment tools. Artificial intelligence (AI) holds
promise in enhancing outcome predictions for congenital cardiac surgery.
This study aims to systematically review the utilization of AI in
predicting post-operative outcomes in this population. Method(s):
Following PRISMA guidelines, a comprehensive search of Pubmed, Scopus, and
Web of Science databases was conducted. Two independent reviewers screened
articles based on predefined criteria. Included studies focused on AI
models predicting various post-operative outcomes in congenital heart
surgery. Result(s): The review included 35 articles, primarily
published within the last four years, indicating growing interest in AI
applications. Models predominantly targeted mortality and survival (n =
16), prolonged length of hospital or ICU stay (n = 7), postoperative
complications (n = 6), prolonged mechanical ventilatory support time (n =
4), with additional focus on specific outcomes such as peri-ventricular
leucomalacia (n = 2) and malnutrition (n = 1). Performance metrics, such
as area under the curve (AUC), ranged from 0.52 to 0.997. Notably, these
AI models consistently outperformed traditional risk stratification
categories. For instance, in assessing the risk of morbidity and
mortality, the AI models demonstrated superior performance compared to
conventional methods. Conclusion(s): AI-driven prediction models show
significant promise in improving outcome predictions for congenital heart
surgery. They surpass traditional risk prediction tools not only in
immediate postoperative risks but also in long-term outcomes such as
1-year survival and malnutrition. Further studies with robust external
validation are necessary to assess the practical applicability of these
models in clinical settings. The protocol of this review was prospectively
registered on PROSPERO (CRD42024550942). Copyright © The
Author(s) 2024.

<44>
Accession Number
2036505119
Title
Remote ischemic preconditioning and cognitive dysfunction following
coronary artery bypass grafting: A systematic review and meta-analysis of
randomized controlled trials.
Source
Saudi Journal of Anaesthesia. 18(2) (pp 187-193), 2024. Date of
Publication: 2024.
Author
Siburian R.; Fadillah R.; Altobaishat O.; Umar T.P.; Dilawar I.; Nugroho
D.T.
Institution
(Siburian) Research Unit, Jakarta Heart Center, Jakarta, Indonesia
(Fadillah) Department of Medical Profession, Faculty of Medicine,
Universitas Sriwijaya, Palembang, Indonesia
(Altobaishat) Faculty of Medicine, Jordan University of Science and
Technology, Irbid, Jordan
(Umar) UCL Centre for Nanotechnology and Regenerative Medicine, Division
of Surgery and Interventional Science, University College London, London,
United Kingdom
(Dilawar, Nugroho) Division of Cardiothoracic Surgery, Jakarta Heart
Center, Jakarta, Indonesia
Publisher
Wolters Kluwer Medknow Publications
Abstract
Introduction: Postoperative cognitive dysfunction (POCD) is a common
neurological issue following cardiopulmonary bypass (CPB)-assisted heart
surgery. Remote ischemic preconditioning (RIPC) increases the tolerance of
vital organs to ischemia/reperfusion injury, leading to reduced brain
injury biomarkers and improved cognitive control. However, the exact
mechanisms underlying RIPC's neuroprotective effects remain unclear. This
systematic review aimed to explore the hypothesis that RIPC lowers
neurocognitive dysfunction in patients undergoing CPB surgery.
 Method(s): All relevant studies were searched in PubMed,
ScienceDirect, EBSCOhost, Google Scholar, Semantic Scholar, Scopus, and
Cochrane Library database. Assessment of study quality was carried out by
two independent reviewers individually using the Cochrane Risk of Bias
(RoB-2) tool. Meta-analysis was performed using a fixed-effect model due
to low heterogeneity among studies, except for those with substantial
heterogeneity. Result(s): A total of five studies with 1,843
participants were included in the meta-analysis. RIPC was not associated
with reduced incidence of postoperative cognitive dysfunction (five RCTs,
odds ratio [OR: ] 0.79, 95% confidence interval [CI]: 0.56-1.11) nor its
improvement (three RCTs, OR: 0.80, 95% CI: 0.50-1.27). In addition, the
analysis of the effect of RIPC on specific cognitive function tests found
that pooled SMD for RAVLT 1-3 and RAVLT LT were -0.07 (95% CI: -0.25,012)
and -0.04 (95% CI: -0.25-0.12), respectively, and for VFT semantic and
phonetic were -0.15 (95% CI: -0.33-0.04) and 0.11 (95% CI: -0.40-0.62),
respectively. Conclusion(s): The effect of RIPC on cognitive
performance in CABG patients remained insignificant. Results from previous
studies were unable to justify the use of RIPC as a neuroprotective agent
in CABG patients. Copyright © 2024 Saudi Journal of Anesthesia.

<45>
Accession Number
2036443505
Title
Fasting vs. no fasting prior to catheterization laboratory procedures: the
SCOFF trial.
Source
European Heart Journal. 45(47) (pp 4990-4998), 2024. Date of Publication:
14 Dec 2024.
Author
Ferreira D.; Hardy J.; Meere W.; Butel-Simoes L.; Sritharan S.; Ray M.;
French M.; McGee M.; O'Connor S.; Whitehead N.; Turner S.; Healey P.;
Davies A.; Morris G.; Jackson N.; Barlow M.; Ford T.; Leask S.; Oldmeadow
C.; Attia J.; Sverdlov A.; Collins N.; Boyle A.; Wilsmore B.
Institution
(Ferreira, Hardy, Butel-Simoes, Sritharan, Ray, French, Turner, Davies,
Morris, Jackson, Barlow, Sverdlov, Collins, Boyle, Wilsmore)
Cardiovascular Department, John Hunter Hospital, Lookout Road, New Lambton
Heights, Newcastle, NSW 2305, Australia
(Ferreira, Attia, Sverdlov, Collins, Boyle, Wilsmore) School of Medicine
and Public Health, Newcastle University, University Drive, Callaghan,
Newcastle, NSW 2308, Australia
(Ferreira, Leask, Oldmeadow, Attia, Sverdlov, Collins, Boyle) Hunter
Medical Research Institute, Lot 1, Kookaburra Circuit, New Lambton
Heights, Newcastle, NSW 2305, Australia
(Meere) Department of Cardiology, Gosford Hospital, Gosford, Australia
(McGee, O'Connor, Ford) Department of Medicine, Tamworth Rural Referral
Hospital, Tamworth, NSW, Australia
(Whitehead) Department of Cardiology, Calvary Mater Hospital, Newcastle,
NSW, Australia
(Healey) Department of Anaesthesia, John Hunter Hospital, Newcastle, NSW,
Australia
Publisher
Oxford University Press
Abstract
Background and Aims: Current guidelines recommend 6 h of solid food and 2
h of clear liquid fasting for patients undergoing cardiac procedures with
conscious sedation. There are no data to support this practice, and
previous single-centre studies support the safety of removing fasting
requirements. The objective of this study was to determine the
non-inferiority of a no-fasting strategy to fasting prior to cardiac
catheterization procedures which require conscious sedation.
 Method(s): This is a multicentre, investigator-initiated,
non-inferiority, randomized trial conducted in Australia with a
prospective open-label, blinded endpoint design. Patients referred for
coronary angiography, percutaneous coronary intervention, or cardiac
implantable electronic device (CIED)-related procedures were enrolled.
Patients were randomized 1:1 to fasting as normal (6 h solid food and 2 h
clear liquid) or no-fasting requirements (encouraged to have regular meals
but not mandated to do so). Recruitment occurred from 2022 to 2023. The
primary outcome was a composite of aspiration pneumonia, hypotension,
hyperglycaemia, and hypoglycaemia assessed with a Bayesian approach.
Secondary outcomes included patient satisfaction score, new ventilation
requirement (non-invasive and invasive), new intensive care unit
admission, 30-day readmission, 30-day mortality, 30-day pneumonia.
 Result(s): A total of 716 patients were randomized with 358 in each
group. Those in the fasting arm had significantly longer solid food
fasting (13.2 vs. 3.0 h, Bayes factor >100, indicating extreme evidence of
difference) and clear liquid fasting times (7.0 vs. 2.4 h, Bayes factor
>100). The primary composite outcome occurred in 19.1% of patients in the
fasting arm and 12.0% of patients in the no-fasting arm. The estimate of
the mean posterior difference in proportions with credibility interval
(CI) in the primary composite outcome was -5.2% (95% CI -9.6 to -.9),
favouring no fasting. This result confirms the non-inferiority (posterior
probability >99.5%) and superiority (posterior probability 99.1%) of no
fasting for the primary composite outcome. The no-fasting arm had improved
patient satisfaction scores with a posterior mean difference of 4.02
points (95% CI 3.36-4.67, Bayes factor >100). Secondary outcome events
were observed to be similar. Conclusion(s): In patients undergoing
cardiac catheterization and CIED-related procedures, no fasting was
non-inferior and superior to fasting for the primary composite outcome of
aspiration pneumonia, hypotension, hyperglycaemia, and hypoglycaemia.
Patient satisfaction scores were significantly better with no fasting.
This supports removing fasting requirements for patients undergoing
cardiac catheterization laboratory procedures that require conscious
sedation. Copyright © 2024 The Author(s). Published by Oxford
University Press on behalf of the European Society of Cardiology. All
rights reserved.

<46>
Accession Number
2032655344
Title
Effect of transcutaneous electro-stimulation in postoperative
rehabilitation pain treatment in thoracic surgery: a randomized clinical
trial.
Source
Trials. 25(1) (no pagination), 2024. Article Number: 839. Date of
Publication: December 2024.
Author
Alamo-Arce D.D.; Lopez-Fernandez D.; Medina-Ramirez R.; Vilchez-Barrera
M.; Etopa-Bitata P.; del Pino Quintana-Montesdeoca M.; Baez-Suarez A.;
Freixinet J.L.
Institution
(Alamo-Arce, Lopez-Fernandez, Medina-Ramirez, Vilchez-Barrera,
Baez-Suarez) Physical Therapy, University of Las Palmas de Gran Canaria,
Las Palmas, Spain
(Etopa-Bitata, del Pino Quintana-Montesdeoca, Freixinet) University of Las
Palmas de Gran Canaria, Las Palmas, Spain
Publisher
BioMed Central Ltd
Abstract
Background: Chest pain is one of the most difficult problems to solve
after thoracic surgery. Its correct control is often quite difficult,
which can cause complications due to an ineffective cough and superficial
respiratory movements. Method(s): This study has been designed with
the purpose of studying the value of transcutaneous electrical stimulation
(TENS) in the postoperative pain rehabilitation of thoracotomy. A
prospective and randomized study has been developed. The patients (n =
109) have been treated after hospital discharge with physiotherapy for 3
weeks. Three groups have been established: experimental (n = 37), control
(n = 35), and placebo (n = 37), experimental and placebo including the
application of TENS during the physiotherapy protocol. Postoperative pain
(McGill test) and spirometry have been studied before and after treatment.
 Result(s): The largest between-group discrepancy occurred between the
experimental and control groups, 16.77 points (p < 0.001). Spirometry has
shown an improvement in FVC (27.11%) and FEV1 (28.68%) (p < 0.001) in the
experimental group, which was statistically significant compared to the
other groups. Conclusion(s): The use of TENS, as an adjunctive
treatment to physiotherapy, leads to an improvement in pain control and
spirometry values in patients after thoracic surgery, without producing
side effects with the technique. These findings provide physiological
evidence for the use of TENS in post-pulmonary surgery and may form the
basis for the development of pain managed-based programs in clinics and
hospitals. Trial registration: NCT04964973 (ClinicalTrials.gov). First
registration: July 16, 2021. Protocol:
https://clinicaltrials.gov/study/NCT04964973. Copyright © The
Author(s) 2024.

<47>
Accession Number
2036565510
Title
Fate of Abstracts Presented at Annual Meetings of The Society of Thoracic
Surgeons From 2015 to 2019.
Source
Annals of Thoracic Surgery. (no pagination), 2024. Date of Publication:
2024.
Author
Valdes C.A.; Bilgili A.; Stinson G.; Sharaf R.M.; Sharaf O.M.; Brennan Z.;
Jimenez-Contreras F.; Peek G.J.; Bleiweis M.S.; Beaver T.M.; Jacobs J.P.
Institution
(Valdes, Bilgili, Stinson, Sharaf, Sharaf, Brennan, Jimenez-Contreras,
Peek, Bleiweis, Beaver, Jacobs) Department of Surgery, University of
Florida College of Medicine, Gainesville, FL, United States
(Brennan) Department of Cardiac Surgery, Smidt Heart Institute, Cedars
Sinai Medical Center, Los Angeles, California, United States
Publisher
Elsevier Inc.
Abstract
Background: Society of Thoracic Surgeons (STS) Annual Meetings provide
opportunities to disseminate cardiothoracic research. We assessed rates of
publication of STS abstracts as manuscripts in peer reviewed journals over
5 years and determined factors associated with successful publication.
 Method(s): The STS "Annual Meeting Archive" was searched online for
abstract books from STS Annual Meetings from 2015 to 2019. Abstract books
were reviewed for information about presented abstracts. PubMed and Google
were then searched to identify corresponding peer reviewed journal
publications. Result(s): There were 1451 abstracts presented at STS
Annual Meetings from 2015 to 2019. The overall publication rate of
accepted abstracts as manuscripts in peer reviewed journals was 1097 of
1451 (75.60%). Most published manuscripts were published in The Annals of
Thoracic Surgery (750 of 1097 [68.37%]). Median duration between abstract
presentation and peer reviewed journal publication was 313 days
(interquartile range [IQR], 212.5-458 days). Only 29 of 1451 abstracts
(2.00%) won an award, and all 29 of these award-winning abstracts were
published as a manuscript. Oral presentation was associated with increased
odds of publication compared with a poster presentation (odds ratio, 1.28;
95% CI, 1.04-1.71; P = .021). Median 5-year impact factor of peer reviewed
journals containing these manuscripts was 5.04 (IQR, 5.04-5.04), and
corresponding manuscripts were cited a median of 4 times (IQR, 1-9 times).
Overall, 836 of 1097 (76.20%) of manuscripts published in peer reviewed
scientific journals had a corresponding North American author.
 Conclusion(s): STS Annual Meetings are a forum for the presentation
of high-quality research. The rate of publication of accepted STS
abstracts as manuscripts in peer reviewed journals is >75%, comparing
favorably with national meetings of other surgical societies, and more
than two-thirds of published manuscripts are published in STS's official
journal. Copyright © 2024 The Society of Thoracic Surgeons

<48>
Accession Number
2036564735
Title
Management of heart disease in renal transplant recipients: a national
Delphi survey-based SET/SEC/SEN consensus document.
Source
Revista Espanola de Cardiologia. (no pagination), 2024. Date of
Publication: 2024.
Author
Garcia-Cosio M.D.; Cruzado J.M.; Farrero M.; Blasco Peiro M.T.; Crespo M.;
Delgado Jimenez J.F.; Diaz Molina B.; Fernandez Rivera C.; Garrido Bravo
I.P.; Lopez Jimenez V.; Melilli E.; Mirabet Perez S.; Perez Tamajon M.L.;
Rangel Sousa D.; Rodrigo Calabia E.; Hernandez Marrero D.
Institution
(Garcia-Cosio) Hospital Universitario 12 de Octubre, Instituto de
Investigacion Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
(Garcia-Cosio, Mirabet Perez) Centro de Investigacion Biomedica en Red de
Enfermedades Cardiovasculares (CIBERCV), Spain
(Cruzado) Servicio de Nefrologia, Hospital Universitario de Bellvitge,
Instituto de Investigacion Biomedica de Bellvitge (IDIBELL), Universidad
de Barcelona, Barcelona, Spain
(Farrero) Hospital Clinic, Barcelona, Spain
(Blasco Peiro) Hospital Universitario Miguel Servet, Zaragoza, Spain
(Crespo) Servicio de Nefrologia, Hospital del Mar, Instituto de
Investigaciones Medicas Hospital del Mar, National Network for Kidney
Research RICORS2040 RD21/0005/0022, Barcelona, Spain
(Delgado Jimenez) Hospital Universitario 12 de Octubre, Instituto de
Investigacion Sanitaria Hospital 12 de Octubre (imas12), Universidad
Complutense de Madrid, Madrid, Spain
(Diaz Molina) Hospital Universitario Central de Asturias, Asturias,
Oviedo, Spain
(Fernandez Rivera) Servicio de Nefrologia, Complexo Hospitalario
Universitario A Coruna, A Coruna, Spain
(Garrido Bravo) Hospital Clinico Universitario Virgen de la Arrixaca,
Murcia, El Palmar, Spain
(Lopez Jimenez) Servicio de Nefrologia, Hospital Regional Universitario de
Malaga, National Network for Kidney Research RICORS2040 RD21/0005/0012,
Instituto Biomedico de Investigacion de Malaga (IBIMA), Universidad de
Malaga, Malaga, Spain
(Melilli) Servicio de Nefrologia, Hospital Universitario de Bellvitge,
Barcelona, Spain
(Mirabet Perez) Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
(Perez Tamajon) Servicio de Nefrologia, Complejo Hospitalario
Universitario de Canarias, Santa Cruz de Tenerife, Spain
(Rangel Sousa) Hospital Universitario Virgen del Rocio, Sevilla, Spain
(Rodrigo Calabia) Servicio de Nefrologia, Hospital Universitario Marques
de Valdecilla, Instituto de Investigacion Valdecilla (IDIVAL), Cantabria,
Santander, Spain
(Hernandez Marrero) Servicio de Nefrologia, Hospital Universitario de
Canarias, Santa Cruz de Tenerife, National Network for Kidney Research
RICORS2040 RD21/0005/0012, Instituto de Tecnologias Biomedicas,
Universidad de La Laguna, Santa Cruz de Tenerife, Spain
Publisher
Ediciones Doyma, S.L.
Abstract
Renal transplantation improves the survival and quality of life of
patients with end-stage renal disease. Cardiovascular disease is the
leading cause of morbidity and mortality in renal transplant recipients.
The bidirectional relationship between renal and heart disease creates a
unique clinical scenario that demands a comprehensive and personalized
approach. This expert consensus, drafted by the Spanish Society of
Transplantation, the Spanish Society of Cardiology, and the Spanish
Society of Nephrology, aims to assess current practices and propose
strategies for the management of heart disease in renal transplant
recipients. A panel of Spanish nephrologists and cardiologists with
expertise in renal and heart transplantation reviewed the scientific
evidence concerning the current management of heart disease in renal
transplant recipients. Subsequently, consensus statements were created
through a 2-round Delphi methodology, resulting in 30 statements covering
key topics such as the identification of renal transplant candidates, the
management of heart disease in renal transplant recipients, and
eligibility for combined heart-kidney transplantation in patients with
both end-stage renal disease and cardiac disease. These consensus
statements provide expert guidance for the management of heart disease in
renal transplant recipients, an area where published clinical evidence
remains limited. Copyright © 2024 Sociedad Espanola de
Cardiologia

<49>
Accession Number
2032112115
Title
Incidence of Infective Endocarditis Post-TPVR with MELODY Valve in
Pediatric Patients: A Systematic Review and Meta-Analysis.
Source
Current Cardiology Reviews. (no pagination), 2024. Date of Publication:
2024.
Author
Veldurthy S.; Shrivastava D.; Majeed F.; Ayaz T.; Munir A.; Haider A.;
Mylavarapu M.
Institution
(Veldurthy) Department of Pediatrics, Mediciti Institute of Medical
Sciences, Telangana, India
(Shrivastava) Department of Anesthesia, University of Minnesota,
Minneapolis, United States
(Majeed) Department of Medicine, Pakistan Medical and Dental Council,
Islamabad, Pakistan
(Ayaz) Department of Medicine, Baqai Medical University, Karachi, Pakistan
(Munir) Department of Anesthesia, Mayo Hospital, Lahore, Pakistan
(Haider) Department of Allied Health Sciences, The University of Lahore,
Gujrat, Pakistan
(Mylavarapu) Department of Public Health, Adelphi University, NY, United
States
Publisher
Bentham Science Publishers
Abstract
Introduction: Infective Endocarditis (IE) has emerged to be one of the
most impactful adverse complications post-transcatheter procedures,
especially Transcatheter Pulmonary Valve Replacement (TPVR). We conducted
a systematic review and meta-analysis with the aim of identifying the
incidence of IE post-TPVR with the MELODY valve in the pediatric
population. Method(s): A comprehensive literature search was
performed across several prominent databases, including PubMed/MEDLINE,
SCOPUS, and Science Direct. Studies compared the clinical outcomes of
pediatric patients who received TPVR using the MELODY valve. Data
extraction was done for variables like the total pediatric patient
population that underwent TPVR with MELODY valve, mean age, the sex of the
patients, the incidence rate of IE following the procedure, and the
duration between the procedure and the occurrence of IE. Inverse Variance
was used to estimate the incidence of IE in patients who underwent TPVR
with respective 95% confidence interval (CI). Result(s): In total, 4
studies with 414 pediatric patients who underwent TPVR using the MELODY
valve were included in the study. The mean age of the study population was
12.7 +/- 3.11 years. The pooled incidence of IE following TPVR with MELODY
valve in the pediatric population was 17.70% (95% Cl 3.84-31.55;
p<0.00001). Additionally, the mean length of duration to develop IE
following TPVR with MELODY valve in the pediatric population was 2.18
years (95% Cl 0.35-4.01; p<0.00001). Conclusion(s): Our meta-analysis
reveals that IE post-TPVR with MELODY valve in pediatric patients is a
significant complication, clinically and statistically. Further research
needs to be done to understand the risk factors and develop better
management strategies. Copyright © 2024 Bentham Science
Publishers.

<50>
Accession Number
646049677
Title
Do Extended Reality Interventions Benefit Patients Undergoing Elective
Cardiac Surgical and Interventional Procedures? A Systematic Review and
Meta-analysis.
Source
Journal of clinical nursing. (no pagination), 2024. Date of Publication:
12 Dec 2024.
Author
Harris E.; Fenton S.; Stephenson J.; Ewart F.; Goharinezhad S.; Lee H.;
Astin F.
Institution
(Harris, Ewart, Goharinezhad, Astin) School of Health, Wellbeing and
Social Care, Faculty of Wellbeing, Education and Language Studies, Open
University, Milton Keynes, United Kingdom
(Fenton, Lee) School of Computing and Engineering, University of
Huddersfield, Huddersfield, United Kingdom
(Stephenson) School of Human and Health Sciences, University of
Huddersfield, Huddersfield, United Kingdom
Abstract
BACKGROUND: Extended reality (XR) interventions have the potential to
benefit patients undergoing elective cardiac surgical and interventional
procedures. However, there are no systematic reviews with meta-analyses to
guide clinical care. AIM: To critically evaluate the evidence on the
effectiveness of XR interventions on patient anxiety and pain and other
associated outcomes. DESIGN: Systematic review and meta-analysis following
the PRISMA 2020 statement. DATA SOURCES: A systematic search of five
databases (CENTRAL, CINAHL, MEDLINE, PsycInfo, Scopus) from inception to
July 2023. METHOD(S): Screening and data extraction was conducted
independently by multiple reviewers. Stata (Version 17) was used to
conduct meta-analyses for patient anxiety and pain. Secondary patient
outcomes were summarised in a synthesis. The Cochrane Risk of Bias
(Version 2) tool was applied to trials and the NHLBI Study Quality
Assessment tools to all other study designs. RESULT(S): Of the 3372
records identified, 22 were included, 10 of which were eligible for
inclusion in the meta-analyses. Fifty-seven percent of randomised trials
were rated as high risk of bias. Virtual reality (VR) was the only XR
technology evaluated. VR significantly reduced pre-procedural anxiety
(standardised mean difference: -1.29; 95% confidence interval-1.96, -0.62,
p<0.001), and peri-procedural anxiety (standardised mean difference:
-0.50; 95% confidence interval-0.83, -0.18, p<0.003) but did not reduce
pain levels, compared with usual care. VR increased pre-procedural
knowledge and postsurgical physical and pulmonary function. VR
interventions may also improve emotional wellbeing, care delivery and
physiological outcomes, but evidence was inconsistent. CONCLUSION(S):
XR potentially benefits cardiac patients undergoing elective invasive
procedures and surgery by reducing pre- and peri-procedural anxiety and
increasing procedural knowledge and physical function. RELEVANCE TO
CLINICAL PRACTICE: Cardiac nurses' role can be supported by VR
interventions to improve the patient experience and several aspects of
patient care. PATIENT OR PUBLIC CONTRIBUTION: Not applicable as this is a
systematic review. Copyright © 2024 The Author(s). Journal of
Clinical Nursing published by John Wiley & Sons Ltd.

<51>
Accession Number
646042851
Title
Transcatheter Aortic Valve Replacement in Heart Failure, Reduced Ejection
Fraction, and Moderate Aortic Stenosis.
Source
Journal of the American College of Cardiology. (no pagination), 2024.
Date of Publication: 03 Dec 2024.
Author
O'Gara P.T.
Institution
(O'Gara) Division of Cardiovascular Medicine, Brigham and Women's
Hospital, Harvard Medical School, Boston, MA, United States

<52>
Accession Number
2035240815
Title
Predictive Performance of Artificial intelligence Models on Heart and Lung
Posttransplant Health Outcomes: A Systematic Review.
Source
Experimental and Clinical Transplantation. 22(11) (pp 823-833), 2024. Date
of Publication: November 2024.
Author
Sargiotis G.C.; Sergentanis T.N.; Pavi E.; Athanasakis K.
Institution
(Sargiotis, Sergentanis) Department of Public Health Policy, University of
West Attica, Athens, Greece
(Pavi, Athanasakis) Laboratory for Health Technology Assessment,
Department of Public Health Policy, University of West Attica, Athens,
Greece
Publisher
Baskent University
Abstract
Objectives: The efficacy and capacity of artificial intelligence models to
predict posttransplant health complications have been disputed over the
past few years. In this systematic review, we assessed the performance of
different artificial intelligence models in predicting health outcomes
after heart and lung transplantations. Material(s) and Method(s): We
researched online databases. We gathered and analyzed data on performance
metrics of artificial intelligence applications in heart and lung
transplantations. In addition, we conducted a risk of bias assessment.
 Result(s): Of the 122 initial studies that we gathered, 15 were
included in the analyses. The artificial intelligence models showed high
performance, with metrics for discrimination such as the area under the
receiver operating curve ranging from 0.620 to 0.921 and good calibration
for long-term outcomes. Random forest and extreme gradient boosting models
outperformed other models, particularly traditional linear models. North
American, White people were the predominant subsample, and pediatric
populations were excluded from the analysis. Most studies demonstrated a
high overall risk of bias, whereas applicability to research questions
showed a low risk. Conclusion(s): Supervised machine learning models
performed well in predicting posttransplant health outcomes. However,
biases and ethical concerns on the application of artificial intelligence
models in transplantation must be considered to draw safe
conclusions. Copyright © Baskent University 2024 Printed in
Turkey. All Rights Reserved.

<53>
[Use Link to view the full text]
Accession Number
2034137896
Title
The Use of Immunomodulators, Biologic Therapies, and Small Molecules in
Patients with Inflammatory Bowel Disease and Solid Organ Transplant.
Source
Journal of Clinical Gastroenterology. 59(1) (pp 24-35), 2024. Date of
Publication: 14 Aug 2024.
Author
Ghusn W.; Mourad F.H.; Francis F.F.; Pasha S.; Farraye F.A.; Hashash J.G.
Institution
(Ghusn) Division of Gastroenterology and Hepatology, Mayo Clinic, MN,
United States
(Ghusn) Department of Internal Medicine, Boston Medical Center, MA, United
States
(Mourad) Division of Gastroenterology and Hepatology, Department of
Internal Medicine, American University of Beirut, Beirut, Lebanon
(Francis) Division of Gastroenterology, Hepatology, and Nutrition,
University of Pittsburgh, Medical Center, PA, United States
(Pasha) Division of Gastroenterology and Hepatology, Mayo Clinic, AZ,
United States
(Farraye, Hashash) Division of Gastroenterology and Hepatology, Mayo
Clinic, FL, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Patients with inflammatory bowel diseases (IBDs) may require solid organ
transplants (SOTs) for multiple reasons, making its prevalence slightly
higher than the general population. Although immunosuppression used in SOT
may help control IBD-related inflammation, many patients still require
additional immunosuppressive medications. We aim to assess the
effectiveness and safety of the combination of SOT-related
immunosuppression and IBD medications in patients with liver, kidney, or
heart transplantation. We conducted a clinical review using PubMed,
Scopus, MEDLINE, Embase, and Google Scholar databases for our search. We
included data from systematic reviews, meta-analyses, case series, and
case reports to assess the safety, effectiveness, and side effect profile
of immunomodulators, biologic therapies, and small molecules in patients
with SOT. Our review encompassed 25 liver, 6 kidney, and 1 heart
transplant studies involving patients with IBD. Common liver transplant
immunosuppressants included tacrolimus, mycophenolate mofetil,
cyclosporine, and steroids. Anti-TNF agents, widely used in all SOT types,
showed no significant safety issues, though infections and malignancies
were noted. Patients with liver transplant on tacrolimus responded well to
anti-integrins and ustekinumab without major complications. For kidney
transplants, cyclosporine and tacrolimus were prevalent, and their
combination with anti-TNF or ustekinumab was generally safe, with rare
reports of malignancy or infection. Hence, the use of anti-TNF,
anti-integrin agents, and ustekinumab appears to be safe in patients with
SOT, regardless of their transplant related immunosuppression. More
studies are needed in patients with kidney and heart transplants and in
patients treated with small molecules for their IBD. Copyright ©
2024 Wolters Kluwer Health, Inc. All rights reserved.

<54>
[Use Link to view the full text]
Accession Number
646037282
Title
Evaluating Outcomes and Perioperative Complications of Combined Heart and
Liver Transplantation in Patients With Failing Fontan Physiology: A
Systematic Review.
Source
American Journal of Gastroenterology. Conference: Annual Scientific
Meeting of the American College of Gastroenterology, ACG 2024.
Philadelphia, PA United States. 119(10 Supplement) (pp S1377), 2024. Date
of Publication: October 2024.
Author
Shahzil M.; Habiba U.; Qureshi M.A.; Faisal M.S.; Mukhtar R.; Khaqan M.A.;
Chaudhry A.J.
Institution
(Shahzil) Penn State Health Milton S. Hershey Medical Center, Hershey, PA,
United States
(Habiba) Dow University of Health Sciences, Karachi, Sindh, Pakistan
(Qureshi) Henry Ford Jackson Hospital, Jackson, MI, United States
(Faisal, Chaudhry) Henry Ford Health, Detroit, MI, United States
(Mukhtar) Weiss Memorial Hospital, Chicago, IL, United States
(Khaqan) John H. Stroger,Jr. Hospital of Cook County, Chicago, IL, United
States
Publisher
Wolters Kluwer Health
Abstract
Introduction: Significant advancements in treating single-ventricle
congenital heart disease have improved survival rates, leading to an
increase in adults with Fontan physiology who require heart transplants
due to end-stage heart failure. Concurrently, the incidence of
Fontan-associated liver disease (FALD) has risen, necessitating more
combined heart and liver transplants (CHLT). However, data on
posttransplant outcomes for these patients remain limited and
inconclusive. This systematic review evaluates perioperative
complications, post-transplant survival, and factors influencing outcomes
in patients undergoing CHLT for FALD, aiming to improve patient selection
and timing for these complex procedures. Method(s): This systematic
review followed Cochrane guidelines and PRISMA standards to evaluate CHLT
outcomes for failing Fontan physiology. Comprehensive searches across
PubMed, Embase, Web of Science, and Cochrane CENTRAL up to May 2024
included randomized controlled trials and observational studies. Data
extraction used PICOS criteria via Excel. Due to varied findings, a
meta-analysis was not feasible; thus, a narrative synthesis was conducted.
 Result(s): From 437 screened studies, 8 studies encompassing 305
patients undergoing CHLT for FALD and heart failure were included. The
mean patient age was 37.7+/-14 years, and 45% were male. The mean
cardiopulmonary bypass time was 282+/-125 minutes. Red blood cell
transfusions ranged from 3 to 46 units. Intensive care unit stay ranged
from 7.5 to 11 days, and hospital length of stay varied from 16 to 42
days. Mechanical circulatory support was required in 15% of patients,
while renal replacement therapy was needed in 26%. Tracheostomy was
performed in 19% of patients. The overall survival rate was 82% at one
year and 74% at 5 years. Infection rates varied, with 7 out of 9 patients
affected, and reoperation rates due to complications were noted.
 Conclusion(s): This systematic review highlights the complexity of
CHLT for patients with failing Fontan physiology, including FALD. Despite
diverse perioperative outcomes, the high one-year and 5-year survival
rates affirm the viability and advantages of CHLT. Future research should
focus on refining patient selection, optimizing perioperative outcomes,
and comparing CHLT to orthotopic heart transplantation (OHT) to establish
comprehensive guidelines for managing failing Fontan physiology.

<55>
[Use Link to view the full text]
Accession Number
646036848
Title
Mortality in Patients With Cirrhosis Presenting With Acute Coronary
Syndrome and Undergoing Coronary Revascularization: A Systematic Review
and Meta-Analysis.
Source
American Journal of Gastroenterology. Conference: Annual Scientific
Meeting of the American College of Gastroenterology, ACG 2024.
Philadelphia, PA United States. 119(10 Supplement) (pp S1459-S1460), 2024.
Date of Publication: October 2024.
Author
Mateo F.R.; De Almeida Cordeiro G.C.; Sabloak R.; Maquera O.R.; Broberg
A.G.; Rahima M.K.; Albuni M.K.; Muddana V.
Institution
(Mateo, Rahima) TriHealth Good Samaritan Hospital, Cincinnati, OH, United
States
(De Almeida Cordeiro) Federal University of Campina Grande, Campina
Grande, Paraiba, Brazil
(Sabloak) Sriwijaya University, Palembang, Sumatera Selatan, Indonesia
(Maquera) Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas,
Lima, Lima, Peru
(Broberg) Nassau University Medical Center, East Meadow, NY, United States
(Albuni) TriHealth, Doha, Ad Dawhah, Qatar
(Muddana) TriHealth, Cincinnati, OH, United States
Publisher
Wolters Kluwer Health
Abstract
Introduction: Studies have documented a high prevalence of coronary artery
disease (CAD) among cirrhotic patients as well as a high risk of
cardiovascular complications and mortality. Limited data exist on the
risks of acute coronary syndrome (ACS) in cirrhotic patients undergoing
emergent percutaneous coronary intervention (PCI) or coronary artery
bypass graft (CABG). Therefore, we conducted a systematic review and
meta-analysis to evaluate the all-cause mortality in this patient
population. Method(s): We performed a comprehensive search for
studies published up to June 2024 across PubMed, Embase, and Cochrane
Databases. These studies evaluated patients with the diagnosis of
cirrhosis presenting with ACS and requiring coronary revascularization.
Our outcome of interest was all-cause mortality. Statistical Analysis was
performed with RevMan 5.4.1 Software. Result(s): Out of 1,514
database results, 5 observational retrospective studies were included.
46,475 with cirrhosis and 1,119,787 non-cirrhotic patients after matching,
all presenting with ACS were included. In the cirrhotic vs non-cirrhotic
cohorts, the mean age was 65 years vs 66 years, the female population was
35% vs 37% and race was White in 70.6% vs 76.4%. All-cause mortality (OR
2.85, CI 2.14-3.79; P< 0.01; Figure 1) was significantly higher in our
cohort of cirrhotic patients undergoing PCI/CABG when compared to
non-cirrhotics. Conclusion(s): Patients with cirrhosis who presented
with ACS and required revascularization were typically younger,
predominantly male and White. These patients experienced a significantly
higher mortality rate after PCI or CABG compared to non-cirrhotic patients
undergoing the same procedures (see Table 1). .

<56>
[Use Link to view the full text]
Accession Number
646039348
Title
Mechanical heart valves between myths and new evidence: a systematic
review and meta-analysis.
Source
Journal of cardiovascular medicine (Hagerstown, Md.). 26(1) (pp 18-28),
2025. Date of Publication: 01 Jan 2025.
Author
Santarpino G.; Serraino G.F.; Cardetta F.; Di Mauro M.; De Feo M.;
Menicanti L.; Paparella D.; Mastroroberto P.; Sorrentino S.; Speziale G.;
Pollari F.; Mauro M.; Torella M.; Coscioni E.; Chello M.; Barili F.;
Parolari A.
Institution
(Santarpino, Serraino, Mastroroberto, Mauro) Department of Experimental
and Clinical Medicine, Magna Graecia University of Catanzaro, Catanzaro,
Italy
(Santarpino) Department of Cardiac Surgery, Citta di Lecce Hospital, GVM
Care and Research, Lecce, Italy
(Santarpino, Pollari) Department of Cardiac Surgery, Klinikum Nurnberg,
Paracelsus Medical University Nuremberg, Nuremberg, Germany
(Cardetta, Chello) Department of Cardiac Surgery, University 'Campus
Biomedico', Rome, Italy
(Di Mauro) Faculty of Health, Medicine and Life Sciences Maastricht
University, Maastricht, Netherlands
(De Feo, Torella) Department of Translational Medical Sciences, University
of Campania 'Luigi Vanvitelli', Naples, United States
(Menicanti, Parolari) Department of Cardiac Surgery, IRCCS Policlinico San
Donato, Milan, United States
(Paparella) Department of Medical and Surgical Sciences, Division of
Cardiac Surgery, University of Foggia, Foggia, Italy
(Paparella) Division of Cardiac Surgery, Santa Maria Hospital, GVM Care &
Research, Bari, Somalia
(Sorrentino) Department of Medical and surgical Sciences, Magna Graecia
University of Catanzaro, Catanzaro, Italy
(Speziale) Division of Cardiac Surgery, Anthea Hospital, GVM Care &
Research, Bari, Somalia
(Coscioni) Division of Cardiac Surgery, AOU San Giovanni di Dio e Ruggi
d'Aragona, Salerno, Italy
(Barili) Department of Biomedical and Clinical Sciences, Universita Degli
Studi Di Milano
(Barili) IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy
(Barili) Department of Epidemiology, Harvard T.H. Chan School of Public
Health, Boston, MA, United States
Abstract
AIMS: The use of mechanical valve prostheses in cardiac surgery remains a
necessary and indicated intervention in a large number of patients.
However, predicted results associated with their use, on which current
guideline recommendations have been developed, are based on dated studies
at risk of bias (e.g. use of old generation models, very high
international normalized ratio regimes). METHOD(S): A comprehensive
search in multiple electronic databases was conducted from January 1995 to
January 2024 using predefined criteria. The primary outcomes included
all-cause death, bleeding events and thromboembolic events (i.e. stroke)
at follow-up. RESULT(S): Overall, 38 studies were included in the
meta-analysis. Cumulative meta-analysis results for mortality,
thromboembolic events and bleeding events were initially extremely
variable and tended to become more consistent over time. A meta-regression
for the impact of age and sex on mortality showed no difference, whereas a
meta-regression for the impact of age and sex on thromboembolic events and
on bleeding events showed a higher risk in the elderly and in female
patients, respectively. CONCLUSION(S): The lack of fundamental
information on the type of anticoagulant treatment (e.g. dosage,
monitoring method) in the studies published to date does not allow us to
draw any definitive conclusions on the outcomes of mechanical valve
prostheses. The most recent studies have provided more consistent results,
which in the past were highly variable, probably due to overcoming the
bias in the use of prosthetic models of different
generations. Copyright © 2024 Italian Federation of Cardiology -
I.F.C. All rights reserved.

<57>
Accession Number
646039823
Title
Erratum: Correction for 'early supervised incremental Resistance Training
(ESpIRiT) following cardiac surgery via a median sternotomy: a study
protocol of a multicentre randomised controlled trial' (BMJ open (2023) 13
7 DOI: 10.1136/bmjopen-2022-067914).
Source
BMJ open. 14(12) (pp e067914corr1), 2024. Date of Publication: 11 Dec
2024.
Author
Anonymous

<58>
Accession Number
2036503881
Title
Aortic Valve and Left Ventricular Outflow Tract Calcium Distribution and
Conduction Outcomes After Transcatheter Aortic Valve Replacement: A
Systematic Review and Meta-Analysis.
Source
Structural Heart. (no pagination), 2024. Article Number: 100389. Date of
Publication: 2024.
Author
Litkouhi P.N.; Rao K.; Baer A.; Hansen P.S.; Bhindi R.
Institution
(Litkouhi, Rao, Baer, Hansen, Bhindi) Department of Cardiology, Royal
North Shore Hospital, Sydney, NSW, Australia
(Litkouhi, Rao, Hansen, Bhindi) School of Medicine, University of Sydney,
Camperdown, Australia
Publisher
Cardiovascular Research Foundation
Abstract
Permanent pacemaker implantation (PPMI) is an important complication
following transcatheter aortic valve replacement (TAVR). The influence of
valvular and subvalvular calcium and its distribution between aortic
leaflets on the risk of PPMI following TAVR remains unclear. We performed
a systematic review of the aortic valve complex (AVC) calcium by leaflet,
left ventricular outflow tract (LVOT) calcium by leaflet, total AVC
calcium, total LVOT calcium, and mitral annular calcium and its
association with post-TAVR atrioventricular block, left bundle branch
block, and new PPMI. The search strategy included five databases
identifying 893 articles. A total of 34 studies with 11,528 patients were
included for qualitative analysis, and seven studies totaling 1056
patients were suitable for quantitative analysis. On meta-analysis, left
coronary cusp calcium and right coronary cusp calcium were significant
predictors of PPMI, while noncoronary cusp (NCC) calcium was not
predictive (left coronary cusp: mean difference: 21.05 mm3, 95%
CI: 5.92-36.19, p < 0.001; right coronary cusp: mean difference: 46.02
mm3, 95% CI: 1.84-90.21, p = 0.04, and NCC: mean difference:
0.19 mm3, 95% CI: -0.32 to 0.50, p = 0.10). On qualitative
review, LVOT calcium in the NCC region was the leaflet most commonly
predictive of post-TAVR conduction outcomes. Total AVC, total LVOT
calcium, and mitral annular calcium had no convincing association with
post-TAVR conduction outcomes. The distribution of calcium rather than its
total volume was associated with post-TAVR conduction abnormalities.
Heterogeneity in methodology and implantation techniques between studies
limits the clinical significance of these findings. Copyright ©
2024

<59>
Accession Number
2036477005
Title
Use of Intraoperative Hemostatic Checklists for Blood Management in
Patients Undergoing Cardiac Surgery: A Scoping Review.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2024.
Date of Publication: 2024.
Author
Irabor B.; Kothari A.; Hong J.; Chiang B.; Kent D.; Duhamel T.A.; Lawal
M.; El-Diasty M.; Arora R.C.
Institution
(Irabor, Lawal) Cumming School of Medicine, University of Calgary,
Calgary, Canada
(Kothari, Arora) Max Rady College of Medicine, University of Manitoba,
Manitoba, Canada
(Hong) Department of Surgery, Section of Cardiac Surgery, Max Rady College
of Medicine, University of Manitoba, Manitoba, Canada
(El-Diasty, Arora) Division of Cardiac Surgery, Harrington Heart and
Vascular Institute, University Hospitals Cleveland Medical Center,
Cleveland, OH, United States
(Arora) Department of Surgery, Case Western Reserve University, Cleveland,
OH, United States
(Chiang) University of Calgary's Libraries and Cultural Resources,
Calgary, Canada
(Kent, Duhamel) Institute of Cardiovascular Sciences, St. Boniface
Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada
(Duhamel) Faculty of Kinesiology and Recreation Management, University of
Manitoba, Winnipeg, MB, Canada
Publisher
W.B. Saunders
Abstract
Background: Using intraoperative hemostatic checklists may improve rates
of surgical re-exploration and utilization of allogenic blood products in
patients undergoing cardiac surgery. In this review, the authors explore
the current evidence describing the impact of using intraoperative
hemostatic checklists on reducing rates of surgical bleeding and
perioperative blood product transfusion in this group of patients.
 Method(s): Following Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines, electronic information was obtained via
sources that included Scopus, MEDLINE, EMBASE, and the Cochrane Library.
Specifically, randomized controlled and observational studies reporting on
hemostatic checklists in cardiac surgery were assessed for the following
inclusion criteria: adult patients undergoing cardiac surgery, use of an
intraoperative hemostatic checklist, a comparative study design, and full
text available in the English language. All conference abstracts,
editorials, and other reviews were excluded. Result(s): A total of
3,022 articles were retrieved. Four articles, with 19,946 patients, were
ultimately included in this review. These studies showed a significant
reduction in bleeding re-exploration rates after implementing an
intraoperative hemostatic checklist. In addition, three studies showed
lower cost per patient, less blood product transfusion, and reduced
intensive care unit stay after using checklists. Conclusion(s): These
findings suggest that using intraoperative hemostatic checklists may
reduce surgical re-exploration rates and improve blood product utilization
after cardiac surgery. Large multicenter studies are needed to endorse the
utilization of these checklists in routine clinical
practice. Copyright © 2024 Elsevier Inc.

<60>
Accession Number
2032687865
Title
Identifying Paediatric Populations with Increased Risk for Oropharyngeal
Dysphagia in Acute and Critical Care Settings: A Scoping Review.
Source
Dysphagia. (no pagination), 2024. Date of Publication: 2024.
Author
Grunke C.; Marshall J.; Miles A.; Carrigg B.; Ward E.C.
Institution
(Grunke, Marshall, Ward) School of Health and Rehabilitation Sciences, The
University of Queensland, Brisbane, Australia
(Marshall) Queensland Children's Hospital, Children's Health Queensland
Hospital and Health Service, Brisbane, Australia
(Miles) Speech Science, School of Psychology, The University of Auckland,
Auckland, New Zealand
(Carrigg) The Royal Children's Hospital, Melbourne, Australia
(Ward) Centre for Functioning and Health Research (CFAHR), Metro South
Hospital and Health Service, Brisbane, Australia
Publisher
Springer
Abstract
Dysphagia is common in hospitalised children. Clarity regarding its
prevalence is required to direct service needs. This review reports
oropharyngeal dysphagia prevalence in children admitted to acute and/or
critical care, following acute illness, medical or surgical intervention.
It also explores patient characteristics significantly associated with
oropharyngeal dysphagia in these settings. Five electronic databases
(EMBASE, CINAHL, Cochrane, PubMed, Scopus) were searched. Studies
identified for inclusion involved children (0-16 years), in acute or
critical care settings, where prevalence data for new-onset or worsening
oropharyngeal dysphagia was reported. Peer reviewed journal articles,
including systematic reviews were included. Data was extracted and
synthesised using a purpose designed extraction tool. A total of 7,522
studies were screened and 67 studies met criteria. The most researched
populations included congenital heart disease surgeries, posterior fossa
tumour resections, stroke and post-extubation dysphagia. Populations with
the highest documented dysphagia prevalence were children after posterior
fossa tumour resection with a new tracheostomy, children using nasal
continuous positive airway pressure, and children following ischemic
stroke. Characteristics significantly associated with oropharyngeal
dysphagia were younger age, lower weight, longer intubation, upper/middle
airway dysfunction (e.g., vocal paresis), and presence of additional
comorbidities. This review presents synthesised prevalence data for
children in acute and critical care settings with new-onset or worsening
oropharyngeal dysphagia. It highlights the broad nature of oropharyngeal
dysphagia in hospitalised children and the need for more rigorous research
into characteristics associated with increased risk to better support
screening and early identification of oropharyngeal dysphagia in these
settings. Copyright © The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

<61>
Accession Number
2032639559
Title
The Utility of Coronary Revascularization to Reduce Ventricular
Arrhythmias in Coronary Artery Disease Patients: A Systematic Review.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2024.
Date of Publication: 2024.
Author
Junarta J.; Siddiqui M.U.; Abaza E.; Zhang P.; Patel A.; Park D.S.; Aizer
A.; Razzouk L.; Rao S.V.
Institution
(Junarta, Park, Aizer, Razzouk, Rao) Leon H. Charney Division of
Cardiology, New York University Langone Health, New York, NY, United
States
(Siddiqui) Jefferson Heart Institute, Thomas Jefferson University
Hospitals, Philadelphia, PA, United States
(Abaza, Zhang) Department of Internal Medicine, New York University
Langone Health, New York, NY, United States
(Patel) Department of Internal Medicine, Thomas Jefferson University
Hospitals, Philadelphia, PA, United States
Publisher
John Wiley and Sons Inc
Abstract
Ventricular arrhythmias (VA) are a major cause of morbidity and mortality
in patients with coronary artery disease (CAD). Current guidelines
recommend revascularization of significant CAD to improve survival in
patients with ventricular fibrillation (VF), polymorphic ventricular
tachycardia (VT), or those who are post-cardiac arrest. However,
revascularization is not recommended for CAD patients with suspected
scar-mediated monomorphic VT. There is a paucity of data detailing the
utility of revascularization in reducing VA in CAD patients who do not
present with acute coronary syndrome (ACS) and are not immediately
post-cardiac arrest, which is the focus of this review. Medline, Scopus,
and the Cochrane Central Register of Controlled Trials were systematically
searched to identify relevant studies addressing this question. Studies
that included patients presenting with ACS or those who were immediately
post-cardiac arrest at the time of revascularization were excluded. In
total, five studies comprising 2663 patients were reviewed. Copyright
© 2024 Wiley Periodicals LLC.

<62>
Accession Number
646041403
Title
Treatment Selection for the High-risk Patient with Stage I Non-Small Cell
Lung Cancer: Sublobar Resection, Stereotactic Ablative Radiotherapy or
Image-guided Thermal Ablation?.
Source
Seminars in thoracic and cardiovascular surgery. (no pagination), 2024.
Date of Publication: 09 Dec 2024.
Author
Pennathur A.; Lanuti M.; Merritt R.E.; Wolf A.; Keshavarz H.; Loo B.W.;
Suh R.D.; Mak R.H.; Brunelli A.; Criner G.J.; Mazzone P.J.; Walsh G.;
Liptay M.; Eileen Wafford Q.; Murthy S.; Blair Marshall M.; Tong B.;
Pettiford B.; Rocco G.; Luketich J.; Schuchert M.J.; Varghese T.K.;
D'Amico T.A.; Swanson S.J.
Institution
(Pennathur, Luketich, Schuchert) Department of Cardiothoracic Surgery,
University of Pittsburgh School of Medicine, University of Pittsburgh
Medical Center, UPMC Hillman Cancer Center. Pittsburgh, PA, United States
(Lanuti) Division of Thoracic Surgery, Massachusetts General Hospital,
Boston, MA, United States
(Merritt) Division of Thoracic Surgery, Ohio State University-Wexner
Medical Center, Columbus, OH, United States
(Wolf) Department of Thoracic Surgery, The Icahn School of Medicine at
Mount Sinai and Mount Sinai Hospital, New York, NY
(Keshavarz, Eileen Wafford) American Association for Thoracic Surgery,
Beverly, MA, United States
(Loo) Department of Radiation Oncology & Stanford Cancer Institute,
Stanford University School of Medicine, Stanford, CA, United States
(Suh) Department of Radiological Sciences, UCLA Medical Center, David
Geffen School of Medicine at UCLA, Los Angeles, CA, United States
(Mak) Department of Radiation Oncology, Brigham and Women's Hospital and
Dana-Farber Cancer Institute, Boston, MA, United States
(Brunelli) Department of Thoracic Surgery, St. James University Hospital,
Leeds, United Kingdom
(Criner) Department of Thoracic Medicine and Surgery, Lewis Katz School of
Medicine at Temple University, Philadelphia, PA, United States
(Mazzone) Respiratory Institute, Cleveland Clinic, Cleveland, OH, United
States
(Walsh) Department of Thoracic Surgery, University of Texas M.D. Anderson
Cancer Center, Houston, TX, United States
(Liptay) Department of Cardiovascular and Thoracic Surgery, Rush
University Medical Center, Chicago, IL, United States
(Murthy) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Columbus, OH, United States
(Blair Marshall) Sarasota Memorial Hospital, Sarasota, FL, Puerto Rico
(Tong) Department of Thoracic Surgery, Duke University Hospital, Durham,
NC, United States
(Pettiford) Section of Cardiothoracic Surgery, Ochsner Health System, New
Orleans, LA, United States
(Rocco) Thoracic Service, Department of Surgery, Memorial Sloan Kettering
Cancer Center, New York, NY
(Varghese) Division of Cardiothoracic Surgery, University of Utah,
Huntsman Cancer Center, Salt Lake City, UT, United States
(D'Amico) Department of Surgery, Duke Cancer Institute, Durham, NC, United
States
(Swanson) Division of Thoracic Surgery, Harvard Medical School and Brigham
and Women's Hospital, Boston, MA, United States
Abstract
OBJECTIVE: A significant proportion of patients with stage I non-small
cell lung cancer (NSCLC) are considered at high risk for complications or
mortality after lobectomy. The American Association for Thoracic Surgery
(AATS) previously published an expert consensus document detailing
important considerations in determining who is at high risk. The current
objective was to evaluate treatment options and important factors to
consider during treatment selection for these high-risk patients.
 METHOD(S): After systematic review of the literature, treatment
options for high-risk patients with stage I NSCLC were reviewed by an AATS
expert panel. Expert consensus statements and vignettes pertaining to
treatment selection were then developed using discussion and a modified
Delphi method. RESULT(S): The expert panel identified sublobar
resection, stereotactic ablative radiotherapy (SABR), and image-guided
thermal ablation (IGTA) as modalities applicable in the treatment of
high-risk patients with stage I NSCLC. The panel also identified
lung-nodule-related factors that are important to consider in treatment
selection. Using this information, the panel formulated 14 consensus
statements and 5 vignettes illustrating clinical scenarios.
 CONCLUSION(S): This article summarizes important factors to consider
in treatment selection using these modalities, which are applicable in
high-risk patients with stage I NSCLC. The choice of which modality
(sublobar resection, SABR, or IGTA) is optimal in high-risk patients with
stage I NSCLC is complex, but a surgical approach is generally favored
when deemed safe. SABR and IGTA are reasonable options in select patients.
SABR is more commonly used than IGTA and is likely the next-best choice. A
multi-disciplinary review of patient and tumor characteristics is
essential for achieving an optimal decision. The clinical treatment
decision should also take patient perspectives, preferences, and quality
of life into consideration. Copyright © 2024. Published by
Elsevier Inc.

<63>
Accession Number
646040864
Title
The Importance of Pulmonary Nodule Features in the Selection of Treatment
for the High-risk Patient with Stage I Non-Small Cell Lung Cancer.
Source
Seminars in thoracic and cardiovascular surgery. (no pagination), 2024.
Date of Publication: 09 Dec 2024.
Author
Pennathur A.; Lanuti M.; Merritt R.E.; Wolf A.; Keshavarz H.; Loo B.W.;
Suh R.D.; Mak R.H.; Brunelli A.; Criner G.J.; Mazzone P.J.; Walsh G.;
Liptay M.; Eileen Wafford Q.; Murthy S.; Blair Marshall M.; Tong B.;
Pettiford B.; Rocco G.; Luketich J.; Schuchert M.J.; Varghese T.K.;
D'Amico T.A.; Swanson S.J.
Institution
(Pennathur, Luketich, Schuchert) Department of Cardiothoracic Surgery,
University of Pittsburgh School of Medicine, University of Pittsburgh
Medical Center, UPMC Hillman Cancer Center. Pittsburgh, PA, United States
(Lanuti) Division of Thoracic Surgery, Massachusetts General Hospital,
Boston, MA, United States
(Merritt) Division of Thoracic Surgery, Ohio State University-Wexner
Medical Center, Columbus, OH, United States
(Wolf) Department of Thoracic Surgery, The Icahn School of Medicine at
Mount Sinai and Mount Sinai Hospital, New York, NY
(Keshavarz, Eileen Wafford) American Association for Thoracic Surgery,
Beverly, MA, United States
(Loo) Department of Radiation Oncology & Stanford Cancer Institute,
Stanford University School of Medicine, Stanford, CA, United States
(Suh) Department of Radiological Sciences, UCLA Medical Center, David
Geffen School of Medicine at UCLA, Los Angeles, CA, United States
(Mak) Department of Radiation Oncology, Brigham and Women's Hospital and
Dana-Farber Cancer Institute, Boston, MA, United States
(Brunelli) Department of Thoracic Surgery, St. James University Hospital,
Leeds, United Kingdom
(Criner) Department of Thoracic Medicine and Surgery, Lewis Katz School of
Medicine at Temple University, Philadelphia, PA, United States
(Mazzone) Respiratory Institute, Cleveland Clinic, Cleveland, OH, United
States
(Walsh) Department of Thoracic Surgery, University of Texas M.D. Anderson
Cancer Center, Houston, TX, United States
(Liptay) Department of Cardiovascular and Thoracic Surgery, Rush
University Medical Center, Chicago, IL, United States
(Murthy) Department of Thoracic and Cardiovascular Surgery, Cleveland
Clinic, Columbus, OH, United States
(Blair Marshall) Sarasota Memorial Hospital, Sarasota, FL, Puerto Rico
(Tong) Department of Thoracic Surgery, Duke University Hospital, Durham,
NC, United States
(Pettiford) Section of Cardiothoracic Surgery, Ochsner Health System, New
Orleans, LA, United States
(Rocco) Thoracic Service, Department of Surgery, Memorial Sloan Kettering
Cancer Center, New York, NY
(Varghese) Division of Cardiothoracic Surgery, University of Utah,
Huntsman Cancer Center, Salt Lake City, UT, United States
(D'Amico) Department of Surgery, Duke Cancer Institute, Durham, NC, United
States
(Swanson) Division of Thoracic Surgery, Harvard Medical School and Brigham
and Women's Hospital, Boston, MA, United States
Abstract
OBJECTIVE: The American Association for Thoracic Surgery (AATS) Clinical
Practice Standards Committee (CPSC) previously published important
considerations in determining who is at high risk for complications or
mortality after lobectomy. Sublobar resection, stereotactic ablative
radiotherapy, or image-guided thermal ablation is typically considered
when the risks associated with lobectomy are high. The current objective
was to evaluate important lung-nodule-related factors to consider during
treatment selection for high-risk patients with stage I non-small cell
lung cancer (NSCLC). METHOD(S): The AATS CPSC assembled an expert
panel. The expert panel generated an a priori list of lung-nodule-related
factors to consider in treatment selection and graded the relative
importance of each factor on a scale of 1-10 in an anonymous survey after
systematic review of the literature. RESULT(S): The expert panel
survey identified several lung-nodule-related factors to consider in
treatment selection. The panel ranked tumor location (peripheral vs
central, mean score 8.4), tumor size (mean score 8.1), proximity to
bronchovascular and critical structures (mean score 7.8), and the presence
of interstitial lung disease/idiopathic pulmonary fibrosis (mean score
7.8) as the most important factors to consider. CONCLUSION(S): This
article summarizes the lung-nodule-related factors to consider when
deciding between sublobar resection, stereotactic ablative radiotherapy,
and image-guided thermal ablation during treatment selection for high-risk
patients with stage I NSCLC. When possible, obtaining a biopsy is very
important prior to non-surgical treatments. The choice of which modality
is optimal in high-risk patients with stage I NSCLC is complex. A
multi-disciplinary review of patient and tumor characteristics is
essential for achieving an optimal decision. Copyright © 2024.
Published by Elsevier Inc.

<64>
Accession Number
2035523330
Title
Quantitative flow ratio versus fractional flow reserve for coronary
revascularisation guidance (FAVOR III Europe): a multicentre, randomised,
non-inferiority trial.
Source
The Lancet. 404(10465) (pp 1835-1846), 2024. Date of Publication: 09 Nov
2024.
Author
Andersen B.K.; Sejr-Hansen M.; Maillard L.; Campo G.; Ramunddal T.; Stahli
B.E.; Guiducci V.; Serafino L.D.; Escaned J.; Santos I.A.; Lopez-Palop R.;
Landmesser U.; Dieu R.S.; Mejia-Renteria H.; Koltowski L.; Ziubryte G.;
Cetran L.; Adjedj J.; Abdelwahed Y.S.; Liu T.; Mogensen L.J.H.; Eftekhari
A.; Westra J.; Lenk K.; Casella G.; Belle E.V.; Biscaglia S.; Olsen N.T.;
Knaapen P.; Kochman J.; Santos R.C.; Scarsini R.; Christiansen E.H.; Holm
N.R.
Institution
(Andersen, Sejr-Hansen, Dieu, Mogensen, Westra, Christiansen, Holm)
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark
(Maillard) GCS ES Axium Rambot, Clinique Axium, Aix-en-Provence, France
(Campo, Biscaglia) Cardiology Unit, Azienda Ospedaliera Universitaria di
Ferrara, Ferrara, Italy
(Ramunddal) Department of Cardiology, Sahlgrenska University Hospital,
Goteborg, Sweden
(Stahli) Department of Cardiology, University Heart Center, University
Hospital Zurich, Zurich, Switzerland
(Guiducci) Cardiology Unit, Azienda USL-IRCCS Reggio Emilia, Reggio
Emilia, Italy
(Serafino) Department of Advanced Biomedical Sciences, University of
Naples Federico II, Naples, Italy
(Escaned, Mejia-Renteria) Hospital Clinico San Carlos IDISSC, Complutense
University of Madrid, Madrid, Spain
(Escaned) Centro de Investigacion Biomedica En Red - Enfermedades
Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
(Santos) Hospital Clinico Universitario de Valladolid, Valladolid, Spain
(Lopez-Palop) Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
(Landmesser, Abdelwahed) Department of Cardiology, Angiology and Intensive
Care Medizin, Deutsches Herzzentrum Charite, Charite-Universitatsmedizin
Berlin, Berlin, Germany
(Landmesser, Abdelwahed) Deutsches Zentrum fur Herz-Kreislaufforschung
(DZHK), Partner Site Berlin, Berlin, Germany
(Koltowski, Kochman) 1st Department of Cardiology, Medical University of
Warsaw, Warsaw, Poland
(Ziubryte) Department of Cardiology, Hospital of Lithuanian University of
Health Sciences Kaunas Clinics, Kaunas, Lithuania
(Ziubryte) Institute of Cardiology, Lithuanian University of Health
Sciences, Kaunas, Lithuania
(Cetran) Hopital Haut-Leveque, Pessac, Bordeaux, France
(Adjedj) Institut Arnault Tzanck, Nice, France
(Liu) Department of Cardiology, Hagaziekenhuis, The Hague, Netherlands
(Eftekhari) Department of Cardiology, Aalborg University Hospital,
Aalborg, Denmark
(Lenk) Klinik und Poliklinik fur Kardiologie, Universitatsklinikum
Leipzig, Leipzig, Germany
(Casella) Cardiology Unit Ospedale Maggiore, AUSL Bologna, Bologna, Italy
(Belle) INSERM U1011 and Department of Interventional Cardiology, Lille
University, Lille, France
(Olsen) Department of Cardiology, Copenhagen University Hospital - Herlev
and Gentofte, Gentofte, Denmark
(Knaapen) VU University Medical Center, Amsterdam, Netherlands
(Santos) Hospital Universitario A Coruna, Coruna, Spain
(Scarsini) Division of Cardiology, Department of Medicine, University of
Verona, Verona, Italy
Publisher
Elsevier B.V.
Abstract
Background: Fractional flow reserve (FFR) or non-hyperaemic pressure
ratios are recommended to assess functional relevance of intermediate
coronary stenosis. Both diagnostic methods require the placement of a
pressure wire in the coronary artery during invasive coronary angiography.
Quantitative flow ratio (QFR) is an angiography-based computational method
for the estimation of FFR that does not require the use of pressure wires.
We aimed to investigate whether a QFR-based diagnostic strategy yields a
non-inferior 12-month clinical outcome compared with an FFR-based
strategy. Method(s): FAVOR III Europe was a multicentre, randomised,
open-label, non-inferiority trial comparing a QFR-based with an FFR-based
diagnostic strategy for patients with intermediate coronary stenosis.
Enrolment was performed in 34 centres across 11 European countries.
Patients aged 18 years or older with either chronic coronary syndrome or
stabilised acute coronary syndrome, and with at least one intermediate
non-culprit stenosis (40-90% diameter stenosis by visual estimate;
referred to here as a study lesion), were randomly assigned (1:1) to the
QFR-guided or the FFR-guided group. Randomisation was done using a
concealed web-based system and was stratified by diabetes and presence of
a left anterior descending coronary artery study lesion. The primary
endpoint was a composite of death, myocardial infarction, and unplanned
revascularisation at 12 months. The predefined non-inferiority margin was
3.4% and the primary analysis was performed in the intention-to-treat
population. The trial was registered with ClinicalTrials.gov (NCT03729739)
and long-term follow-up is ongoing. Finding(s): Between Nov 6, 2018,
and July 21, 2023, 2000 patients were enrolled and randomly assigned to
the QFR-guided strategy (1008 patients) or the FFR-guided strategy (992
patients). The median age was 67.3 years (IQR 59.9-74.7); 1538 (76.9%)
patients were male and 462 (23.1%) were female. Median follow-up time was
365 days (IQR 365-365). At 12 months, a primary endpoint event had
occurred in 67 (6.7%) patients in the QFR group, and in 41 (4.2%) patients
in the FFR group (hazard ratio 1.63 [95% CI 1.11-2.41]). The event
proportion difference was 2.5% (90% two-sided CI 0.9-4.2). The upper limit
of the 90% CI exceeded the prespecified non-inferiority margin of 3.4%.
Therefore, QFR did not meet non-inferiority to FFR. A total of 18 (1.8%)
patients in each group experienced an adverse procedural event, the most
frequent being procedure-related myocardial infarction, which occurred in
ten (1.0%) patients in the QFR group and seven (0.7%) in the FFR group.
One patient in the QFR group died in relation to the index procedure.
 Interpretation(s): The results of the FAVOR III Europe trial do not
support the use of QFR if FFR is available to guide revascularisation
decisions in patients with intermediate coronary stenosis. This finding
could have implications for current clinical guidelines recommending QFR
for this purpose. Funding(s): Medis Medical Imaging Systems and
Aarhus University. Copyright © 2024 Elsevier Ltd

<65>
Accession Number
2035244447
Title
Remote ischemic preconditioning in non-cardiac surgery (PRINCE): a
multinational, double blind, sham-controlled, randomized clinical trial.
Source
Signa Vitae. 20(12) (pp 1-9), 2024. Date of Publication: December 2024.
Author
Greco M.; Lombardi G.; Konkayev A.; Brusasco C.; Lei C.; Roasio A.; Rana
N.; Mantilla-Gutierrez H.A.; Micali M.; Gazivoda G.; Gandini M.; Ti L.K.;
Bosso S.; Konkayeva M.; Meroi F.; Wang L.; Russo A.; Efremov S.; Fresta
G.; Berikashvili L.; Livi F.; Situm I.; Guarracino F.; Leonova E.;
Cavenago F.; Shemetova M.; Cristallo E.; Smirnova A.; Schiavoni L.;
Subbotin V.; Boffa N.; Giardina G.; Introna M.; Nakhnoukh C.; Covello
R.D.; Pieri M.; Turi S.; Ajello V.; Monaco F.; Corradi F.; Yavorovskiy A.;
Likhvantsev V.; Longhini F.; Bove T.; Bellomo R.; Landoni G.; Zangrillo
A.; Lembo R.
Institution
(Greco) Department of Biomedical Sciences, Humanitas University, MI, Pieve
Emanuele 20072, Italy
(Greco) Department of Anesthesiology and Intensive Care, IRCCS Humanitas
Research Hospital, MI, Rozzano 20089, Italy
(Lombardi, Cavenago, Cristallo, Giardina, Nakhnoukh, Pieri, Turi, Monaco,
Landoni, Zangrillo, Lembo) Department of Anesthesia and Intensive Care,
IRCCS San Raffaele Scientific Institute, Milan 20132, Italy
(Konkayev, Konkayeva) Astana Medical University, Astana 010000, Kazakhstan
(Konkayev, Konkayeva) National Scientific Center of Traumatology and
Orthopedia Named N.Batpenov, Astana 010000, Kazakhstan
(Brusasco, Micali, Gandini) Anesthesia and Intensive Care Unit, Galliera
Hospital, Genova 16128, Italy
(Lei, Wang) Department of Anesthesiology and Perioperative Medicine,
Xijing Hospital, Shaanxi, Xi'an 710032, China
(Roasio, Bosso) Department of Anaesthesia and Intensive Care, Cardinal
Massaia Hospital, Asti 14100, Italy
(Rana) Division of Anaesthesiology, Ospedale Regionale di Lugano, TI,
Lugano 6900, Switzerland
(Mantilla-Gutierrez) Department of Anesthesiology, Fundacion
Cardioinfantil-Instituto de Cardiologia, Bogota 111321, Colombia
(Gazivoda) Cardiovascular Institute Dedinje, Belgrade 11040, Serbia
(Ti) Department of Anaesthesia, National University Hospital 119074,
Singapore
(Meroi, Bove) Department of Anesthesia and Intensive Care Medicine, ASUFC
University-Hospital of Central Friuli, Udine 33100, Italy
(Russo, Fresta) Department of Anesthesiology, Fondazione Policlinico
Universitario Agostino Gemelli, IRCCS, Roma 00168, Italy
(Efremov, Leonova) Saint-Petersburg State University Hospital,
Saint-Petersburg 190103, Russian Federation
(Berikashvili, Shemetova, Smirnova, Likhvantsev) Federal Research and
Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow
107031, Russian Federation
(Livi) Department of Anesthesia and Critical Care, Azienda
Ospedaliero-Universitaria Careggi, Florence 50134, Italy
(Situm) Department of Anesthesiologyand ICU University Hospital Centre
Zagreb, Zagreb 10000, Croatia
(Guarracino) Department of Cardiothoracic and vascular Anaesthesia and
Intensive Care, Azienda Ospedaliero Universitaria Pisana, Pisa 56123,
Italy
(Shemetova) Oncological Center No. 1 of the S. S. Yudin City Clinical
Hospital of the Moscow Department of Health, Moscow 117152, Russian
Federation
(Smirnova, Yavorovskiy) I.M. Sechenov First Moscow State Medical
University of the Russian Ministry of Health, Moscow 119991, Russian
Federation
(Schiavoni) Department of Anesthesia and Intensive Care, Fondazione
Policlinico Universitario Campus Bio-Medico, Roma 00128, Italy
(Subbotin) A. Loginov Moscow Clinical Scientific Center, Moscow 111123,
Russian Federation
(Boffa) Department of Anesthesia and Intensive Care, Azienda Ospedaliera
San Dona di Piave, Venezia 30027, Italy
(Introna) NeuroAnesthesia and NeuroIntensive Care, Fondazione IRCCS
Istituto Neurologico Carlo Besta, Milan 20133, Italy
(Covello) Anesthesia and Intensive Care Unit, Emergency Department, Busto
Arsizio Hospital, ASST Valle Olona, Varese 21052, Italy
(Ajello) Department of Cardiothoracic Anesthesia, Tor Vergata University
Hospital, Rome 00100, Italy
(Corradi) Department of Surgical, Medical, Molecular Pathology and
Critical Care Medicine, University of Pisa, Pisa 56126, Italy
(Longhini) Anesthesia and Intensive Care, Department of Medical and
Surgical Sciences, "Magna Graecia" University, Catanzaro 88100, Italy
(Bove) Department of Medicine (DMED), University of Udine, Udine 33100,
Italy
(Bellomo) Department of Critical Care, The University of Melbourne,
Melbourne, VIC 3010, Australia
(Bellomo) Australian and New Zealand Intensive Care Research Centre,
Monash University, Melbourne, VIC 3800, Australia
(Landoni, Zangrillo) School of Medicine, Vita-Salute San Raffaele
University, Milan 20132, Italy
Publisher
Pharmamed Mado Ltd
Abstract
Remote ischemic preconditioning (RIPC) is a clinical procedure aimed at
inducing myocardial protection by causing brief ischemia-reperfusion
episodes in an organ remote from the heart. We aim to assess whether RIPC
provides myocardial protection in patients undergoing non-cardiac surgery.
This study, called remote ischemic PReconditioning In Non-Cardiac surgEry
(PRINCE), is a double-blind, multinational randomized clinical trial (1:1
allocation ratio) which plans to enroll 1100 patients. The intervention
arm will receive RIPC at the beginning of surgery by inflating a blood
pressure cuff around a limb for three cycles of ten minutes (inflated cuff
for five minutes followed by deflated cuff for five minutes). In the
control group, a blood pressure cuff will be put on a limb, and a sham
inflation will be performed. Given a potential interaction of propofol
with RIPC, induction and maintenance of anesthesia will be performed
without propofol. The primary endpoint of the study is to document a
significant reduction in postoperative cardiac troponin values among
patients receiving RIPC. Secondary endpoints will be cardiac ischemic
events at 30 days and 1 year, mortality at 30 days and 1 year, neurologic
events at 30 days and 1 year, acute kidney injury at 7 days, need for
intensive care unit admission and length of hospital stay. The trial will
provide evidence for the effects of RIPC on cardioprotection and other
relevant outcomes in high-cardiac risk patients undergoing non-cardiac
surgery. Clinical Trial Registration: NCT02427867. Copyright ©
2024 The Author(s).

<66>
Accession Number
2035244441
Title
Esmolol as a cardioprotective agent to reduce low cardiac output syndrome
after cardiac surgery.
Source
Signa Vitae. 20(12) (pp 69-77), 2024. Date of Publication: December 2024.
Author
Crescenzi G.; Torracca L.; Pierri M.D.; Capestro F.; Rosica C.; Oliva
F.M.; Landoni G.
Institution
(Crescenzi, Rosica) Postoperative Intensive Care Unit, Humanitas Research
Hospital, Milan 20089, Italy
(Torracca) Cardiac Surgery Unit, Humanitas Research Hospital, Milan 20089,
Italy
(Pierri, Capestro) Cardiac Surgery Unit, Lancisi Cardiovascular Center,
Polytechnic University of Marche, Ancona 60126, Italy
(Oliva, Landoni) Department of Anesthesia and Intensive Care, IRCCS San
Raffaele Scientific Institute, Milan 20132, Italy
(Landoni) School of Medicine, Vita-Salute San Raffaele University, Milan
20132, Italy
Publisher
Pharmamed Mado Ltd
Abstract
Early postoperative left ventricular dysfunction due to myocardial
stunning can negatively affect outcomes in patients with mitral
regurgitation undergoing mitral valve surgery. The aim of this study was
to evaluate the impact of the ultra-short acting beta-blocking agent
esmolol, administered after the anesthesia induction and before aortic
cross-clamping, on myocardial protection and on postoperative clinical
course in patients undergoing mitral valve surgery for mitral
regurgitation. Patients undergoing mitral valve surgery for primary mitral
regurgitation were analyzed according to the use or not of esmolol.
Clinical, procedural and laboratory data were collected. A 1:2 propensity
score matching analysis (esmolol vs. control) was performed to adjust for
baseline differences. The primary endpoint was the occurrence of
postoperative low cardiac output syndrome. Out of 322 patients (age: 66
+/- 11 years 140 women) with mitral regurgitation undergoing mitral valve
surgery, 99 received esmolol while 223 patients did not. Low cardiac
output syndrome occurred significantly less frequently in patients treated
with esmolol as compared to patients not receiving it (12.1% vs. 33.2%, p
< 0.001 before matching and 13.0% vs. 30.4%, p = 0.006 after matching).
Peak post-procedural creatin kinase MB release was lower in patients
treated with esmolol as compared to those not treated with esmolol (57 +/-
30 microg/mL vs. 82 +/- 70 microg/mL, p < 0.001 before matching and 57 +/-
31 microg/mL vs. 83 +/- 79 microg/mL, p = 0.008 after matching). Acute
kidney injury and length of intensive care unit stay were reduced in the
esmolol group both before and after matching. In conclusion esmolol
administered after anesthesia induction and before aortic cross-clamping
could improve myocardial protection in patients with mitral regurgitation
undergoing mitral valve surgery. Copyright © 2024 The Author(s).

<67>
[Use Link to view the full text]
Accession Number
2034916689
Title
Benefits and Harms of Coronary Revascularization in Non-Dialysis-Dependent
Chronic Kidney Disease and Ischemic Heart Disease: A Systematic Review and
Meta-Analysis.
Source
Clinical Journal of the American Society of Nephrology. 19(12) (pp
1562-1573), 2024. Date of Publication: 01 Dec 2024.
Author
Patel D.M.; Wilson L.M.; Wilson R.F.; Yang X.; Gharibani T.; Robinson K.A.
Institution
(Patel) Division of Nephrology, Department of Medicine, Johns Hopkins
University School of Medicine, Baltimore, MD, United States
(Wilson, Wilson, Yang, Gharibani, Robinson) Department of Health Policy
and Management, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, United States
(Robinson) Department of Medicine, Johns Hopkins University School of
Medicine, Baltimore, MD, United States
(Robinson) Department of Epidemiology, Johns Hopkins University School of
Medicine, Baltimore, MD, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Key PointsIn people with non-dialysis-dependent CKD, revascularization may
lower all-cause mortality and risk of cardiovascular events.Adverse kidney
events, which are often cited as a reason to avoid revascularization, were
uncommon.Additional research on the effect of revascularization on
patient-reported outcomes in people with non-dialysis-dependent CKD is
needed.BackgroundCardiovascular disease is the leading cause of death in
people with CKD. Coronary revascularization can improve cardiac function
and prognosis in people with ischemic heart disease; however, in people
with CKD, there is concern that potential harms could outweigh benefits of
revascularization. Evidence on the balance of these risks and benefits,
specifically in people with non-dialysis-dependent CKD, is
lacking.MethodsWe conducted a systematic review of randomized controlled
trials to assess the risks and benefits of revascularization, compared
with medical management, among adults or children with ischemic heart
disease and CKD not requiring KRT (dialysis or transplantation). We
searched PubMed, Embase, and the Cochrane Central Register of Controlled
Trials through December 12, 2023. Two people independently screened titles
and abstracts followed by full-Text review, serially extracted data using
standardized forms, independently assessed risk of bias, and graded the
certainty of evidence (COE).ResultsEvaluating data from nine randomized
controlled trials, we found that people with CKD and ischemic heart
disease treated with revascularization may experience lower all-cause
mortality compared with people receiving medical management (risk ratio
[RR], 0.80; 95% confidence interval [CI], 0.64 to 0.98; COE, low).
Revascularization may reduce incidence of myocardial infarction (RR, 0.81;
95% CI, 0.64 to 1.04; COE, low) and heart failure (RR, 0.80; 95% CI, 0.52
to 1.23; COE, low). The effect on cardiovascular mortality is uncertain
(hazard ratio, 0.67; 95% CI, 0.37 to 1.20; COE, very low). Evidence was
insufficient for patient-reported outcomes and adverse kidney events. Data
were limited by heterogeneity of patient populations and the limited
number of trials.ConclusionsIn people with non-dialysis-dependent CKD,
revascularization may be associated with lower all-cause mortality
compared with medical management and may also lower the risk of
cardiovascular events. Additional data surrounding kidney and
patient-reported outcomes are needed to comprehensively engage in shared
decision making and determine optimal treatment strategies for people with
CKD and ischemic heart disease.Clinical Trial registry name and
registration number:CRD42022349820 (PROSPERO). Copyright © 2024
The Author(s). Published by Wolters Kluwer Health, Inc.

<68>
Accession Number
2036319745
Title
Right ventricular outlet tract reconstruction for tetralogy of Fallot:
systematic review and network meta-analysis.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 39(6) (no
pagination), 2024. Article Number: ivae180. Date of Publication: 01 Dec
2024.
Author
Yamaguchi A.; Shimoda T.; Kinami H.; Yasuhara J.; Takagi H.; Fukuhara S.;
Kuno T.
Institution
(Yamaguchi) Division of Cardiovascular Surgery, University of Tsukuba,
Ibaraki, Tsukuba, Japan
(Shimoda) Department of Medicine, Ibaraki Prefectural University of Health
Sciences, Ibaraki, Ami, Japan
(Kinami) Division of Pediatric Cardiac Surgery, Lucile Packard Children's
Hospital, Stanford University School of Medicine, Palo Alto, CA, United
States
(Yasuhara) Department of Cardiology, The Royal Children's Hospital,
Melbourne, VIC, Australia
(Takagi) Department of Cardiovascular Surgery, Shizuoka Medical Center,
Shizuoka, Japan
(Fukuhara) Department of Cardiothoracic Surgery, University of Michigan,
Ann Arbor, MI, United States
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, NY, United States
(Kuno) Division of Cardiology, Jacobi Medical Center, Albert Einstein
College of Medicine, NY, United States
(Kuno) Cardiology Division, Massachusetts General Hospital, Harvard
Medical School, Boston, MA, United States
Publisher
Oxford University Press
Abstract
OBJECTIVES: Concerns persist regarding pulmonary regurgitation after
transannular patch repair (TAP) for tetralogy of Fallot. Despite the
introduction of various architectural preservation techniques, the optimal
strategy remains controversial. Our goal was to compare different right
ventricular outlet tract reconstruction techniques. METHOD(S):
PubMed, EMBASE and Cochrane Central were searched through March 2024 to
identify comparative studies on right ventricular outlet tract
reconstruction techniques (PROSPERO ID: CRD42024519404). The primary
outcome was mid-term pulmonary regurgitation, with secondary outcomes
including postoperative mortality, postoperative pulmonary regurgitation,
length of intensive care unit stays, postoperative right ventricular
outlet tract pressure gradient and mid-term mortality. We performed a
network meta-analysis to compare outcomes among TAP, valve-repairing (VR),
TAP with neo-valve creation (TAPN) and valve-sparing (VS). RESULT(S):
Two randomized controlled studies and 32 observational studies were
identified with 8890 patients. TAP carried a higher risk of mid-term
pulmonary regurgitation compared to TAPN [hazard ratio, 0.53; 95%
confidence interval (CI) (0.33; 0.85)] and VS [hazard ratio, 0.27; 95% CI
(0.19; 0.39)], with no significant difference compared to VR. VS was also
associated with reduced postoperative mortality compared to TAP [risk
ratio, 0.31; 95% CI (0.18; 0.56)], in addition to reduced ventilation
time. TAP also carried an increased risk of postoperative pulmonary
regurgitation compared to the other groups. The groups were comparable in
terms of length of intensive care unit stay, right ventricular outlet
tract pressure gradient and mid-term mortality. CONCLUSION(S): VR was
associated with a reduced risk of postoperative pulmonary regurgitation,
whereas TAPN was associated with reduced risks of both postoperative and
mid-term pulmonary regurgitation. Copyright © The Author(s) 2024.

<69>
Accession Number
2032572557
Title
A Dual Challenge: Coxiella burnetii Endocarditis in a Patient with
Familial Thoracic Aortic Aneurysm-Case Report and Literature Review.
Source
Journal of Clinical Medicine. 13(23) (no pagination), 2024. Article
Number: 7155. Date of Publication: December 2024.
Author
Cozlac A.-R.; Streian C.G.; Boca M.I.; Crisan S.; Lazar M.-A.; Virtosu
M.-D.; Ionac A.; Staicu R.E.; Dugaci D.-C.; Emandi-Chirita A.; Lascu A.;
Gaita D.; Luca C.-T.
Institution
(Cozlac, Streian, Crisan, Lazar, Ionac, Gaita, Luca) Department VI
Cardiology-Cardiovascular Surgery, "Victor Babes" University of Medicine
and Pharmacy of Timisoara, Eftimie Murgu Square No. 2, Timisoara 300041,
Romania
(Cozlac, Streian, Boca, Crisan, Lazar, Virtosu, Ionac, Staicu, Dugaci,
Lascu, Gaita, Luca) Institute for Cardiovascular Diseases of Timisoara,
"Victor Babes" University of Medicine and Pharmacy of Timisoara, G. Adam
Str. No. 13A, Timisoara 300310, Romania
(Cozlac, Streian, Crisan, Lazar, Ionac, Gaita, Luca) Advanced Research
Center of the Institute for Cardiovascular Diseases, Victor Babes"
University of Medicine and Pharmacy of Timisoara, Eftimie Murgu Square No.
2, Timisoara 300041, Romania
(Virtosu) Department VI Cardiology Internal Medicine and Ambulatory Care,
Prevention and Cardiovascular Recovery, "Victor Babes" University of
Medicine and Pharmacy of Timisoara, Eftimie Murgu Square No. 2, Timisoara
300041, Romania
(Virtosu, Staicu) Doctoral School Medicine-Pharmacy, "Victor Babes"
University of Medicine and Pharmacy of Timisoara, Eftimie Murgu Square No.
2, Timisoara 300041, Romania
(Emandi-Chirita) Centre of Genomic Medicine, Genetics Discipline, "Victor
Babes" University of Medicine and Pharmacy of Timisoara, Timisoara 300041,
Romania
(Lascu) Department III Functional Sciences-Pathophysiology, "Victor Babes"
University of Medicine and Pharmacy of Timisoara, Eftimie Murgu Square No.
2, Timisoara 300041, Romania
(Lascu) Centre for Translational Research and Systems Medicine, "Victor
Babes" University of Medicine and Pharmacy of Timisoara, Eftimie Murgu
Square No. 2, Timisoara 300041, Romania
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background/Objectives: Thoracic aortic aneurysms (TAAs) are potentially
life-threatening medical conditions, and their etiology involves both
genetic and multiple risk factors. Coxiella burnetii endocarditis is one
of the most frequent causes of blood culture-negative infective
endocarditis (BCNIE) in patients with previous cardiac surgery. Our review
aims to emphasize the importance of genetic testing in patients with
thoracic aortic aneurysms but also the importance of additional testing in
patients with suspected endocarditis whose blood cultures remain negative.
The reported case has a history of acute DeBakey type I aortic dissection
that developed during her second pregnancy, for which the Bentall
procedure was performed at that time. Ten years after the surgery, the
patient started developing prolonged febrile syndrome with repeatedly
negative blood cultures, the serological tests revealing the presence of
an infection with Coxiella burnetii. Considering her family history and
the onset of her aortic pathology at a young age, genetic tests were
performed, disclosing a missense variant in the actin alpha-2 (ACTA2) gene
in heterozygous status. Method(s): For a better understanding of both
conditions, our research was conducted in two directions: one reviewing
the literature on patients with Coxiella burnetii BCNIE and the other
focusing on patients who had a familial thoracic aortic aneurysm (FTAA)
due to the ACTA2 variant. This review incorporates studies found on PubMed
and ResearchGate up to August 2024. Conclusion(s): BCNIE represents a
condition with several diagnostic challenges and may lead to severe
complications if timely treatment is not initiated. Also, diagnosing an
FTAA requires genetic testing, enabling better follow-up and
management. Copyright © 2024 by the authors.

<70>
Accession Number
2036395028
Title
The effectiveness of a nurse-led home-based cardiac rehabilitation based
on instant information intervention in the prognosis of patients with
TAVR: A randomized controlled trial protocol.
Source
Current Problems in Cardiology. 50(3) (no pagination), 2025. Article
Number: 102967. Date of Publication: March 2025.
Author
Jia Y.Y.; Dong M.Q.; Feng J.; Hu J.N.; Hu H.T.; Yuan T.M.; Song J.P.
Institution
(Jia, Feng, Hu, Yuan, Song) Nursing Department, The Second Affiliated
Hospital of Zhejiang University School of Medicine, Hangzhou 310000, China
(Jia) Nursing Department, Zhejiang University School of Medicine, Hangzhou
310000, China
(Dong) School of Nursing, Zibo Vocational Institute, Zibo 255000, China
(Hu) Nursing Department, Zhejiang Chinese medical university, Hangzhou
310000, China
Publisher
Elsevier Inc.
Abstract
Background: Patients with poor prognosis after TAVR surgery require
high-quality cardiac rehabilitation. Digital home-based rehabilitation
based on real-time information intervention can improve outcomes. However,
the parameters of the text message intervention, such as text message
content, intervention duration, text message frequency, and other
parameters, may vary. Method(s): This is an evaluator-blinded
randomized controlled trial. TAVR patients will be recruited from the
cardiology intensive care unit of a hospital and randomly assigned to
either the control group or the experimental group. The control group will
receive standard cardiac rehabilitation, while the experimental group will
receive instant message rehabilitation intervention over six months in
addition to the standard care. The primary outcomes are home-based cardiac
rehabilitation adherence and six-minute walk distance. Secondary outcomes
include quality of life, frailty, activities of daily living scale scores,
incidence of adverse events, death during follow-up, NYHA functional
classification, readmission rate, and length of hospital stay. Data will
be collected at three time points: baseline, three months after
intervention, and six months after intervention. Generalized equation
assessment will be used to evaluate the effectiveness of the instant
message intervention. Discussion(s): Using behavior change theory as
the overall framework, guided by behavior change techniques and based on
evidence-based medicine, the digital HBCR intervention program that can be
implemented by caregivers has been designed. If the intervention proves
effective, it will promote the development of home-based rehabilitation
for TAVR patients. Trial registration: NCT06418555. Copyright ©
2024 Elsevier Inc.

<71>
[Use Link to view the full text]
Accession Number
645485086
Title
Protamine Dosing for Heparin Reversal after Cardiopulmonary Bypass: A
Double-blinded Prospective Randomized Control Trial Comparing Two
Strategies.
Source
Anesthesiology. 142(1) (pp 98-106), 2025. Date of Publication: 01 Jan
2025.
Author
Jain P.; Silva-De Las Salas A.; Bedi K.; Lamelas J.; Epstein R.H.; Fabbro
M.
Institution
(Jain, Silva-De Las Salas, Epstein) Department of Anesthesiology,
Perioperative Medicine, Pain Management, University of Miami Miller School
of Medicine, Miami, FL, Puerto Rico
(Bedi) University of Miami, Miller School of Medicine, Miami, FL, Puerto
Rico
(Lamelas) Department of Surgery, University of Miami Miller School of
Medicine, Miami, FL, Puerto Rico
(Fabbro) Department of Anesthesiology, Perioperative Medicine, Pain
Management, University of Miami, Miller School of Medicine, Miami, FL,
Puerto Rico
Abstract
BACKGROUND: Drug shortages are a frequent challenge in current clinical
practice. Certain drugs (e.g., protamine) lack alternatives, and
inadequate supplies can limit access to services. Conventional protamine
dosing uses heparin ratio-based calculations for heparin reversal after
cardiopulmonary bypass and may result in excess protamine utilization and
potential harm due to its intrinsic anticoagulation. This study
hypothesized that a fixed 250-mg protamine dose would be comparable, as
measured by the activated clotting time, to a 1:1 (1mg for every 100 U)
protamine-to-heparin ratio-based strategy for heparin reversal and that
protamine would be conserved. METHOD(S): In a single-center,
double-blinded trial, consenting elective adult cardiac surgical patients
without preexisting coagulopathy or ongoing anticoagulation and a
calculated initial heparin dose greater than or equal to 27,500 U were
randomized to receive, after cardiopulmonary bypass, protamine as a fixed
dose (250mg) or a ratio-based dose (1 mg:100 U heparin). The primary
outcome was the activated clotting time after initial protamine
administration, assessed by Student's t test. Secondary outcomes included
total protamine, the need for additional protamine, and the cumulative
24-h chest tube output. RESULT(S): There were 62 and 63 patients in
the fixed- and ratio-based dose groups, respectively. The mean
postprotamine activated clotting time was not different between groups
(-2.0s; 95% CI, -7.2 to 3.3s; P = 0.47). Less total protamine per case was
administered in the fixed-dose group (-2.1 50-mg vials; 95% CI, -2.4 to
-1.8; P < 0.0001). There was no difference in the cumulative 24-h chest
tube output (difference, -77ml; 95% CI, 220 to 65ml; P = 0.28).
 CONCLUSION(S): A 1:1 heparin ratio-based protamine dosing strategy
compared to a fixed 250-mg dose resulted in the administration of a larger
total dose of protamine but no difference in either the initial activated
clotting time or the amount postoperative chest-tube
bleeding. Copyright © 2024 American Society of Anesthesiologists.
All Rights Reserved.

<72>
Accession Number
645948681
Title
Effectiveness of acupuncture as an adjunct to cardiac rehabilitation after
coronary artery bypass grafting.
Source
Acupuncture in medicine : journal of the British Medical Acupuncture
Society. 42(6) (pp 311-318), 2024. Date of Publication: 01 Dec 2024.
Author
Roshanzamir S.; Mohamadi Jahromi L.S.; Zakeri M.; Ghaderpanah R.; Parvin
R.
Institution
(Roshanzamir) Shiraz Medical School, Shiraz University of Medical
Sciences, Shiraz, Iran, Islamic Republic of
(Mohamadi Jahromi) Shiraz University of Medical Sciences, Shiraz, Iran,
Islamic Republic of
(Zakeri, Parvin) Department of Physical Medicine and Rehabilitation,
Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of
(Ghaderpanah) Students Research Committee, School of Medicine, Shiraz
University of Medical Sciences, Shiraz, Iran, Islamic Republic of
Abstract
BACKGROUND: Considering the importance of cardiac rehabilitation after
coronary artery bypass grafting (CABG) and the development of acupuncture
over the past few decades, the aim of this study was to evaluate the
effects of acupuncture on patients' exercise tolerance, heart rate and
blood pressure after CABG. METHOD(S): Thirty-four patients with a
history of recent CABG were recruited between 2019 and 2020 for this
clinical trial and randomly divided into two groups receiving acupuncture
plus cardiac rehabilitation (group A) and cardiac rehabilitation alone
(group B). In both groups, exercise-based rehabilitation exercise was
performed. Group A additionally received acupuncture at PC6, PC4, HT7 and
GB20 bilaterally. Changes in blood pressure, heart rate and Borg scale
score were evaluated before, during and after the course of the treatment.
 RESULT(S): Heart rate was significantly lower in group A compared to
group B after completion of the course of the treatment (P=0.022).
However, there were no statistically significant differences between the
two groups in systolic or diastolic blood pressure or Borg scale scores
(P>0.05). Nevertheless, the Borg scale scores showed a significant
decrease within each group over time (P<0.001), reflecting an improvement
in the patients' ability to tolerate activity after cardiac rehabilitation
with or without acupuncture. CONCLUSION(S): Acupuncture in
combination with exercise-based cardiac rehabilitation was more effective
at decreasing heart rate than cardiac rehabilitation alone after CABG.
Both approaches appeared to be similarly effective at improving exercise
tolerance. In this study, the addition of acupuncture at the
aforementioned traditional acupuncture point locations to exercise-based
cardiac rehabilitation did not affect blood pressure. TRIAL REGISTRATION
NUMBER: IRCT20171208037793N1 (Iranian Registry of Clinical Trials).

<73>
Accession Number
2035055705
Title
Exeporfinium chloride (XF-73) nasal gel significantly reduces
Staphylococcus aureus nasal carriage in cardiac surgery patients
throughout surgery and the early recovery period: Results from a
randomized placebo-controlled Phase 2 study.
Source
Infection Control and Hospital Epidemiology. 45(11) (pp 1355-1357), 2024.
Date of Publication: 01 Nov 2024.
Author
Mangino J.E.; Firstenberg M.S.; Rhys-Williams W.; Lees J.P.; Dane A.; Love
W.G.; Gonzalez Moreno J.; Martina Y.; Barker D.
Institution
(Mangino) Division of Infection Diseases, Department of Internal Medicine,
The Ohio State University, Columbus, OH, United States
(Firstenberg) Department of Surgery, Maui Memorial Medical Center, Maui,
HI, United States
(Rhys-Williams, Love, Barker) Destiny Pharma Plc, Brighton, United Kingdom
(Dane) Danestat Consulting Ltd., Macclesfield, United Kingdom
(Lees, Gonzalez Moreno, Martina) Formerly at Destiny Pharma Plc, Brighton,
United Kingdom
Publisher
Cambridge University Press
Abstract
Staphylococcus aureus nasal carriers were randomized (1:1) to XF-73 or
placebo nasal gel, administered 5x over ~24hrs pre-cardiac surgery. S.
aureus burden rapidly decreased after 2 doses (-2.2log<inf>10</inf>
CFU/mL; placebo -0.01log<inf>10</inf> CFU/mL) and was maintained to 6 days
post-surgery. Among XF-73 patients, 46.5% received post-operative
anti-staphylococcal antibiotics versus 70% in placebo (P = 0.045).
 Copyright © Destiny Pharma Limited, 2024.

<74>
Accession Number
2036450162
Title
The Palouse Trial: PAthological comparison between in vivo LObectomy with
ex vivo SEgmentectomy for early-stage NSCLC.
Source
European Journal of Surgical Oncology. Conference: 43rd Congress of the
European Society of Surgical Oncology (ESSO 2024). Antwerp Belgium.
50(Supplement 2) (no pagination), 2024. Article Number: 109150. Date of
Publication: December 2024.
Author
I. M.A.; Broek R.T.; Leeuwis J.W.; Hekma E.; de Roos M.
Institution
(I., Broek) Radboudumc, Surgery, Nijmegen, Netherlands
(Leeuwis) Rijnstate Ziekenhuis, Pathology, Arnhem, Netherlands
(Hekma, de Roos) Rijnstate Ziekenhuis, Surgery, Arnhem, Netherlands
Publisher
W.B. Saunders Ltd
Abstract
Background: The current treatment of early-stage non-small cell lung
cancer is a lobectomy with systemic lymph node dissection. However, many
patients are found medically unfit to undergo a lobectomy. Lung parenchyma
sparing surgery has recently gained interest as an alternative for
treatment. Comparable survival between lobar and lung parenchyma sparing
resections has been reported in meta-analysis. The JCOG0802/WJOG4607L
trial showed higher survival for small tumors after segmentectomy when
compared to lobectomy. However, comparison of segmentectomy and lobectomy
for gaining adequate surgical margins has not been studied extensively. A
proposed rule of the thumb is that the resection margin of segmentectomy
should be at least 2 cm or at least the diameter of the tumor, otherwise a
rise in local recurrence is observed. The Palouse trial (PAthological
comparison of LObectomy and SEgmentectomy), is a prospective cohort study
comparing the pathological resection between lobar resections and
segmentectomy for early-stage non-small cell lung cancer. Material(s)
and Method(s): Adult patients with clinically-staged T1-T3N0M0 non-small
cell lung cancer were included if they were found medically fit to undergo
a lobectomy. To compare lobectomy and segmentectomy pathologically, a
two-step surgical approach was applied. All patients underwent in vivo
lobectomy through video-assisted thoracic surgery with systematic lymph
node dissection. Afterwards, the surgeon performed an ex vivo
segmentectomy in the operation theatre. The specimen was examined
according to current standards, where the rate of R0 resections of the
segmentectomy was compared to the rate of R0 resection of lobectomy. This
method provided a safe opportunity to study pathological results of
segmentectomy without exposing patients to potential inferior treatment.
The main endpoint was the number of R0 resections of ex vivo
segmentectomies. A R0 resection was defined as a resection of at least 1mm
parenchymal resection margin. Secondary outcomes were the percentage of
segmentectomy with a resection margin > 2 cm or at least the size of the
tumor. Results (For Surgical Trial Proposals fill in 'the Feasibility',
for Surgical Trial in Progress fill in the 'Current status'): A total of
39 patients were included. All ex vivo segmentectomies had a parenchymal
resection margin of at least 0.4cm, a vascular resection margin of at
least 0.7cm and a bronchial resection margin of at least 0.7cm. However, a
parenchymal resection margin > 2 cm or margin at least size of tumor was
obtained for 49% of the tumors. Stratified outcomes for T1a and T1b tumors
showed comparable results. Conclusions (For Surgical Trial in Progress and
Surgical Trial Proposals fill in 'NA'): All tumors were resected radically
by ex vivo segmentectomy. However, a parenchymal resection margin > 2 cm
or margin at least size of tumor was obtained for only 49% of the tumors.
These data show that segmentectomy does not fulfill pathological rule of
the thumb reported in literature. To obtain these margins, around half of
the patients needed to have lobar resection. Copyright © 2024

<75>
Accession Number
2036315532
Title
Erratum: Effect of home-based prehabilitation on objectively measured
physical activity in patients undergoing elective major cardiac and
non-cardiac surgery. Data from a randomized controlled trial (European
Journal of Preventive Cardiology (2024) 31:1 DOI:
10.1093/eurjpc/zwae175.195).
Source
European Journal of Preventive Cardiology. 31(17) (pp e126), 2024. Date of
Publication: 01 Nov 2024.
Author
Anonymous
Publisher
Oxford University Press
Abstract
This is a correction to: T Vetsch, D Engel, C M Beilstein, P Y Wuethrich,
P Eser, M Wilhelm, Effect of home-based prehabilitation on objectively
measured physical activity in patients undergoing elective major cardiac
and non-cardiac surgery. Data from a randomized controlled trial, European
Journal of Preventive Cardiology, Volume 31, Issue Supplement-1, June
2024, https://doi.org/10.1093/eurjpc/zwae175.195 In the originally
published version of the manuscript there was a typographical error in the
last name of the sixth author. This should read: "M Wilhelm". The
emendation has been made in the article online. Copyright © The
Author(s) 2024. Published by Oxford University Press on behalf of the
European Society of Cardiology. All rights reserved.

<76>
Accession Number
646021017
Title
Effect of Intravenous Ketamine Administration on the Incidence of Delirium
after Coronary Artery Bypass Graft Surgery: A Triple-Blind Randomized
Clinical Trial.
Source
Iranian biomedical journal. 28(7) (pp 77), 2024. Date of Publication: 01
Dec 2024.
Author
Sedigh Maroufi S.; Mesbah Kiae M.; Aligholizadeh M.; Saiea A.; Sangi S.
Institution
(Sedigh Maroufi) Department of Anesthesia School of Allied Medicine, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Mesbah Kiae) School of Medicine, Hasheminejad Kidney Center, Iran
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Aligholizadeh, Sangi) Student Research Committee, Iran University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Saiea) Research Center for Trauma in Police Operations, Directorate of
Health, Rescue & Treatment, Tehran, Iran, Islamic Republic of
Abstract
Introduction: Delirium is a consciousness and cognitive disorder which
occurs primarily in the postoperative period. The incidence of delirium
after open heart surgery has been reported to be more than 90%. Delirium
can delay the discharge of patients admitted to the intensive care unit
(ICU). Ketamine is a psychoactive drug with unique properties. The present
study was conducted to determine the effect of intravenous ketamine during
induction of anesthesia on the incidence of delirium in patients
undergoing coronary artery bypass surgery. Methods and Materials: This
study is a randomized, triple-blind, placebo-controlled trial with a
statistical population of 60 candidates for coronary artery bypass graft
surgery at Hazrat Rasool Akram's Education and Treatment Center. Patients
were divided into two groups of 30 individuals, with one group receiving
ketamine and the other receiving a placebo, using a random block sampling
method. The research team prepared and coded the drug regimens in
envelopes, randomized them, and distributed them to trained
anesthesiologists for blind administration. The anesthesia method was
consistent for all patients involved in the study, with the exception
that, immediately following the induction of anesthesia, ketamine was
administered to the ketamine group, while 0.9% normal saline was given to
the placebo group. After surgery, the incidence of delirium was assessed
in the ICU using the ICDSC tool during the first 24 and 48 hours of
admission, conducted by an individual who was unaware of the
interventions. The results were analyzed using descriptive and inferential
statistics in SPSS 23 statistical software. Result(s): Eligible
participants were randomly divided to receive ketamine or placebo. The
intervention group received intravenous ketamine immediately after
anesthesia induction, and the control group received saline solution as a
placebo. The results of this study showed that the incidence of
postoperative delirium was significantly lower in the ketamine group (2%)
compared to the placebo group (35%), with a p value =0.01, as determined
by Fisher's exact test. Based on logistic regression analysis, the odds of
postoperative delirium in placebo-treated patients compared with
ketamine-treated patients were significantly higher, with an odds ratio of
11.6 (95% CI: 1.5-107.5). Conclusion and Discussion: Ketamine's
anti-inflammatory properties significantly reduce postoperative delirium
in cardiac surgery patients undergoing cardiopulmonary bypass. Based on
previous studies that show ketamine's anti-inflammatory properties, our
findings also support its effectiveness in reducing the incidence of
delirium. This finding helps to optimize postoperative management
strategies and emphasizes the importance of considering ketamine as part
of a comprehensive approach to reducing postoperative complications and
improving patient outcomes.

<77>
Accession Number
2036477223
Title
A randomized study of cryoablation of intercostal nerves in patients
undergoing minimally invasive thoracic surgery.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2024.
Date of Publication: 2024.
Author
Weksler B.; Maxwell C.; Drake L.; Crist L.; Specht K.; Kuchta P.; DeHaven
K.; Weksler I.; Williams B.A.; Fernando H.C.
Institution
(Weksler, Maxwell, Drake, Crist, Specht, Kuchta, DeHaven, Weksler,
Williams, Fernando) Division of Thoracic and Esophageal Surgery,
Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, United
States
Publisher
Elsevier Inc.
Abstract
Objectives: Minimally invasive thoracic surgery can cause significant
pain, and optimizing pain control after surgery is highly desirable. We
examined pain control after intercostal nerve block with or without
cryoablation of the intercostal nerves. Method(s): This was a
randomized study (NCT05348447) of adults scheduled for a minimally
invasive thoracic procedure. Each intercostal space near the incision site
was injected with lidocaine and bupivacaine with epinephrine (standard of
care). The cryoanalgesia group also had 5 to 6 intercostal nerves ablated.
The primary outcome was the amount of narcotics (in morphine milligram
equivalents taken during the postoperative hospital stay and the first 2
weeks postdischarge. Secondary outcomes were incentive spirometry volume
and pain scores in the hospital and pain and neuropathy scores at 2 weeks.
 Result(s): Our final cohort contained 103 patients (52 standard of
care and 51 cryoanalgesia). There were no differences between the
treatment groups in morphine milligram equivalents administered during the
hospital stay (44.9 vs 38.4 mg), total morphine milligram equivalents at 2
weeks (108.8 vs 95.2 mg), or pain assessed by visual analog scale on
postoperative day 1 (3.8 and 3.3), postoperative day 2 (2 and 3.5), or 2
weeks (2 and 3.5) for standard of care and cryoanalgesia group patients,
respectively. The decrease in incentive spirometry during the
postoperative period was not significantly different between the 2 groups.
Patients in the cryoanalgesia group had higher neuropathy scores (8 vs 13;
P = .019) 2 weeks after surgery. Conclusion(s): In this randomized
study, cryoanalgesia did not decrease postoperative pain or narcotic
requirements. Cryoanalgesia increased neuropathic pain 2 weeks after
surgery. Copyright © 2024 The American Association for Thoracic
Surgery

<78>
Accession Number
2032635170
Title
Albuminuria Prevalence in Fontan Patients: A Systematic Review and
Meta-Analysis.
Source
Pediatric Cardiology. (no pagination), 2024. Article Number: n71. Date of
Publication: 2024.
Author
Van Belle H.; Van den Eynde J.; Cieplucha A.; Ladouceur M.; Martinod K.;
Pierard S.; Coats L.; Jansen K.; Opotowsky A.; Van Craenenbroeck A.H.;
Budts W.; Van De Bruaene A.
Institution
(Van Belle, Van den Eynde, Cieplucha, Martinod, Budts, Van De Bruaene)
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium
(Budts, Van De Bruaene) Division of Structural and Congenital Cardiology,
University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium
(Cieplucha) Department of Cardiology, Poznan University of Medical
Sciences, Poznan, Poland
(Ladouceur) Departement of Cardiology, University Hospital of Geneva,
Geneva, Switzerland
(Pierard) Department of Cardiology, Cliniques Universitaires Saint-Luc,
Brussels, Belgium
(Coats, Jansen) Adult Congenital Heart Unit, Freeman Hospital, Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United
Kingdom
(Coats, Jansen) Population Health Sciences Institute, Newcastle
University, Newcastle Upon Tyne, United Kingdom
(Opotowsky) Department of Pediatrics, Heart Institute, Cincinnati
Children's Hospital, University of Cincinnati College of Medicine,
Cincinnati, OH, United States
(Van Craenenbroeck) Department of Microbiology, Immunology and
Transplantation, Nephrology and Kidney Transplantation Research Group, KU
Leuven, Leuven, Belgium
(Van Craenenbroeck) Department of Nephrology and Kidney Transplantation,
University Hospitals Leuven, Leuven, Belgium
Publisher
Springer
Abstract
Patients with a Fontan circulation are at risk for chronic kidney disease
(CKD), which is defined as persistently reduced glomerular filtration rate
(GFR) <60ml/min/1.732 or elevated marker of kidney injury such
as urinary albumin-to-creatinine ratio (UACR) >30mg/g. We determined the
prevalence of albuminuria in patients with a Fontan circulation. The
MEDLINE, EMBASE, Trip, and Cochrane databases were searched for studies
reporting the prevalence of albuminuria in Fontan patients. Case reports,
reviews, and univentricular patients pre-Fontan completion or post-heart
transplantation were excluded. Studies were assessed for potential
confounders and measurement, patient selection, intervention, and
reporting biases, reported in a table. After systematic review, the pooled
prevalence of albuminuria was calculated using the quality effects model
for meta-analysis. Secondary outcomes were the clinical determinants of
albuminuria. Thirteen studies were included in the systematic review, of
which 11 were included in the meta-analysis (6 prospective, sample size
per study 25-195 patients, 873 patients in total). The pooled prevalence
of albuminuria was 28.4% (95% confidence interval 23.5-33.5%). GFR was
mostly preserved in these patients. Albuminuria was associated with
elevated systemic venous pressure in 5 studies. Other associations were
inconclusive. The main limitations of our study are the predominantly
retrospective and cross-sectional nature of the included studies with
small sample sizes and heterogeneous study populations. Our findings show
albuminuria is more prevalent than reduced GFR in patients with a Fontan
circulation, implicating the potential value of UACR in addition to GFR
when screening for CKD in these patients. Copyright © The
Author(s), under exclusive licence to Springer Science+Business Media,
LLC, part of Springer Nature 2024.

<79>
Accession Number
2032623449
Title
A Meta-Analysis of Mitral Surgery in Patients Undergoing Surgery for
Anomalous Left Coronary Artery: When to Perform Repair?.
Source
Pediatric Cardiology. (no pagination), 2024. Date of Publication: 2024.
Author
Brancaccio G.; Chinali M.; Dionisi S.; Trezzi M.; Esposito C.; Iacobelli
R.; Miraldi F.; Labriola V.; Alessia R.; Francesco B.; D'Inzeo V.; Perri
G.; Butera G.; Galletti L.
Institution
(Brancaccio, Trezzi, Labriola, Alessia, Francesco, D'Inzeo, Perri,
Galletti) Pediatric Cardiac Surgery Unit, Bambino Gesu Children's
Hospital, IRCCS, Rome, Italy
(Chinali, Esposito, Iacobelli, Butera) Pediatric Cardiology Unit, Bambino
Gesu Children's Hospital, IRCCS, Rome, Italy
(Dionisi, Miraldi) Department of Cardiac Surgery, University "La Sapienza"
of Rome, Rome, Italy
(Labriola, Francesco) Department of Cardiac Surgery, University of "Tor
Vergata", Rome, Italy
Publisher
Springer
Abstract
The present study is the first meta-analysis comparing long-term outcomes
in patients undergoing correction for anomalous left coronary artery
(ALCAPA) regarding concomitant mitral valve surgery. A systematic
literature review was conducted to identify all relevant studies with
comparative data on mitral valve surgery performed during surgery for
ALCAPA correction. Predefined primary end points included mortality and
mitral valve (re)operation. Echocardiographic outcomes were assessed when
available (including severity of mitral regurgitation). Fifty-three
relevant retrospective studies with comparative data for ALCAPA patients
with concomitant mitral valve surgery were identified from the existing
literature. The study population included 3,851 patients, of whom 55% were
girls. The mean age at surgery was 6 months [0-99 months]. The mean
follow-up after surgery was 22.7 years [6.3-37.2]. Among patients with
available echocardiographic data at the time of ALCAPA correction, 283 had
no mitral regurgitation (13%), 642 had mild mitral regurgitation (30%),
756 had moderate mitral regurgitation (36%), and 437 had severe mitral
regurgitation (21%). A subgroup of patients who underwent mitral valve
surgery (yMVS; n = 753; 19.5% of the total population) was identified. A
total of 228 patients died during follow-up (5.9%), with no differences
among patients who underwent vs those who did not undergo mitral valve
concomitant surgery at baseline (p = ns). Among the 1,536 patients with
available follow-up echocardiographic data, 519 had no mitral
regurgitation (34%), 663 had mild mitral regurgitation (43%), 268 had
moderate mitral regurgitation (17%), and 86 had severe mitral
regurgitation (6%). Overall, during follow-up, 91 patients underwent
mitral valve surgery (first MVS for 20 pts and reintervention for 71 pts,
representing a 10% reintervention rate). In regression analysis, we found
no association between the mean age at first surgery and the need for
reoperation (p = 0.458). Mitral valve surgery is performed in about 20% of
patients undergoing ALCAPA correction. Indications for MVS vary among
centers, although the severity of MV regurgitation was the most common
criterion (more than 50% of the yMVS group). Of yMVS patients,
approximately 10% underwent a second MVS during follow-up, regardless of
age at first surgery. Overall, long-term mortality in these patients is
over 5%, with no evident impact related to concomitant MV
surgery. Copyright © The Author(s), under exclusive licence to
Springer Science+Business Media, LLC, part of Springer Nature 2024.

EPICORE Embase Updates

Saturday, December 28, 2024

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Followers

Blog Archive

About Me